Role of aquaporins during hepatocellular carcinoma initiation and progression. by Mattocks, Matthew Adrian & NC DOCKS at The University of North Carolina at Charlotte
ROLE OF AQUAPORINS DURING HEPATOCELLULAR CARCINOMA INITIATION 
AND PROGRESSION
by
Matt hew Adrian Matt ocks
A dissertation submitt ed to the faculty of
Th e University of North Carolina at Charlott e
in partial fulfi llment of the requirements
for the degree of Doctor of Philosophy in
Biology
Charlott e
2010
Approved by:
Dr. Iain H. McKillop
Dr. Mark Clemens
Dr. Didier Dréau
Dr. Laura Schrum
Dr. Charles Lee
ii
© 2010
Matt hew Adrian Matt ocks
ALL RIGHTS RESERVED
iii
ABSTRA CT
MATT HEW ADRIAN MATT OCKS.  Role of aquaporins during hepatocellular carcinoma 
initiation and progression. (Under direction of DR. IAIN HUGH MCKILLOP)
Aquaporins (AQPs) are a family of proteinaceous water channels involved in bile 
production and apoptosis.  Aquaporins 8, 9 and 0 are expressed in hepatocytes and cAMP 
dependent signalling regulates AQP8 expression and localization in normal hepatocytes.  Also, 
AQP9 has promoter binding sites for AP-1, a downstream transcription factor in IL-6 signaling.  
Th e role of AQP8 and 9 in hepatocellular carcinoma (HCC) initiation and progression has not 
been determined.  Th e role of AQP8/9 in HCC initiation and progression was examined in 
rodent models of HCC as well as human HCC. Further, the role of cAMP and IL6 in regulating 
AQP8/9 expression and/or localization was examined.  To examine the role of AQP8/9 in HCC 
initiation and progression both a rat, hepatoma cell inoculation model and a diethylnitrosamine 
(DEN) initiated, hepatocarcinogenic, progressive mouse model, were used.  A rat hepatoma cell 
line was used to examine the role of cAMP and IL6 on AQP8/9 expression and localization.  
While IL6 signifi cantly aff ected AQP8 membrane localization, cAMP did not.  Further, there was 
no signifi cant aff ect on AQP8/9 expression from cAMP pathway modulation or IL6 exposure.  
However, cAMP pathway modulation did signifi cantly aff ect cell responsiveness to osmotic 
challenge.  In a mouse model of HCC, AQP8 expression in plasma membrane was signifi cantly 
higher in mice euthanized 24 weeks aft er DEN injection compared to control mice.  However, 
AQP8 and 9 membrane localization was signifi cantly lower in mice euthanized 48 weeks aft er 
DEN injection compared to control mice.  In human HCC, AQP9 membrane localization is 
signifi cantly decreased in tumor tissue compared to non-tumor tissue.  Also, AQP8/9 expression 
did not correlate with known risk factors for HCC.  Lastly, doxycycline controlled expression 
of AQP8, in a rat model of HCC, signifi cantly inhibited tumor progression in vivo.  In summary, 
AQP8 membrane localization is aff ected by IL6 exposure but cAMP signifi cantly aff ects cell 
responsiveness to osmotic stress.  Also, AQP9 membrane expression is reduced in rodent models 
of HCC as well as human HCC.  Finally, expression of AQP8 in a rat model HCC, in vivo, 
reduced tumor proliferation.
iv
ACKNOWLEDGMENTS
I would fi rst like to thank my mentor, Dr. Iain McKillop.  Dr. McKillop has been nothing 
but generous with his time, his advice and I am very thankful and grateful that I was able to do a 
Ph.D. in his lab.  I could not have asked for a bett er mentor.
I would also like to thank Dr. Eugene Sokolov.  He taught me most of what I know 
about laboratory molecular biology and has always been willing to help me.  Th e work in this 
dissertation would have taken considerably more time and been much more diffi  cult without Dr. 
Sokolov.  I would also like to thank other members of the McKillop laboratory, in particular, Dr. 
David Foreau and Liza Warner.
I would like to thank Dr. Fredrick Greene for his generous support of the work in this 
dissertation.  Also, I would like to thank the following Carolinas Medical Center HPB surgeons: 
Dr. David Iannitt i, Dr. John Martinie and Dr. David Sindram for providing the human samples 
used in this work.  I would also like to thank Dr. William Ahrens from the Carolinas Medical 
Center Pathology department.
I am indebted to the other members of my committ ee, Dr. Mark Clemens, Dr. Laura 
Schrum, Dr. Didier Dréau and Dr. Charles Lee.  Not only were they my teachers inside and 
outside the classroom but they always knew when to humble me, when to bolster me or when to 
ignore me.  I appreciate all that they did for me.
Earning a Ph.D. is difficult but it was made easier by the love and support of Judy Mattocks 
and John Stafford.  They have always been there for me and I am grateful.  I love you both.
Lastly, my beloved wife Kym.  This work is dedicated to her.
v
TABLE OF CONTENTS
LIST OF ABBREVIATIONS x
CHAPTER 1:INTRODUCTION 1
1.1. Hepatocellular Carcinoma 1
1.1.1. Epidemiology 1
1.1.2. Viral Hepatitis B & C 3
1.1.3. Alcohol & Cirrhosis 5
1.1.4. Afl atoxins 7
1.2. Guanine Nucleotide-Binding Proteins & Related Pathways 8
1.2.1. Structure & Function 8
1.2.2. Adenylate Cyclase & cAMP 8
1.2.3. Protein Kinase A 10
1.3. Cell Death 12
1.3.1. Necrosis 12
1.3.2. Initiation  & Regulation Of Apoptosis 14
1.3.3. Cellular Events 16
1.4. Aquaporins 18
1.4.1. History & Structure 18
1.4.2. Prevalence & Function 19
1.4.3. Regulation of Aquaporins 21
1.4.4. Aquaporins in Liver Physiology and Apoptosis 22
CHAPTER 2:GENERA L METHODS 27
2.1. Assurances 27
2.2. Cell Culture 27
2.2.1. Materials 27
2.2.2. Medium Preparation 28
vi
2.2.3. Cell Lines 28
2.2.4. Cell Propagation 28
2.2.5. Cell Passage and Splitt ing 29
2.2.6. Cell Storage 29
2.3. In Vivo Model of Hepatocellular Carcinoma 29
2.3.1. Materials 29
2.3.2. Tumor Inoculation in ACI Rats 30
2.3.3. Tumor Resection and Culture 32
2.4. Cell Swelling Assay 32
2.4.1. Materials 32
2.4.2. Methods 32
2.5. Reverse Transcription-Polymerase Chain Reaction 33
2.5.1. Materials 33
2.5.2. RNA Isolation 33
2.5.3. Reverse Transcription 35
2.5.4. Polymerase Chain Reaction 36
2.6. Cell Lysate Preparation 36
2.6.1. Materials 36
2.6.2. Methods 36
2.7. Western Blot 37
2.7.1. Materials 37
2.7.2. Sample Protein Concentration Measurement 37
2.7.3. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis Gels (SDS-PAGE) 38
2.7.4. Protein Resolution and Transfer 38
2.7.5. Blocking, Antibody Probe and Developing 38
2.8. Immunohistochemistry & Immunocytochemistry 39
2.8.1. Materials 39
vii
2.8.2. Tissue Preparation 39
2.8.3. Immunohistochemical / Immunocytochemical Analysis 40
2.8.4. Slide Scoring 41
2.9. Antibodies 41
2.10. Densitometry & Statistics 41
CHAPTER 3: EFFECT OF CYCLIC-AMP OR INTERLEUKIN-6 ON AQUAPORIN 8   
 AND 9 EXPRESSION AND LOCALIZATION IN HEPATOCELLULAR   
 CARCINOMA IN VITRO. 
3.1. Introduction 42
3.2. Materials & Methods 47
3.2.1. Cell Line 47
3.2.2. Protein & Pharmacological Agents 47
3.2.3. Sample Generation for Western blot and RT-PCR analyses 47
3.2.4. Membrane/Cytoplasm Sample Preparation 48
3.2.5. Western Blot 48
3.2.6. Immunohistochemistry & Immunocytochemistry 49
3.2.7. Statistical Analysis 49
3.3. Results 50
3.3.1. Analysis of cAMP/PKA  Signaling in Cultured H4IIE Cells. 50
3.3.2. Analysis of cAMP/PKA  Signaling in Freshly Isolated Tumors. 50
3.3.3. Analysis of AQP8 and 9 Responses to IL-6 Signaling in Cultured H4IIE Cells. 53
3.4. Discussion 60
CHAPTER 4: AQUAPORIN 8 AND 9 LOCALIZATION IN A MOUSE MODEL OF   
 HEPATOCELLULAR CARCINOMA 
4.1. Introduction 65
4.2. Materials & Methods 68
4.2.1. Assurances 68
4.2.2. Materials 68
42
65
viii
4.2.3. Methods 68
4.2.4. Statistical Analysis 69
4.3. Results 70
4.3.1. Aquaporin 8 localization is signifi cantly aff ected in a DEN model of HCC. 70
4.3.2. Aquaporin 9 localization is signifi cantly aff ected in a DEN model of HCC. 77
4.4. Discussion 85
CHAPTER 5: ANALYSIS OF AQUAPORIN 8 AND 9 IN HUMAN      
 HEPATOCELLULAR CARCINOMA 
5.1. Introduction 90
5.2. Material & Methods 94
5.2.1. Materials 94
5.2.2. Patient Information 94
5.2.3. Immunohistochemistry 94
5.2.4. Immunofl uorescent Histochemistry 94
5.2.5. Cell Swelling Analysis 95
5.2.6. Caspase Assay 95
5.2.7. Statistical Analysis 95
5.3. Results 101
5.3.1. Location of AQP8 and 9 in normal, non-tumor liver. 101
5.3.2. Localization of AQP8 and 9 in normal and HCC, in the context of underlying   
           cirrhosis. 
5.3.3. AQP8 localization is signifi cantly aff ected by the tumor size, tumor origin and       
           focality.
5.3.4. AQP9 localization is signifi cantly diff erent in patients with histories of chronic   
           alcohol or drug abuse. 
5.3.5. Role of aquaporins 8 and 9 in apoptotic progression of human HCC cells 
           in vitro. 
5.4. Discussion 111
90
101
105
105
109
ix
CHAPTER 6: TETRA CYCLINE CONTROLLED EXPRESSION OF    
                     AQUAPORIN 8 & 9 IN A RA T MODEL OF HEPATOCELLULAR    
 CARCINOMA IN VIVO. 
6.1. Introduction 114
6.2. Methods 118
6.2.1. Assurances 118
6.2.2. Materials 118
6.2.3. Cell Culture Material and Methods 118
6.2.4. Immunohistochemical Analysis 118
6.2.5. Construction of pTRE2-AQP-HA. 121
6.2.6. Generation of double stable H4IIE cells. 122
6.2.7. Establishing tumorigenicity of transformed H4IIE cells 123
6.2.8. Necropsy 126
6.2.9. Statistical Analysis 126
6.3. Results 127
6.3.1. Constitutive AQP8 expression signifi cantly aff ected tumor formation and
           tumor volume. 
6.3.2. pTet-AQP9 H4IIE cells fail to reestablish tumorigenicity. 127
6.4. Discussion 131
CHAPTER 7:DISCUSSION 135
REFERENCES
114
152
127
x
LIST OF ABBREVIATIONS
Abbrv. Meaning
AFB1 Afl atoxin B1
AFP Alpha Fetoprotein
ATP Adenosine Triphosphate
AVD Apoptotic Volume Decrease
C/EBP CCAAT/Enhancer Binding Protein 
cAMP Cyclic Adenosine 3’,5’-Monophosphate
CPI Complete Protease Inhibitor
CRE cAMP Response Element
DAPI 4′,6-Diamidino-2-phenylindole dihydrochloride
DEN Diethylnitrosamine
DMEM Dulbecco’s minimum essential media
DMSO Dimethylsulphoxide
EDTA Ethylenediaminetetraacetic Acid
EMEM Eagle’s minimum essential media
ER Endoplasmic Reticulum
EtBr Ethidium Bromide
EtOH Ethyl alcohol
FBS Fetal Bovine Serum
GDP Guanine Diphosphate
GTP Guanine Triphosphate
HBV Hepatitis B Virus
HCC Hepatocellular Carcinoma
HCV Hepatitis C Virus
HSC Hepatic Stellate Cell
ICER Inducible cAMP Early Repressor
IL-6 Interleukin-6
IL-6Rα Interleukin-6 α-Receptor
MCS Multiple Cloning Site
MDL MDL-12,330A Hydrochloride
MIP Membrane Intrinsic Protein
NFDM Non-Fat Dry Milk
PBS Phosphate Buff ered Saline
PCR Polymerase Chain Reaction
PKA Protein Kinase A
xi
PKC Protein Kinase C
rrIL-6 Recombinant Rat Interleukin-6
TEMED N,N,N`,N`-Tetramethylethylenediamine
TetR (Bacterial) Tetracycline Repressor
TGFβ Transforming Growth Factor Beta
TNFα Tumor Necrosis Factor Alpha
TRA IL Tumor necrosis factor Related Apoptosis Inducing Ligand
TRE Tetracycline Response Element
CHAPTER 1: INTRODUCTION
1.1. Hepatocellular Carcinoma
1.1.1. Epidemiology
Th e World Health Organization (WHO) estimated that in 2002 approximately seven 
million years of life were lost worldwide due to hepatocellular carcinoma (HCC) (World Health 
Organization 2002).  Hepatocellular carcinoma killed approximately 600,000 people in 2002 
and was the 4th leading cause of cancer death (World Health Organization 2002) (Figure 1.1).  
In the United States alone, approximately 15,000 people were diagnosed with some form of 
primary liver cancer, in 2004, (predominately  HCC or cholangial carcinoma) and in that same 
year approximately 14,000 people died (U.S. Cancer Statistics Working Group 2007).  Only 
pancreatic cancer has a higher percentage of people killed among the individual cancers tracked 
by the Centers for Disease Control (CDC) (U.S. Cancer Statistics Working Group 2007).  
Th e American Cancer Society, along with the CDC, estimates that by 2030 as many as twenty 
million people could die of cancer a year in the U.S., which is estimated to account for 12% of all 
deaths from any cause (Mackay et al. 2006).
Hepatocellular carcinoma is a disease that disproportionately aff ects men (Bosch et al. 
2005), and is most prevalent in sub-Saharan Africa, China and East Asia (Mackay et al. 2006).  
Globally, men are approximately two-and-half times more likely to develop HCC than women 
and in southern Africa and in south-east Asia men are 3 times more likely to develop HCC 
than women (Bosch et al. 2005).  Even in migrant  populations, the relative risk of Asian men 
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Figure 1.1:  Liver Cancer Deaths in 2002.  Geographical distribution of reported deaths from 
hepatocellular carcinoma worldwide (World Health Organization 2002).
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in the United States developing  HCC is 10.9 (Bosch et al. 2005).  And for west African men in 
England and Wales the relative risk of developing HCC is 31.6 (Bosch et al. 2005).  Th e etiology 
of HCC has largely been determined.  Up to 80% of  HCC cases are related to chronic viral 
hepatitis B (HBV) and C (HCV) infection, which are known risk factors for the development 
of HCC (Bosch et al. 2005; Sherman 2004; Th omas et al. 2005).  Th ere is also a correlation 
between high alcohol consumption and HCC (via cirrhosis and fi brosis) (Voigt 2005).  Lastly, 
hepatotoxic agents as well as hormones have been associated with the development of HCC 
(McKillop et al. 2006).
1.1.2. Viral Hepatitis B & C
Hepatitis B virus is a known risk factor for HCC and in areas with a high prevalence of 
HBV it is the primary cause of HCC (Tran et al. 2004).  Individuals who have chronic HBV 
are approximately 100 times more likely to develop HCC than those not infected (Sherman 
2004) and it is estimated that 60-80% of worldwide cases of HCC are due to chronic HBV 
infection(Lavanchy 2005).  It is estimated that in 2000 there were 22,000 cases of HBV in 
the United States alone (Tran et al. 2004).  Further, in Eastern Europe as many as 55% of the 
population tests positive for antibodies against the Hepatitis B antigen and in southeast Asia, 
as well as certain parts of China and Africa, as many as 95% of the population tests positive for 
these antibodies (Tran et al. 2004).
Hepatitis C virus is also a known risk factor for HCC and is associated with a higher 
incidence of HCC than HBV (Bosch et al. 2005).   Like HBV, HCV is endemic in northern and 
central Africa and high incidence rates occur in most Asian nations (Bosch et al. 2005; Shepard 
et al. 2005).  In the United States, rates of chronic liver disease were declining through most of 
the 1980s but have been rising steadily since the 1990s and the increase in chronic liver disease 
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is thought to be due, in large part, to the increased prevalence of HCV (Shepard et al. 2005).  
Indeed, while hospitalization rate of HCC associated with HBV infection remained constant 
through the 1990s, the hospitalization rate of HCC associated with HCV infection more than 
doubled (Bosch et al. 2005).
Among the fi ve known hepatitis virus types (A-E), current data indicates that only 
hepatitis B and C are associated with the development of HCC (Dash et al. 2005).  Th is 
represents something of an anomaly as HBV and HCV are from diff erent viral families, have 
diff erent modes of infection (HBV is a DNA virus while HCV is an RNA virus) and diff erent 
relationships to the host genome (HCV is episomal while HBV is integrated into the host 
genome)(Dash et al. 2005).  Despite these diff erences both viruses result in the same end-stage 
disease pathology, HCC.  Namely, chronic infection by one or both of these viruses can result in 
liver cirrhosis, which if uncleared, can result in HCC development (Dash et al. 2005; Villeneuve 
2005).  It should be noted though, that a given patient is about half as likely to develop cirrhosis 
if only infected with HBV compared to HCV (Rehermann et al. 2005).
Th ere are two commercially available vaccines for HBV, Recombivax HB (Merck) and 
Engerix-B (GSK).  Hepatitis B virus vaccines have been reported to have high effi  cacy, 80-90%, 
and are well tolerated, though antibody titers decline over time (Hassan et al. 2007; Yu et al. 
2004).  Th ough, older people, males, obesity, smoking and immunocompromised patients are 
all at statistically signifi cantly higher risk of not responding to HBV vaccination (Yu et al. 2004).  
Further, post HBV exposure vaccination has reported to be 70% eff ective in preventing the 
HBV infection (Yu et al. 2004).  Also, HBV vaccination can be used with patients with mild-
to-moderate chronic liver disease although it is contraindicated in advanced cirrhotic patients 
(Yu et al. 2004).  Hepatitis B virus vaccination has been reported to reduce viral load in HBV 
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infected patients (Yu et al. 2004).
Th ere are no commercially available vaccines for HCV.  Th is is due in part to the absence 
of an in vitro cell culture system for HCV and lack of a suitable rodent model to study HCV.  In 
a study using chimpanzees as a model, data indicated that immunization against nonstructural 
proteins of HCV resulted in subclinical HCV infection in previously immunized chimps (Puig 
et al. 2006).  Th at is, a naïve chimp immunized against the same HCV proteins showed highly 
signifi cant decrease in viral load as well as a robust CD4+ T-cell response (Puig et al. 2006).  
Unfortunately, this eff ect only persisted for 10 weeks whereby a new viral population dominated 
and infection set it in, as well as a loss of eff ective CD4+ T-cell response (Puig et al. 2006).
1.1.3. Alcohol & Cirrhosis
In Africa and Asia as high as 80% of HCC cases arise from viral hepatitis (Bosch et al. 
2005), while in the United States, alcohol consumption is a greater risk factor for HCC (El-
Serag et al. 2000; Voigt 2005).  In 2000, hospitalization rates of patients with HCC, due to 
alcoholic cirrhosis, were twice that of patients with a HCV pathology and six times greater 
than HBV patients (El-Serag et al. 2000).  Th e distinction between a normal liver and a 
cirrhotic liver is not discrete.  It is a continuum based on levels of extracellular  membrane 
proteins (specifi cally, collagen, laminin and fi bronectin) which results in capillarization of the 
sinusoids (Poli 2000).  Th ere are many factors involved in the development of liver fi brosis.  
Data indicates that, among the many factors which play a role in the development of liver 
fi brosis, three are critical, TNF, TGF (Poli 2000) and reactive oxygen species(Parola et 
al. 2001; Poli 2000).  Chronic, heavy ethanol consumption results in numerous hepatic and 
systemic responses.  Broadly, chronic ethanol consumption results in the initial activation of 
pro-infl ammatory pathways yet, in mid and late stage alcoholic liver disease anti-infl ammatory 
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pathways become activated (Crews et al. 2006).  Specifi cally, the metabolism of ethanol by 
cytochrome P450 2E1 (CYP2E1) results in the production of reactive oxygen species (ROS)
(Neuman 2003).  Further, metabolism of ethanol by ADH results in downstream production of 
TNF (a Th 1/pro-infl ammatory cytokine) by Kupff er cells (Neuman 2003).  Under chronic 
exposure ethanol stimulates Kupff er cells to release TGF (a Th 2/anti-infl ammatory cytokine), 
which acts to activate hepatic stellate cells (HSCs)(Crews et al. 2006).  It is hypothesized that 
chronic, heavy ethanol consumption results in a switch from Th 1 cytokines to Th 2 cytokines 
and it is, in part, this switch that drives fi brosis and cirrhosis (Crews et al. 2006).  Th e exact 
mechanisms at work, and the critical factors that drive this switch, remain to be determined, as 
does the mechanism whereby HCC arises from the underlying cirrhotic liver.
Th e International Agency for Research on Cancer has determined, based on 
epidemiological data, that ethanol is a carcinogen (Seitz et al. 2007).  Th e mechanism 
proposed establishes acetaldehyde, a product of alcohol metabolism, as the primary driver of 
carcinogenesis (Seitz et al. 2007).  Acetaldehyde, a toxic product of ethanol metabolism, is 
carcinogenic (Poschl et al. 2004; Seitz et al. 2001; Seitz et al. 2007; Stickel et al. 2002).  Previous 
studies indicate that acetaldehyde acts through two mechanisms to initiate and drive cancer 
progression.  Th e fi rst is by acting as an enhancer of fi brosis by causing the production of ROS 
and the activation of hepatic stellate cells (Siegmund et al. 2005) and the second is as a direct 
mutagen by disrupting DNA synthesis and repair (Poschl et al. 2004).  Acetaldehyde is known 
to covalently bond to DNA froming DNA adducts both in vitro and in vivo (Brooks et al. 2005).  
In vitro high concentrations of borohydride compounds are required for adduct formation but 
in vivo, no enzyme has been decisively identifi ed. Although vitamin C and glutathione have 
been reported to catalize adduct formation in vitro (Brooks et al. 2005). Further, acetaldehyde 
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inhibits O6 methyl-guanyltranferase, which repairs adducts resulting from exposure to 
alkylating agents (Poschl et al. 2004).  It should be noted though, that the exact mechanism by 
which acetaldehyde results in HCC remains to be fully elucidated.
1.1.4. Afl atoxins
Afl atoxins are fungal products which are known to be hepatotoxic and carcinogenic 
(Stickel et al. 2002).  While afl atoxin exposure is relatively low in the United States (Hoque et al. 
1999), in Asia (China especially) afl atoxin exposure is endemic (Wang et al. 2001; Wang et al. 
1996).
Th e role of afl atoxins (specifi cally afl atoxin B1—AFB1) in the initiation and progression 
of HCC has been the subject of a great deal of research.  Similar to ethanol, AFB1 is not directly 
carcinogenic, but when converted into exo-8,9-epoxide by cytochrome p450, DNA adducts 
result (Zhang et al. 2006).  Th e carcinogenic eff ect of chronic afl atoxin exposure results from 
these DNA adduct lesions and direct mutation of p53 (Kensler et al. 2004; Stickel et al. 2002).  
Further, high AFB1 exposure promotes DNA hypermethylation which is proposed to play a role 
in hepatocyte DNA damage and p53 mutation (Zhang et al. 2003).  Previous studies reported 
afl atoxin mutates p53 by guanine to thymine transversions on codon 249 (Bosch et al. 2005; 
Lasky et al. 1997).  Also, AFB1 appears to act synergistically with HBV and HCV infections 
in HCC progression (Bosch et al. 2005).  Lastly, AFB1 is metabolized by CYP2E1, which is 
induced by ethanol consumption as such, it is hypothesized that alcohol consumption can 
exacerbate the gene damage caused by AFB1 exposure (Voigt 2005).  Indeed, previous studies 
have reported that even moderate ethanol consumption (24 grams per day, which is equivalent 
to having two coff ees and Kahlua) concomitant with AFB1 exposure results in a thirty-fi ve fold 
increase in risk of developing HCC (Voigt 2005).
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1.2. Guanine Nucleotide-Binding Proteins & Related Pathways
1.2.1. Structure & Function
Guanine nucleotide-binding proteins (G-proteins) are heterotrimeric proteins, consisting 
of three subunits: α, β and γ.  At the time of writing (2006), sixteen diff erent α subunits 
(Bünemann et al. 2003), fi ve diff erent β subunits (Watson et al. 1994) and eleven diff erent 
γ subunits have been identifi ed in mammals (Morishita et al. 1995). Canonically, G-protein 
dependent pathways are activated by a receptor mediated conformational change in the 
α subunit resulting in the displacement of guanine diphosphate (GDP) and the binding 
of guanine triphosphate (GTP)(Miller et al. 1988).  Th e exchanging of GDP with GTP is 
catalyzed by guanine exchange factors (GEFs).  While α subunits have inherent GTPase activity, 
this activity is typically slow (as long as hours), but hydrolysis is enhanced by GTPaseactivating 
proteins (GAPs) (Sprang 1997).  Th e presence of GAPs can reduce the hydrolysis rate by as 
much as 100-fold (Sprang 1997).  Th e exchange of GDP with GTP activates the α subunit 
and causes the dissociation of the α subunit from the βγ heterodimer (Forse 2000).  However, 
studies indicate that activation of the α and βγ subunits may rearrange instead of complete 
dissociation (Bünemann et al. 2003; Cherfi ls et al. 2003; Robishaw et al. 2004).  While the 
exact mechanism by which heterotrimeric G-proteins are activated remains, in part, uncertain, 
there are convincing data that indicates that in response to Gα-receptor activation, the α 
subunit initiates the production of cyclic adenosine 3’,5’-monophosphate (cAMP) by activating 
adenylate cyclase (Dessauer et al. 1998; Simonds 1999; Sunahara et al. 1997; Whisnant et al. 
1996; Yan et al. 1997).
1.2.2. Adenylate Cyclase & cAMP
Adenylate cyclase (AC) is an enzyme which catalyzes the conversion of ATP to cAMP.  
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Because cAMP is an essential second messenger and because adenylate cyclase is tethered to 
the plasma membrane, and is responsive to hormones, it plays a critical role in transmitt ing 
signals into the cell (Mayer et al. 1998).  Adenylate cyclase activity is signifi cantly reduced in 
HCC compared to normal hepatocytes but is signifi cantly higher when the tumor is exposed to 
glucagon (Mayer et al. 1998).
First described in 1958 by Rall and Sutherland, cAMP is a ubiquitous, intracellular 
signaling molecule (Rall et al. 1958; Zhang et al. 2005).  Cyclic-AMP is formed by the bonding 
of  C3 oxygen to the C5 phosphate and is catalyzed by adenylate cyclase.  Cyclic-AMP 
functions as a second messenger in a wide array of signaling pathways, from development, to 
liver regeneration, to apoptosis (Fimia et al. 2001; Servillo et al. 2002).  Of particular interest 
regarding the work in this dissertation, is the role that cAMP plays in the translocation of 
proteins and tissue and cellular polarization.  While a great deal of work remains to be done, 
preliminary reports suggest cAMP plays a role in determinating central nervous system 
polarity via modulation of protein expression.  For example, sonic hedgehog plays a critical 
role in the correct polarization of the dorsal/ventral aspects of the development of the central 
nervous system (Epstein et al. 1996).  Further, cAMP-dependent protein kinase A (PKA ) is 
a negative regulator of Sonic hedgehog activity and removal of PKA  activity is suffi  cient to 
activate Sonic hedgehog (Epstein et al. 1996).  In addition to tissue polarization, cAMP also 
regulates cell polarity.  In HepG2 cells (a human derived HCC cell line), glucosylceramide 
and sphingomyelin (both sphingolipids) are preferentially located in the apical and basolateral 
membranes, respectively. However, following cAMP treatment, this arrangement is disturbed 
and sphingomyelin remains in the apical membrane (van Ijzendoorn et al. 1997).  Further, 
glucosylceramide and sphingomyelin are, in part, responsible for the creation of  membrane 
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domains in the apical and basolateral membrane and current data supports that it is to 
these domains that aquaporins, as well as other proteins, are targeted (Tietz et al. 2005; van 
IJzendoorn et al. 1999).
In the liver, cAMP is involved in liver regeneration (Diehl et al. 1992),bile production (via 
glucose) and cell proliferation where cAMP is either anti- or pro-proliferative depending on the 
concentration of cAMP and the presence or absence of other factors) (Diehl et al. 1992; LeSage 
et al. 2001).  In HCC, cAMP inhibits HCC cell proliferation in vitro (Kovach et al. 2006; Liu 
et al. 2005) but the exact mechanism by which this inhibition occurs remains to be elucidated.  
Currently data suggest cAMP may inhibit HCC cell  proliferation by acting on TGFβ (Schiller 
et al. 2003), by modulation of the regulatory subunits of PKA  (Cho-Chung et al. 2002), by 
modulating Akt (Liu et al. 2005), and by induction of inducible cAMP early repressor (ICER) 
(Servillo et al. 2002).
1.2.3. Protein Kinase A
Canonically, PKA  is activated by the cooperative binding of two cAMP molecules to each 
of the two regulatory subunits which repress PKA  activity (Taylor et al. 1999).  Binding of 
cAMP to the regulatory subunits initiates their dissociation from the two catalytic subunits, 
which are the eff ector subunits of PKA  (Taylor et al. 1999).  Th ere are many downstream targets 
for PKA , in fact most of the cell signaling which occurs in response to cAMP production is due 
to the activity of PKA  (Mayr et al. 2001; Montminy 1997; Taskén et al. 2004).  Currently, there 
appears to be no independent role (i.e. one that is not in response to cAMP stimulation) for 
PKA  in hepatocellular carcinoma  (Figure 1.2).
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Figure 1.2:  Cyclic-AMP Signaling Pathway.  In response to G-protein coupled receptor 
activation, GDP bound to GαS is displaced by GTP, activating GαS.  Activated GαS, stimulates 
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12
1.3. Cell Death
1.3.1. Necrosis
Th ere are two processes by which a cell dies; necrosis or apoptosis (Table 1.1).  Necrosis 
was once thought to be a passive, unregulated process which occurs when the cell is exposed to 
severe physical or metabolic challenge resulting in acute disruption of the plasma membrane, 
followed by the cellular contents being released into the extracellular environment (Lemasters 
2005).   Th e release of cellular constituents results in an increase in local infl ammation (Henke 
et al. 2005).  Th is localized immune response is exacerbated by the fact that it is rare for a single 
cell to undergo necrosis. Rather, large numbers of contiguous cells will be stimulated to undergo 
apoptosis following a dramatic insult (Malhi et al. 2006).  With this being said, more recent data 
indicates that necrosis may not be as passive or as unregulated as previously thought (Harwood 
et al. 2005; Majno et al. 1995).  It has been reported that under severe chemical or metabolic 
challenge the cell will undergo necrosis via ATP depletion resulting in cell swelling and if left  
unchecked the plasma membrane will be compromised resulting in the cell rupturing (Malhi et 
al. 2006).  While there are mechanistic pathways involved in this process, necrosis still results in 
signifi cant damage to neighboring cells and neighboring tissues (Harwood et al. 2005; Henke 
et al. 2005).  Typically, the infl ammatory response is local but necrosis can cause widespread 
tissue damage and compromise organ function (Henke et al. 2005).  Because of the large scale 
damage resulting from necrosis, a more controlled process has evolved.  A process by which a 
single cell can be removed from a population of cells in such a way that damage to neighboring 
cells is reduced, if not ameliorated, and that does not initiate an infl ammatory response by the 
body; the process which evolved is apoptosis.
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Apoptosis Necrosis
Initiation Th rough receptors or 
mitochondria.
Severe chemical or 
mechanical insult.  Rapid ATP 
withdrawl.
Regulation Highly regulated through a 
large network of proteins.
Largely unregulated.
Immune Response None.  Released cellular 
constiutients are confi ned 
within vessicals.
High.  Cell rupture results in 
release antigenic proteins and 
infl ammation. 
DNA Breakdown DNA is cleaved following 
PARP deactivation.  Complete 
DNA destruction results.
Litt le.  Th e rapidity of necrosis 
largely prevents any orderly 
breakdown of DNA.  
Water Movement Water fl ows out of the cell 
resulting in cell shrinkage.
Water fl ows into the cell 
resulting in cell swelling and 
eventual rupture.
Speed Slow.  Can take hours. Fast.  Can occur in minutes.
Table 1.1:  Comparison of apoptosis and necrosis.
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1.3.2. Initiation  & Regulation Of Apoptosis
Apoptosis can be initiated either extrinsically or intrinsically (Figure 1.3).  As the name 
implies, extrinsic  apoptosis is initiated when a ligand binds to an extracellular receptor 
(Guicciardi et al. 2005).  Th ere are a limited number of ligands which activate the extrinsic 
apoptotic pathway, the principal ones being Fas ligand (FasL), Tumor necrosis factor-α 
(TNFα), tumor necrosis factor related apoptosis inducing ligand (TRA IL) and granzyme 
B (Guicciardi et al. 2005).  Binding of these ligands (with the exception of Granzyme B) to 
their respective receptors results in the binding of adaptor proteins to form the death inducing 
signaling complex (DISC), which results in the activation of caspase 8 (Lemasters 2005).  
Granzyme B is an enzyme secreted by cytotoxic T lymphocytes during T cell mediated killing 
of a cell (Bleackley 2005) and should be noted, that the discovery of caspases was due to work 
done involving granzyme B (Bleackley 2005).  In contrast to other apoptotic signals, granzyme 
B bypasses most of the regulatory pathways of apoptosis and directly activates caspase 3 
(Bleackley 2005).
Th ere are many regulatory points, and a great deal of cross-talk, in both extrinsic and 
intrinsic apoptotic pathways.  In the extrinsic pathway, DISC formation results in the activation 
of caspase 8 (Harwood et al. 2005).  Th is is followed by cleavage activation of BH3 domain-only 
death agonist (Bid) to truncated Bid  (tBid) (Harwood et al. 2005).  Truncated Bid then 
translocates to the mitochondria whereby Bax and Bak are recruted, resulting in Bax/Bak 
dimerization and insertion into the mitochondrial membrane (Lemasters 2005).  Insertion of 
Bax/Bak results in the membrane permeability transition (MPT), which permits the release 
of cytochrome c into the cytoplasm (Lemasters 2005).  Cytochrome c, ATP and apoptotic 
protease activating factor-1 (Apaf-1) form the apoptosome, which in turn activates caspase 
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Figure 1.3:  Extrinsic apoptotic pathway:  Following activation of a death receptor (Fas, 
TNFα or TRA IL), Caspase 8 is activated and cleaves BH3 interacting domain death agonist 
(Bid) to truncated-bid (tBid).  Truncated-Bid translocates to the mitochondria and recruits 
Bcl-2 associated X protein (Bax) and Bcl-2 agonist killer (Bak).  Th ere, Bax and Bak form a 
heterodimer resulting in mitochondrial membrane permeability transition (MPT).  MPT results 
in the release of cytochrome c which forms a heteromeric protein complex with apoptotic 
protease activating factor 1 (Apaf-1) and ATP.  Th is complex initiates a caspase cascade resulting 
in activation of caspase 3, the inactivation of polyadenosine ribose polymerase (PARP) and 
DNA destruction.  Alternatively, Granzyme-B (Grzm) enters into the cell by perforin pores and 
it then directly activates caspase 3.  Apoptosis can be inhibited by a number of proteins, such as 
B-cell CLL/lymphoma 2 (Bcl-2) and Bcl2-like 1 (Bcl-xL).
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9 by cleaving procaspase 9 (Harwood et al. 2005).  Activated caspase 9 cleaves procaspase 3 
resulting in caspase 3 (the activated isoform of the enzyme), which is a central control point for 
apoptotic pathways (Guicciardi et al. 2005; Harwood et al. 2005; Lemasters 2005).  Caspase 3 is 
the last regulatory point in both extrinsic and intrinsic apoptosis and, once activation of caspase 
3 occurs, there are no further regulatory checkpoints and a chain reaction of caspase activation 
proceeds, culminating with cleavage inhibition of polyadenosine ribose polymerase (PARP)and 
preventing DNA repair mechanisms from being activated (Lemasters 2005).  Th e activation of 
PARP results in DNA fragmentation and cell death (Guicciardi et al. 2005).
Intrinsic apoptosis usually occurs in response to severe DNA damage which cannot be 
repaired (typically due to chemical or γ-radiation exposure) (Guicciardi et al. 2005).  Th is type 
of DNA damage results in phosphorylation of p53 which in turn activates Bax (Hanahan et 
al. 2000).  Along with its role in the MPT, Bax also functions as a repressor of anti-apoptotic 
proteins Bcl-2 and Bcl-xL (Hanahan et al. 2000).  Mitochondria are the convergence points 
between extrinsic and intrinsic apoptotic pathways.  Whether apoptosis is initiated by an 
extracellular ligand or catastrophic DNA damage, activated pathways that result in cell death 
merge at the mitochondria with the MPT (Cheng et al. 2001; Donovan et al. 2004; Guicciardi 
et al. 2005).  Following the MPT, the caspase cascade and the subsequent cellular events are the 
same regardless of the event which initiated apoptosis (Donovan et al. 2004; Guicciardi et al. 
2005; Lemasters 2005).  It should be noted that even at late stages of apoptosis, a cell can switch 
to a necrotic process if a second cellular insult occurs (in the case of extrinsic initiation), or if 
DNA damage worsens (Majno et al. 1995). 
1.3.3. Cellular Events
Th e purpose of apoptosis, as opposed to necrosis, is to selectively remove a cell with 
17
minimal damage to surrounding cells.  Necrosis is characterized by a depletion of ATP, thereby 
halting Na+ /K+  ion pumps, which results in water rapidly entering the cells and rupture of the 
plasma membrane.  In contrast, apoptosis is a highly regulated process resulting in radically 
diff erent morphological changes.  Caspase activation requires a decrease in intracellular K+ 
from 145mM to less than 50mM (Hughes et al. 1997).  To eff ectuate this change water exits the 
cell via aquaporins (Bortner et al. 2002).  Th is results in characteristic cell shrinkage observed 
in all apoptotic cells.  Further, the nuclear membrane is broken down and DNA is cleaved by 
nonspecifi c nucleases (Lemasters 2005).  Th e last morphological event observed is cell blebbing 
(Majno et al. 1995).  To prevent the infl ammation response that accompanies necrosis, cellular 
constituents are broken down while the plasma membrane is intact, and then exocytosed in 
compartments (called cell bodies) formed from the plasma membrane (Malhi et al. 2006).  Th is 
permits phagocytosis of these cell bodies by neighboring cells (Malhi et al. 2006).
1.4. Aquaporins
1.4.1. History & Structure
As early as the 1950’s it was hypothesized that a channel must exist to permit the volume 
and rate of water movement that was observed in red blood cells (Engel et al. 2000).  By 1983 
it was becoming clear, though still controversial, that this channel existed, but it had yet to 
be characterized (Lewis 1983).  In 1986, a seminal paper by  Benga, et.al. provided a clear 
demonstration of the presence of water channels in red blood cells (Benga 2003; Benga et al. 
1986).  Later, in what has now resulted in controversy, Peter Agre’s group published a article 
demonstrating the sequence of a water channel (later claiming it to be the discovery of a water 
channel) by injecting mRNA from then called CHIP28 (now referred to as aquaporin 1) 
into oocytes and examining swelling changes in the oocyte in response to osmotic challenge 
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(Preston et al. 1992).  
Th irteen known mammalian members of the membrane intrinsic protein (MIP) family 
(AQP0-AQP12) have now been described.  Aquaporin’s 0-12 proteins demonstrate a high 
degree of conservation between mammalian species.  Th ough there is very litt le similarity 
(19-52%) between specifi c aquaporin isoforms within the same species (Verkman et al. 
2000).  In hepatocytes three aquaporin isoforms have been detected: AQP8, AQP9 and 
AQP0 (Matsuzaki et al. 2004; Portincasa et al. 2003).  While AQP8 and AQP9 are regulated 
and respond to stimuli, AQP0 is constitutively expressed in the cytoplasm and has not been 
reported to respond to any stimuli tested to date (Huebert et al. 2002).  For mammals the 
crystal structure has only been resolved for AQP0, AQP1 and AQP9, yet it is currently believed 
that all aquaporin family members will have similar structural characteristics despite the 
primary structure diff erences (Verkman et al. 2000).  Th is belief is predicated on the notion 
that given the similar function for aquaporin members, the structure of each will be similar.  
While all aquaporin members permit the passage of water, recent data indicates that certain 
aquaporin proteins (AQP3, AQP7, AQP9 and AQP10) also permit passage of other water 
soluble molecules including glycerol, ammonium, urea, and other uncharged, small molecules 
(Carbrey et al. 2003; King et al. 2001; Saparov et al. 2006).  Th ese aquaporin proteins are termed 
aquaglyceroporins (it should be noted that “aquaporin” is still used as a general term to refer to 
all aquaporins regardless of what is able to pass through the pore).
Generally, aquaporins consist of six alpha helices each of which span the membrane 
into which they are inserted (Engel et al. 2000).  Despite the diff erences in the sequences 
of aquaporin proteins, several conserved residues (the NPA motifs) exist that distinguish 
aquaporins from aquaglyceroporins .  Th ese residues act to provide passage specifi city to the 
19
pore (Engel et al. 2000).
1.4.2. Prevalence & Function
Of the thirteen currently identifi ed mammalian aquaporin family members, at least one is 
found in every cell type and organ in the body (Badaut et al. 2004; Elkjaer et al. 2000; Ishibashi 
et al. 1998; Knüpfer et al. 2007; Labbozzett a et al. 2006; Matsuzaki et al. 2004; McConnell et al. 
2002).  Beyond mammals, aquaporins are also found in bacteria (Gonen et al. 2006) and play a 
critical role in plant physiology (Tritt o et al. 2007).
Most simply, aquaporins permit the passage of water (and in some instances small, 
uncharged molecules) through the plasma membrane (Gonen et al. 2006).  Th is process does 
not require ATP and water movement occurs along a solute concentration gradient (Preston 
et al. 1992).  Aquaporin function is dictated by form.  Specifi c residues within the aquaporin 
channel itself determine what is capable of passing through the pore (Engel et al. 2000; Verkman 
et al. 2000).  One of the fi rst questions that arose following the discovery of aquaporins was how 
do they permit the passage of water but exclude protons?  Th e answer was found by observing 
the E. coli. aquaglyceroporin, GlpF(Gonen et al. 2006).  Th ese studies revealed that water has to 
act as a proton donor in a hydrogen bonding mechanism which requires an opposite orientation 
(both in terms of the water molecule and the residues which comprise the pore) between 
water molecules entering the pore and those leaving it (Gonen et al. 2006).  In contrast, proton 
passage would require uniform orientation and therefore protons are precluded from passing 
through the aquaporin channel (Gonen et al. 2006).
Some aquaporins are sensitive to mercury chloride (HgCl2) and exposure to HgCl2 will 
inhibit movement of any molecule through the pore (Verkman et al. 2000).  Mercury chloride 
acts by binding of Hg2+ to cysteine 189 in the pore thereby physically blocking the channel 
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(Preston et al. 1993).  Th e primary function of aquaporins is water and glycerol movement 
and thus they are involved in numerous water and glycerol mediated physiological activities 
(Sambrook et al. 2001).  Aquaporins play a critical role in the production of urine (Verkman 
2005).  Previous work has reported that humans with an AQP1 deletion develop a rare 
condition resulting in the person being unable to form concentrated urine (King et al. 2001). 
Further, a mutation in AQP2 results in a hereditary form of diabetes (van Lieburg et al. 1994).  
Aquaporins also play a critical role in the clearance of brain edema.  Work with AQP4-null 
mice showed that these mice were highly resistant to brain swelling following edema and had 
signifi cantly reduced edema following ischemic stroke (Manley et al. 2000).  Interestingly, 
aquaporins also seem to play a role in tumor angiogenesis and metastatsis.  Recent data reports 
that aquaporins may play a role in tumor neoangiogenesis (Saadoun et al. 2005).  Aquaporin 
1-null mice showed a signifi cantly lower rate of vessel formation and a signifi cantly higher 
survival rate compared to wild-type control (Saadoun et al. 2005).   Also, migration and wound 
healing experiments reported that AQP1 knockout endothelial cells exhibit signifi cantly 
inhibited migration compared to normal endothelial cells (Saadoun et al. 2005).  Lastly, one 
of the questions that arose when it was discovered that some aquaporins allow the passage of 
glycerol was ‘why’?  Th e answer, in part, lay in the fact that glycerol plays a role in adipocyte 
regulation (Hara-Chikuma et al. 2005).  Data using AQP7-null (an aquaglyceroporin) mice 
reported that the lack of AQP7 resulted in signifi cantly higher adipocyte hypertrophy, fat mass 
accumulation and signifi cantly higher triglyceride production and free fatt y acid release (Hara-
Chikuma et al. 2005).  
1.4.3. Regulation of Aquaporins
Current data indicates that aquaporin regulation occurs post-translationaly.  While there 
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is some transcriptional regulation, the majority of the regulatory framework of aquaporins 
occurs by controlling aquaporin location within the cell.  For example, in the kidney, AQP2 
is responsive to vasopressin exposure via a cAMP/PKA  signaling pathway (Noda et al. 2005).  
Following vasopressin binding to its receptor, Gs protein activation occurs, thereby activating 
AC resulting in increased intracellular cAMP (Noda et al. 2005).  Cyclic-AMP then activates 
PKA  which in turn stimulates AQP2 translocation from intracellular vesicles to the apical 
membrane of renal principal cells (Noda et al. 2005).  In the brain, a similar regulatory scheme 
to that of kidneys exists.  Th ere are three aquaporins expressed in the brain, AQP1, AQP4, 
AQP9 (Gunnarson et al. 2004).  AQP1 and AQP4 appear to be regulated by phosphorylation, 
both in terms of expression and localization (Gunnarson et al. 2004).  Further, AQP4 activity 
is regulated by arginine vasopressin (Gunnarson et al. 2004).  Previous work with cultured 
astrocytes reports that arginine vasopressin exposure resulted in a signifi cantly higher cell 
swelling rate compared to control (Sarfaraz et al. 1999).  Arginine vasopressin regulates AQP4 
activity by modulating the cAMP/PKA  pathway (Gunnarson et al. 2004).  Lastly in the brain, 
AQP1 is regulated by ubiquitination (Leitch et al. 2001).
In hepatocytes three aquaporins have been detected, AQP0, AQP8 and AQP9 (Elkjaer et 
al. 2000; Huebert et al. 2002; Koyama et al. 1997).  Current research suggests that AQP0 plays 
no role in the formation of bile since it remains intracellular (Huebert et al. 2002).  Further, 
AQP0 localization is not responsive to cAMP and remains localized to intracellular vesicles 
(Huebert et al. 2002).  Similarly, AQP9 localization is also unresponsive to cAMP exposure 
(Huebert et al. 2002).  Unlike AQP0, AQP9 is localized to the basolateral membrane and 
plays a critical role in bile formation (Huebert et al. 2002).  Neither AQP0 nor AQP9 protein 
expression is increased by exposure to cAMP (Huebert et al. 2002).   In contrast, AQP8 protein 
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expression is increased in response to cAMP exposure (Huebert et al. 2002).  Further, AQP8, 
which normally resides in intracellular vesicles, translocates to the canalicular membrane in 
response to glucagon exposure (Gradilone et al. 2003) (Figure 1.4).
1.4.4. Aquaporins in Liver Physiology and Apoptosis
Compliment production, red blood cell removal, blood detoxifi cation and bile production 
are some of the numerous physiological functions performed by the liver.  Bile is critical for 
fat and vitamin absorption.  Bile is approximately 95% water and this requires considerable 
water transport through the hepatocytes.  Bile acid is produced by degradation of cholesterol 
and occurs via two pathways, the classical pathway and the alternate pathway (Chiang 1998).  
Both pathways are enzymatically catalyzed and these enzymes represent regulatory focal points 
during bile production (Chiang 1998).  Th ese enzymes are regulated by hormones, diurnal 
rhythms and bile itself (Chiang 1998).  Hepatocytes actively transport bile acids into the bile 
canaliculus (Anwer 2004).  Along with the transport of bile acids, water must be passaged 
as well.  In humans, bile production can reach up to 600mL a day, and studies report that 
passive diff usion would occur too slowly for this production level to be maintained (Ma et al. 
1999).  Th erefore, aquaporins are critical for transporting water from the sinusoid into the bile 
canaliculus via the hepatocytes (Ma et al. 1999; Marinelli et al. 1997) (Figure 1.4).  
Apoptosis is a the primary means by which a single cell can be eliminated with minimal 
damage to surrounding cells.  Th e process of apoptosis is highly regulated and a predetermined 
sequence of events must occur for progression (Lemasters 2005).  Aquaporins play a critical 
role in apoptotic progression( Jablonski et al. 2007; Jablonski et al. 2004; Seitz et al. 2007).  
Aft er apoptosis is initiated (either intrinsically or extrinsically), a cellular volume decrease is 
observed, termed the apoptotic volume decrease (AVD) (Bortner et al. 2002).  Before the AVD 
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occurs, the cell depolarizes by inhibiting potassium ion movement into the cell, by an infl ux of 
sodium ions into the cell and by an deactivation of the Na+ /K+ -ATPase pump, which is largely 
responsible for maintaining normal osmotic balance in the cell (Beauvais et al. 1995; Bortner 
et al. 1997; Nobel et al. 2000).  While K+ movement into the cell is inhibited, K+ movement 
out of the cell is not and this reduction of K+ concentration is critical for apoptotic progression 
(Bortner et al. 2002; Bortner et al. 1997).  In fact, caspase activation is inhibited by intracellular 
K+ concentrations higher than 50mM (Hughes et al. 1997).  Th is lowering of K+ concentration 
drives water movement via aquaporins  ( Jablonski et al. 2004).  Once the cell has completed 
the AVD, then aquaporin activity is inhibited, ion loss ends and apoptotic progression occurs 
( Jablonski et al. 2004).  In HCC, previous work reports that if aquaporin mediated water 
movement is inhibited then apoptosis is also inhibited ( Jablonski et al. 2007).
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Figure 1.4:  AQP8 and 9 regulation and function in normal hepatocytes.  In the resting 
hepatocyte AQP9 is basolaterally expressed and AQP8 is (predominantly) cytoplasmic.  
Following enteric stimulation (e.g. glucagon; Glu) G stimulatory α (Gsα) activates adenylate 
cyclase (AC) and the resulting increase in cAMP/PKA  activity stimulates AQP8 translocation 
to the canalicular membrane.  Th is eff ectively creates a conduit from the sinusoid to the bile 
canaliculus from which water moves along the concentration gradient created by bile salt 
synthesis and secretion.
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Summary
Hepatocellular carcinoma is the 4th leading cause of cancer death.  HCC rarely arises 
spontaneously, with most cases occurring due to chronic viral hepatitis B or C infection, chronic 
ethanol abuse and/or exposure to afl atoxins.  G-proteins are important intracellular signaling 
pathways by which cells transduce extracellular, ligand mediated signaling and G-protein 
expression is altered in HCC.  One of the primary downstream eff ects of Gs-protein signaling 
is the activation of adenylate cyclase resulting in the production of cAMP.  Cyclic-AMP is a 
ubiquitous second messenger which activates PKA  by initiating the dissociation of regulatory 
subunits from PKA  resulting in the release of the catalytic subunits.
Aquaporins are a class of proteins which permit the rapid passage of water across the 
plasma membrane along concentration gradient.  Th e regulatory mechanisms that govern 
aquaporin expression and localization in the liver remains unclear.   Some aquaporins permit 
passage of small, non-polar solutes, such as glycerol.  In hepatocytes, AQP8 is initially localized 
to intracellular vesicles, while AQP9 is predominantly constitutively expressed in the basolateral 
membrane.  In response to glucagon initiated activation of cAMP/PKA  signaling, AQP8 
translocates to the canalicular membrane thereby forming a conduit for rapid water movement 
between sinusoid and bile canaliculis.  Glucagon does not aff ect AQP9 location in normal 
hepatocytes.
Apoptosis is a highly regulated process by which cells are stimulated to die in such a 
way as to minimize damage to neighboring cells.  Apoptosis is characterized by the apoptotic 
volume decrease (AVD) simultaneous with  ion concentration changes followed by caspase 
activation, cytochrome c release, DNA fragmentation and fi nally cell blebbing.  In order for the 
AVD to occur, as well as changes in ion concentration, water must rapidly effl  ux from the cell 
to maintain changes in ion concentrations.  Th is effl  ux is mediated by aquaporins.  Previous 
work in Dr. McKillop’s laboratory has reported that AQP8 and AQP9 expression in a rat model 
of HCC is signifi cantly decreased, and that these tumor cells are resistant to apoptosis.  But 
following in vitro culturing AQP8 and AQP9 expression is signifi cantly upregulated and these 
cells are once again sensitized to apoptotic stimuli.  Th ese observations led to an examination of 
the mechanisms by which this change occurs.
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Hypothesis
Changes in aquaporin-8 and aquaporin-9 expression and/or localization are critical in 
mediating inherent resistance to apoptotic progression in HCC.
Objective 1:
Examine the role of the cAMP/PKA  pathway in regulating AQP8 and AQP9 expression, 
localization and function in HCC cells in vitro.
Objective 2:
Examine the role of AQP8 and AQP9 in tumor formation and progression in vivo.
CHAPTER 2: GENERA L METHODS
2.1. Assurances
All animals were housed in a vivarium approved by the Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC) and protocols were approved by either 
the Carolinas Medical Center or University of North Carolina at Charlott e, Institutional Animal 
Care and Use Committ ee (IACUC).
2.2. Cell Culture
2.2.1.  Materials
Eagle’s minimum essential medium (EMEM), Dulbecco’s minimum essential medium 
(DMEM), Hank’s F12 medium, phosphate buff ered saline (PBS),  fetal bovine serum (FBS), 
fungizone, penicillin/streptomycin (Pen/Strep), sodium bicarbonate (7.5% w/v), trypsin-
ethylenediaminetetraacetic acid (EDTA; 0.25% w/v), and gentamicin sulfate were purchased 
from Invitrogen ( Carlsbad, CA).  Trypan blue, dimethylsulphoxide (DMSO), sucrose, sodium 
chloride (NaCl) and calcium phosphate were purchased from Sigma-Aldrich (St. Louis, MO).  
500mL fi ltering system with 0.22μm fi lter, 50mL fi ltering tubes with 0.22μm fi lter, a “Mr. 
Frosty” Cryo 1°C freezing container (Nalgene, Rochester, NY), sterile tissue culture fl asks 
(Nunc, Rochester, NY), plates and dishes (BD Falcon, Franklin Lakes, NJ) were purchased 
from VWR (West Chester, PA).  A Bright Line hemocytometer was purchased from Hausser 
Scientifi c (Horsham, PA).
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2.2.2.  Medium Preparation
Medium was prepared in a sterile, laminar fl ow hood.  Medium constituents were 
combined in the fi lter container of a 500mL fi ltering fl ask and then fi ltered through a 0.22μm 
fi lter.  H4IIE complete medium was comprised of: 433mL EMEM, 50mL FBS, 10mL sodium 
bicarbonate, 5mL Pen/Strep and 2mL fungizone (10% FBS medium--v/v).  A low serum 
variant of this medium was also used and comprised the same constituents with the expection 
of FBS—500μL was used instead of 50mL (0.1% FBS medium--v/v).  Medium was stored at 
4°C, in darkness.  When the possibility of cell culture contamination was deemed especially 
high, gentamicin (1 μL/mL medium) was added.  Freezing medium was prepared by combining 
55.5% FBS, 33.3% complete medium, 11.1% DMSO (v/v) and fi ltering this solution with a 
50mL fi ltering tube with 0.22μm fi lter.  
2.2.3.  Cell Lines
H4IIE, a rat HCC cell line derived from rat hepatomas, was purchased from ATCC 
(Manassas, VA).  H4IIE cells are tumorogenic and P0 stock of these can be replenished by 
direct injection of these cells into the fl anks of ACI rats .  Th e method for this is as follows:  
1x107H4IIE cells were injected into the rear fl anks of male ACI rats (175-225g), purchased 
from Harlan Laboratories (Indianapolis, IN).  Aft er two weeks, fl ank tumors were resected 
and mechanically disrupted (in 10% FBS v/v, EMEM medium), and cells cultured in fl asks 
using 10% FBS (v/v) H4IIE medium, until 95% confl uency.  Th e cells were recovered by 
trypsinization and frozen in liquid nitrogen as P0 stock (McKillop et al. 1998).
2.2.4.  Cell Propagation
Vials of frozen cells were removed from liquid nitrogen storage, thawed rapidly in a 37°C 
water bath, and the cell suspension transferred to a 15mL tube and centrifuged at 700 x g for 
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5 minutes at room temperature.  Th e supernatant was aspirated and the pelleted cells were 
suspended in 37°C 10% FBS H4IIE medium (v/v).  Th e cell suspension was instilled into a 
culture fl ask with 10% FBS (v/v) H4IIE medium (37°C).
2.2.5.  Cell Passage and Splitt ing
Monolayer cell cultures were removed from culture dishes using trypsin-EDTA. Briefl y, 
medium was aspirated from the culture vessel, washed once with PBS and an 10mL/175cm2 
of 0.25% trypsin-EDTA (v/v) was instilled into the dishes and incubated at 37°C, 5% CO2 for 
5 minutes. Th e cell suspension was collected into a 15mL tube and centrifuged at 700 x g for 5 
minutes at room temperature.  Th e supernatant was aspirated and the pellet was suspended in 
10% FBS medium (v/v).  Fresh, sterile culture dishes were prepared by adding an appropriate 
volume of medium to each dish and an equal amount of the cell suspension per dish.  Th e dishes 
were then stored in a 37°C, 5% CO2, 95% air, 100% humidity incubator.
2.2.6.  Cell Storage
Cells were detached using trypsin-EDTA method except, following the centrifugation the 
cell pellet was suspended in a freezing medium solution and aliquoted into cryo vials (1mL/
vial).  Vials were placed in a Mr. Frosty Cryo 1°C Freezing Container and stored in a -80°C 
freezer overnight.  Cryo vials were removed from the freezing container and stored long-term in 
liquid nitrogen.
2.3.  In Vivo Model of Hepatocellular Carcinoma
2.3.1.  Materials
Male, ACI/SegHsd (ACI) rats (175-225g) were purchased from Harlan Laboratories 
(Indianapolis, IN).  General animal care (including food, water, housing and veterinary 
care) was provided by the Department of Comparative Medicine, Cannon Research Center, 
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Carolinas Medical Center (Charlott e, NC).  H4IIE cells were acquired from one of three 
sources:  1) ATCC (Manasses, VA); 2) Cells, less than passage 3, drawn from frozen stocks; 
3) From H4IIE fl ank tumors initiated in male, ACI rats (175-225g) which were then cultured, 
expanded and then frozen in liquid nitrogen.  Surgeries to inject H4IIE cells and to resect 
tumors were carried out in operating facilities with supplies (including anesthesia)  provided by 
the Department of Comparative Medicine, Cannon Research Center, Carolinas Medical Center. 
All animal surgeries were carried out in accordance with approved IACUC protocols.
2.3.2.  Tumor Inoculation in ACI Rats
H4IIE cells (≤P3) were cultured in a T175 fl ask with 10% FBS H4IIE medium (v/v) 
to 90% confl uency.  Cells were trypsinized by incubating the fl asks with 10mL of trypsin-
EDTA at 37°C for 3-5 minutes.  5mL of EMEM was added to the fl ask and the total volume 
was transferred to a 15mL tube.  Cells were centrifuged at 800 x g for 5 minutes at 20°C.  
Supernatant was aspirated and the pellet was suspended in 10mL of 37°C PBS.  Th e cell 
suspension was centrifuged at 800 x g for 5 minutes at 20°C, the supernatant aspirated, and the 
resulting pellet suspended in 2mL of warm PBS.
Anesthesia was induced using an initial mixture of oxygen (3L/min) and isofl urane 
(5%--v/v) in an air tight Plexiglas box.  Once unconscious, the animals were removed from 
the box and abdominal fur was sheared and scrubbed with betadine.  Animals were placed 
on a heating plate (37°C) and anaesthesia was continually provided via nose cone (oxygen = 
3L/min, isofl urane = 2.5%--v/v).  A mid line incision was performed and the liver exposed.  
Approximately 1x107 cells were injected into the left  hepatic lobe and the incision closed using 
3-0 vicryl suture.  Animals were then returned to a clean cage for recovery.  Buprenorphine 
(0.03mg/Kg) was provided every 12 hours (i.p.) for 48 hours.
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Figure 2.1:  Representative images of HCC created by parenchymal H4IIE inoculation.  
Male, ACI rats (175-225g) were injected with H4IIE cells.  Approximately 14 days later, tumors 
were present in 85% of rats.  Top image shows a tumor (white arrow).  Bott om image shows a 
cross-section of the same tumor in situ in a resected lobe.
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2.3.3. Tumor Resection and Culture
Tumor resection occurred fourteen to sixteen days following surgery (Figure 2.1).  
Anesthesia was induced with isofl uorane and the liver exposed and examined for the presence 
of a tumor.  If no tumor was present the animal was closed and examined again three to fi ve 
days later.  If aft er this period no gross tumor, the animal was euthanized using Euthasol.  If a 
tumor was present the animal was euthanized by cardiac exsanguination and the liver resected.  
Th e tumor was grossly dissected and placed in 0.5% FBS H4IIE medium and homogenized 
by vortexing, shaking and vigorous pipett ing.  Th e tumor homogenate was collected and 
centrifuged at 800 x g for 4 minutes.  Th e supernatant was aspirated, the pellet of cells was 
suspended in 0.1% FBS H4IIE medium (v/v) and the suspension then evenly aliquoted into 
appropriate tissue culture vessels.
2.4.  Cell Swelling Assay
2.4.1. Materials
Mercury chloride (HgCl2) and DMSO were purchased from Sigma-Aldrich (St. Louis, 
MO).  A  model FACSCalibur fl ow cytometer was purchased from Becton Dickinson (Franklin 
Lakes, NJ).  Falcon FACS tubes were purchased from Becton Dickinson (Franklin Lakes, NJ).  
EDTA free trypsin and PBS were purchased from Invitrogen (Carlsbad, CA).
2.4.2. Methods
Cell  monolayers were harvested by EDTA free trypsin, collected, centrifuged at 700 x g 
for 5 minutes (4°C), the trypsin solution was aspirated and cells suspended in PBS (37°C).  
Th is cell suspension was centrifuged at 700 x g for 5 minutes at 4°C, the PBS aspirated and cells 
suspended in minimum medium (37°C).
To measure cell size, a series of analyzes were conducted for each sample: 1) 350μL of 
33
cell suspension was mixed with 150μL of room temperature PBS.  2) 350μL of cell suspension 
was mixed with 150μL of ultrapure water for 1 minute to adjust the osmolality to 210mOsm.  
3) 350μL of cell suspension was mixed with 10mM HgCl2 (in ultrapure water) to yield the 
indicated fi nal HgCl2 concentration for an indicated time period 4) 350μL of cell suspension 
was mixed with 10mM HgCl2 for the indicated period of time then ultrapure water was added 
to make the fi nal volume of 500μL for 1 minute. 
2.5. Reverse Transcription-Polymerase Chain Reaction
2.5.1. Materials
RNeasy kits and Shedder kits were purchased from Qiagen (Valencia, CA).  Isopropyl 
alcohol, ethyl alcohol, glycerol, sodium acetate, 100x Tris(hydroxymethyl)aminomethane 
(Tris)–Ethylenediaminetetraacetic acid (EDTA) solution, ethidium bromide solution and 
diethyl pyrocarbonate (DEPC) were purchased from Sigma-Aldrich (St. Louis, MO).  Model 
5402, model 5415 centrifuges  and model 5331 thermocycler were purchased from Eppendorf 
(Hauppauge, NY).  Primers against AQP8, 9 and β-actin were purchased from IDT (Coralville, 
IA) (Table 2.2).  Reverse transcription kits and GoTaq Green polymerase chain reaction (PCR) 
kits were purchased from Promega (Madison, WI).  Agarose, power packs, gel boxes and DNA 
loading dye were purchased from Biorad (Hercules, CA).  10x Tris-Boric Acid-EDTA (TBE) 
buff er was purchased from USB (Cleveland, OH).  100 b.p. DNA ladder was purchased from 
New England Biolabs (Ipswich, MA).  Glycogen was purchased from Fermentas (Glen Burnie, 
MD).  Digital camera, camera box, transilluminator, and photo acquisition soft ware were 
purchased from Eastman-Kodak (Rochester, NY).
2.5.2.  RNA Isolation
RNA was isolated, as per manufacturer’s instructions, using RNeasy® kits.  Briefl y, cells 
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Gene Sense (5'-3') Antisense (5'-3') Product 
Length 
(bp)
AQP8 TCATT GCTACCTT GGGGAAC GCTCCTGCTCCTGGACTATG 222
AQP9 CGCCAGGTGCCTT TGTAG GAAGACCTCAAACCCCCATC 239
β-Actin GAGCTATGAGCTGCCTGACG GGATGTCAACGTCACACTT C 150
Table 2.2:  Primer sequences against AQP8, 9 and β-actin.  Primer sequnces were selected 
using IDTDNA's Primer Quest soft ware.  All primer sequences were  BLAST analyzed to ensure 
gene specifi city.
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were collected directly using RLT buff er.  Th is solution was then loaded into Shedder® spin 
columns and the columns centrifuged at 16,000 x g for 1 minute.  One volume of 70% EtOH 
(v/v, in DEPC water) was added to the fl ow-through and transferred to an RNeasy® column.  
Columns were centrifuged at 16,000 x g for 15 seconds.  Washed three times (16,000 x g: 15 
seconds, 15 seconds, and 2 minutes) with proprietary buff ers provided with the kit.  A fi nal spin 
(16,000 x g, 1 minute) was performed for drying purposes with a fresh collection tube.  Th e 
last spin (16,000 x g) was performed with 35-50μL of nuclease free water.  Typical yields were 
between 250-600ng RNA/μL depending on the number of cells collected (e.g. a confl uent well 
of a 6-well plate typically yielded 250-350ng/μL in 35μL. 
2.5.3. Reverse Transcription
Reverse transcription was performed, as per manufacturer’s instructions using the Promega 
ImProm-II® RT system.  Briefl y,  0.5μL of random hexomers and 1μg RNA template were added 
to a 0.5mL PCR tube and nuclease-free water was added to adjust the fi nal volume up 5μL.  Th is 
mixture was incubated at 70°C for 5 minutes and the tubes placed on ice while a master mix was 
prepared.  A master mix was made containing the following constituents (per reaction):  4.5μL 
nuclease free water, 4.0μL ImProm-II 5x reaction buff er, 4.0μL 25mM MgCl2, 1.0μL dNTP mix, 
0.5μL RNase inhibitor (10 units) and 1.0μL ImProm-II Reverse Transcriptase.  Th e total master 
mix volume per reaction was 15μL and the total reaction volume was 20μL.  Aft er preparation 
of the master mix, it was aliquoted to a reaction tube.  Tubes were transferred to a thermocycler 
and the following program was used: 95°C (2:00 minutes), 95°C (0:30 seconds), 50°C (0:30 
minutes), 72°C (0:30 seconds)—28 cycles of the 30 seconds steps—72°C (5:00 minutes).  
Following, 2μL of 3M sodium acetate, 1μL of glycogen and 300μL of isopropyl alcohol was 
added to each reaction tube. Tubes were incubated at -20°C overnight.  Next, tubes were 
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centrifuged at 16,000 x g (10 minutes, 4°C).  Th e supernatant was removed and 500μL of 70% 
EtOH was added to each tube.  Th e tubes were very briefl y vortexed and centrifuged at 16,000 
x g for 10 minutes at 4°C.  Th e alcohol was removed using a pipett e and the tubes were left  to air 
dry for 10 minutes.  Finally, 30μL of 1x tris-EDTA was added to each reaction tube and DNA 
concentration was measured using a NanoDrop. 
2.5.4. Polymerase Chain Reaction
A master mix containing (per reaction): 12.5μL Green GoTaq, 1μL forward primer, 1μL 
reverse primer, and 8.5μL nuclease free water was prepared.  A 1% agarose (w/v) containing 
10μL/100mL of ethidium bromide (EtBr) was prepared.  5μL of DNA loading buff er was added 
to each tube and mixed by pipett ing.  20μL from each tube was then instilled into each well of 
the agarose gel and the gel was resolved at 90mA until the dye front reached the end of the gel.  
At this point, the gel was transferred to a transilluminator and a digital image was captured.
2.6. Cell Lysate Preparation
2.6.1. Materials
β-mercaptoethanol and sodium deoxycholate were purchased from Sigma-Aldrich (St. 
Louis, MO).  Cell scrapers were purchased from Becton Dickinson (Franklin Lakes, NJ).  
Laemmli buff er was purchased from Biorad (Hercules, CA).  Tris buff ered saline (TBS) was 
purchased from USB (CLEVELAND, OH).  6, 12 and 24-well plates, D100 dishes, T-75, T-175 
and T-225 fl asks were all purchased from Becton Dickinson (Franklin Lakes, NJ).
2.6.2. Methods
Laemmli collection buff er was prepared by adding 50μL of β-mercaptoethanol to every 
950μL of Laemmli buff er. Cell collection was performed by aspirating medium, washing cells 
in ice cold PBS, and cell lysis using Laemmli collection buff er.  Th e plates/dishes were then 
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scraped to ensure maximum protein yield.  Samples were boiled for 10 minutes and stored at 
-80°C prior to analysis.
2.7.  Western Blot
2.7.1. Materials
Methanol, glycine, ammonium persulfate (APS), N,N,N`,N`-Tetramethylethylenediamine 
(TEMED), Tween-20 and sodium dodecyl sulfate (SDS) were purchased from Sigma-Aldrich 
(St. Louis, MO).  Filter paper (Fisher brand, P8 grade) Pierce ECL kit, Pierce X-ray fi lm and 
a Nutator were purchased from Fisher (Waltham, MA).  Nitrocellulose paper was purchased 
from GE-Amersham (Piscataway, NJ).  Tris base, transfer sponges, 30% acrylamide/0.8% 
bisacrylamide solution (also referred to as “acrylamide mix”), non-fat dry milk and a Mini-
Protean Western system for gel running and transfer were purchased from Biorad (Hercules, 
CA).  See-Blue Plus 2 protein ladder standard was purchased from Invitrogen (Carlsbad, CA).  
A Nanodrop 1000 and a Pierce 660nm protein assay kit, with detergent compatibility reagent 
(Pierce catalog numbers: 22662, 22663), were purchased  from Fisher (Waltham, MA).
2.7.2. Sample Protein Concentration Measurement
Sample protein concentration was measured using a 660nm protein assay purchased 
from Fisher (Waltham, MA).  Th e assay was performed following the microplate procedure, 
except that measurements were conducted by taking 2μL from each well and measuring protein 
concentration using the Nanodrop.  Briefl y, protein concentration was measured by adding 
150μL of assay reagent to each well and then adding 10μL of sample.   Samples were mixed by 
covering the plate and placing it on a orbital shaker set to ≈ 70 RPM for 1 minute.  Th e plate was 
then incubated at room temperature (25°C) for 5 minutes.  Protein concentration of each well 
was then measured using the Nanodrop.  A standard curve was generated per the manufacturer’s 
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instructions.
2.7.3. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis Gels (SDS-PAGE)
Western blot gels were prepared using glass plates and the Mini-Protean 3 multi-casting 
chamber, were purchased from Biorad (Hercules, CA).  15% resolving gels were prepared as 
follows (per 50mL): 11.5mL ultrapure H2O, 25.0mL 30% acrylamide mix, 12.5mL 1.5M Tris 
(pH 8.8), 0.5mL 10% SDS(v/v), 0.5mL 10%APS(v/v) and 0.02mL TEMED (Sambrook et al. 
2001).  5% stacking gels were prepared as follows (per 10mL): 6.8mL ultrapure H2O, 1.7mL 
30% acrylamide mix, 1.25mL 1.0M Tris (pH 6.8), 0.1mL 10% SDS(v/v), 0.1mL 10%APS(v/v) 
and 0.01mL TEMED (Sambrook et al. 2001).  Approximately 10mL of the resolving gel 
solution and 5mL of the stacking gel solution was used per gel.
2.7.4. Protein Resolution and Transfer
Protein samples and protein ladder were loaded onto the gel.  A 50 volt (V) diff erence 
was applied until the protein sample had reached the resolving gel and then the voltage was 
increased to 125V until the die front reached the bott om of the gel.  Th e gel was placed on 
nitrocellulose membrane between 4 sheets of fi lter paper (on each side) and sponges.  A 300mA 
current was applied for 70 minutes.
2.7.5. Blocking, Antibody Probe and Developing
Following transfer, membranes were incubated in blocking buff er (5% (w/v) non-fat dry 
milk in 1x TBS), in boxes, at room temperature, on a rocking platform for 1 hour.  Membranes 
were incubated, in bags containing antibody diluted in blocking buff er on a Nutator at 4°C 
overnight.  Membranes were washed three times (10 minutes / wash) in 1x TBS/0.2% 
Tween-20 (v/v) and placed in bags containing a 1:5000 dilution of secondary antibody in 
blocking buff er, at room temperature, on a Nutator, for 1 hour.  Next, the membranes were 
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washed three times (5 minutes / wash) in 1x TBS/0.2% Tween-20 (v/v), followed by  three 
washes (3 minutes / wash) in 1x TBS.  Lastly, membranes are developed using ECL following 
manufacturer’s instructions and band intensity was measured by densitometry.  Membranes 
were then stripped and then reprobed with an antibody specifi c against β-actin (house keeping 
protein). 
2.8.  Immunohistochemistry & Immunocytochemistry
2.8.1.  Materials
95% and 100% ethanol were purchased from Pharmco Products (Brookfi eld CT).  ABC 
staining kit and goat normal serum were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA).  Hematoxylin(Mayer’s Modifi ed) and 10mM citrate buff er (pH 6.0) was purchased 
from Poly Scientifi c (Bay Shore, NY).  Eosin was purchased from Surgipath (Richmand, IL).  
PBS, hydrogen peroxide, ammonium hydroxide, collagen (type I) and Accustain 10% neutral 
buff ered formalin solution was purchased from Sigma-Aldrich (St. Louis, MO).  Xylene and 
glass microscope slides were purchased from Cardinal Health (McGaw Park, IL).  Cover 
glass and Permount were purchased from Fisher (Waltham, MA).  A steamer was purchased 
from Black & Decker (Towson, MD).  Glass chamber slides and plastic chamber slides were 
purchased from Nunc (Rochester, NY).  A tissue processor (model ATP1) was purchased from 
Triangle Biomedical Sciences (Durham, NC).
2.8.2.  Tissue Preparation
Hepatic tissues were collected and stored in 10% neutral buff ered formalin for at least 24 
hours (room temperature).  Samples were then transferred to an appropriate tissue mold and 
are dehydrated by a series of graded ethanol washes and processed into paraffi  n blocks by a 
series of xylene washes followed by paraffi  n (these steps were automatically performed by a 
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tissue processor machine).  Th e resulting embedded tissue block was cut into 4μm sections and 
each slice was adhered to a positively charged glass slides.
2.8.3.  Immunohistochemical / Immunocytochemical Analysis
To prepare tissue samples for analysis, slides were incubated at 60°C for 20 minutes.  
Next slides were deparaff anized and rehydrated by three washes in xylene (3 minutes / wash), 
followed by two washes in 100% EtOH (3 minutes / wash), followed by two washes in 95% 
EtOH (3 minutes / wash), followed by one wash 70% EtOH (3 minutes), lastly, slides are 
placed in distilled water until the slides run clear.
A Coplin jar was fi lled with 10mM citrate buff er (pH 6.0) and the slides were placed in 
the jar.  Next the Coplin jar was placed in the steamer for 40 minutes.  Following, the jar was 
removed from the steamer and allowed to cool to room temperature for 20 minutes.  Next, the 
slides were rinsed in two changes of deionized H2O and one wash in 1x PBS.
Slides were incubated in 0.5% hydrogen peroxide (diluted in PBS) in a humidifi ed chamber 
for 7 minutes.  Th en washed in 1x PBS (x2, 5 minutes / wash).  Th en slides processed per 
manufacturer’s instructions provided with ABC staining kit (Cat# sc-2018. Note: all subsequent 
steps were carried out in a humidifi ed histology chamber).  Briefl y, slides were blocked in 1.5% 
goat serum for 1 hour.  Th en slides were incubated in primary antibody, diluted in blocking 
serum overnight at 4°C.  Next, the slides were incubated in biotinylated secondary antibody 
for 30 minutes, followed by 3, 5 minute washes in 1x PBS.  Th en, slides were incubated for 30 
minutes in an a diluted enzyme solution (i.e. the AB enzyme), followed by 3, 5 minute washes 
in 1x PBS.  Next, slides were incubated in 3 drops of peroxidase substrate until desired staining 
was achieved.  Lastly, slides were counter stained with Gill’s formulation #2 hematoxylin for 5 
seconds, washed in several changes of deionized H2O, followed by mounting of a glass coverslip.
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2.8.4.  Slide Scoring
3 representative shots were blind scored by at least 3 independent scorers.  Th e mean of the 
three scores was used as the value for analysis.
2.9.  Antibodies
Polyclonal AQP8 and AQP9 antibodies were generously provided by Dr. Francis Hughes 
Jr. (McConnell et al. 2002).  Monoclonal AQP8 and AQP9 antibodies, β-actin monoclonal 
antibody, normal goat serum, anti-rabbit biotinylated secondary antibody and anti-goat HRP 
conjugated secondary antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA).
2.10. Densitometry & Statistics
All densitometry was performed using ImageJ (Rasband 1997-2009).  All statistics 
were calculated and charts created using SAS JMP8.0.2 (Cary, NC).  p < 0.05 was considered 
signifi cant.
CHAPTER 3: EFFECT OF CYCLIC-AMP OR INTERLEUKIN-6 ON 
AQUAPORIN 8 AND 9 EXPRESSION AND LOCALIZATION IN 
HEPATOCELLULAR CARCINOMA IN VITRO.
3.1. Introduction
Aquaporins are a conserved class of proteins which play a central role in water movement 
across cell membranes (Gonen et al. 2006).  Further, certain aquaporins permit the movement 
of neutral solutes (Gonen et al. 2006).  In the liver, there are currently three identifi ed 
aquaporins, Aquaporin 0 (AQP0), Aquaporin 8 (AQP8), and Aquaporin 9 (AQP9).  AQP0 
is intracellular and there have been no reports of stimuli which initiate AQP0 translocation in 
the liver (Masyuk et al. 2006).  AQP 8 is the most abundant aquaporin in hepatocytes and like 
AQP0 is primarily intracellular (Masyuk et al. 2006).  However in response to glucagon, in a 
cyclic-adenosine monophosphate (cAMP) dependent manner,  AQP8 expression increases and 
translocation occurs from intracellular vesicles to the bile canalicular membrane (Garcia et al. 
2001; Tani et al. 2001).  In contrast, AQP9 is predominately found on the basolateral membrane 
of normal hepatocytes but currently no published study has reported AQP9 expression or 
localization to be glucagon/cAMP dependent (Masyuk et al. 2006).  Work from the McKillop 
laboratory has reported that AQP8 and 9 expression drops to barely detectable levels in freshly 
isolated HCC tumors but is expressed strongly twenty-four hours aft er culture ( Jablonski et 
al. 2007).  Further, freshly isolated tumors, which were cultured and exposed to transforming 
growth factor β (a pro-apoptotic agent) immediatly aft er in vitor culture showed similar levels of 
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caspase 3 activation to serum starved cells ( Jablonski et al. 2007).  Th ough twenty-four hours 
aft er tumors were cultured, these cells had signifi cantly higher caspase 3 activation in response 
to TGFβ ( Jablonski et al. 2007).  Our article presented no data on the mechanism by which 
AQP8 and 9 expression was decreased in HCC.  Given the partial mechanism presented for 
normal hepatocytes cAMP represents a reasonable choice.
Cyclic-adenosine monophosphate is a ubiquitous, intracellular, second-messager molecule 
which plays a critical role in the intracellular transduction of extracellular signals following 
activation of membrane recptors (Pavio et al. 2005; Rall et al. 1958; Zhang et al. 2005).  
Following production by adenylate cyclase, cAMP binds to the regulatory subunits of PKA , 
causing these regulatory subunits to dissociate, and the activation of PKA  (Cho-Chung et al. 
2002).  Activated PKA  is a transcription factor which binds to the cAMP response element 
(CRE) thereby activating cAMP dependent gene transcription (Cho-Chung et al. 2002).  It has 
been reported that HCC is characterized by reduced adenylate cyclase activity (Schmidt et al. 
1997).  Cyclic-AMP has also been reported to act as an anti-mitotic agent in HCC (Kovach et 
al. 2006; Schmidt et al. 1999).  While a partial mechanism for the role of cAMP in AQP8 and 9 
expression and localization has been demonstrated in normal hepatocytes (Garcia et al. 2001), 
it is currently unknown whether cAMP plays the same role in HCC.  Th ese studies seek to 
determine the role of cAMP on AQP8 and 9 expression and localization in vitro.
Interleukin-6 (IL-6) is a 21-28kDa cytokine which is involved in liver regeneration 
(Koniaris et al. 2003), plays a role it T-cell diff erentiation(Diehl et al. 2002), T-cell growth 
(Houssiau et al. 1992), is mitogenic in some cells (Culig et al. 2005) and growth inhibitory 
in others (Moran et al. 2005). Interleukin-6 signal activation is initiated by the formation of a 
binary complex of IL-6 and the nonsignaling IL-6α receptor (IL-6Rα) (Boulanger et al. 2003) 
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(Figure 3.1).  Th is complex interacts with a gp130 homodimer to form a competent signaling 
complex (Boulanger et al. 2003).  Th e complete signaling complex causes the activation of 
Janus kinase ( JAK) and gp130. Inactive JAK constitutively binds to gp130 (Akira 1999). JAK 
is then activated which in turn, most commonly, activates signal transducer and activator of 
transcription 3(STAT3) which then forms a homodimer STAT3 (Akira 1999).  Th is STAT3-
STAT3 dimer is a competent transcription factor and translocates to the nucleus where it binds 
to, among other sites, CRE sites on DNA.  In the liver, previous work has reported a signifi cant 
role for IL-6 in liver regeneration and hepatocellular carcinoma progression (Moran et al. 2005; 
Zimmers et al. 2003; Fausto 2000).  Previous work in our lab has reported that IL-6 inhibits 
H4IIE cell growth (Moran et al. 2005).
Along with the cAMP response element binding protein (CREB) sites on AQP8, the 
promoter regions of AQP8 and 9 contain many other promoter binding sites (Figure 3.2).  Of 
particular interest are CCAAT/enhancer binding protein (C/EBP) sites, AP-1 sites on AQP9 
and NF-κB sites.  C/EBP both regulates and is responsive to cAMP (Wilson et al. 2002).  Also, 
downstream activation of the IL-6 pathway, particularly STAT3, is known to activate genes with 
C/EBP sites (Alonzi et al. 2001; Cantwell et al. 1998).
  Because of the role IL-6 plays in hepatocyte proliferation during liver regeneration and 
that IL-6 inhibits growth in this model of HCC, and because of the presence of IL-6 activated 
promoter regions on both AQP8 and 9 promoters, I examined whether IL-6 causes AQP8 or 
9 expression or location changes in H4IIE cells in vitro.  Also, I examined the functional role of 
IL-6 on water movement. 
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Figure 3.1:  IL-6 JAK-STAT Pathway.  Binding of IL-6 to IL-6Rα recuits gp130 forming 
a competent signaling complex.  Janus kinase ( JAK) is then recruited and phosphorylated 
which phosphorylates gp130.  Activated gp130 recruits and activates STAT which then is 
phosphorylated (p-STAT).  p-STAT forming a dimer that translocates to the nucleus.  Amongst 
the genes stimulated by p-STAT is supressor of cytokine signaling (SOCS).  SOCS inhibits IL-6 
signaling by binding to JAK and the phosphorylated tyrosines on gp130 to prevent further signal 
propagation. (Carbia-Nagashima et al. 2004).
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Figure 3.2:  Partial promoter map for AQP8 and 9.  Promoter analysis indicates a number of 
transcription factor binding sequences.  Th e numbers indicate the distance (in base pairs) from 
the start site (black arrow).  Th e hollow arrow indicates the direction of transcription.   Th e 
promoters of interest in this study are shown.
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3.2. Materials & Methods
3.2.1. Cell Line
H4IIE cells were used throughout this chapter and were stored and cultured as described 
in Chapter 2.2.4.
3.2.2. Protein & Pharmacological Agents
8-Bromoadenosine 3′,5′-cyclic monophosphate (8-BrcAMP) and cis-N-(2-
Phenylcyclopentyl)-azacyclotridec-1-en-2-amine hydrochloride (MDL) were purchased 
from Sigma-Aldrich (St. Louis, MO).  N-[2-((p-Bromocinnamyl)amino)ethyl]-5-
isoquinolinesulfonamide, 2HCl (H89) was purchased from Calbiochem-EMD (Gibbstown, 
NJ). Recombinant rat interleukin-6 (rrIL-6) was purchased from Invitrogen (Carlsbad, CA).
3.2.3. Sample Generation for Western blot and RT-PCR analyses
H4IIE cells were grown in 6-well plates, using 10% FBS (v/v) medium until ~90% 
confl uence.  Medium was then aspirated and replaced with 0.1% FBS (v/v) medium for 24 
hours.  At this point, the medium was aspirated and replaced with 0.1% FBS (v/v) medium 
alone or medium plus 10μM 8-BrcAMP, 10μM H89 or 10μM MDL for 1 hour.  After the hour, 
10μM 8-BrcAMP was added to the medium containing H89 or MDL.
Experiments involving IL-6 were performed similarily to cAMP experiments.  H4IIE cells 
were  grown in 10% FBS (v/v) medium until ~90% confl uence.  Medium was then aspirated 
and replaced with 0.1% FBS (v/v) medium containing IL-6 (concentration range: 0ng/mL — 
100ng/mL).
For Western blot analysis, cells were collected in Laemmli buff er with 5% 
β-mercaptoethanol (v/v), boiled for 10 minutes and stored at -80°C.  For RT-PCR, cells were 
collected in Qiagen stock RLT buff er and stored at -80°C (Chapter 2.5.2).
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3.2.4. Membrane/Cytoplasm Sample Preparation
3.2.4.1. Materials
Beckman-Coulter Ultracentrifuge TL and 1.5mL ultracentrifuge tubes were purchased 
from Beckman Coulter (Brea, CA).  Complete protease inhibitor (CPI) tablets were 
purchased from Roche (Basel, Switzerland). Tris(hydroxymethyl)aminomethane (Tris), 
Ethylenediaminetetraacetic acid (EDTA) and β-mercaptoethanol were purchased from Sigma-
Aldrich (St. Louis, MO).  Phosphate buff ered saline (PBS) was purchased from Invitrogen 
(Carlsbad, CA).  Laemmli buff er was purchased from Biorad (Hercules, CA).  20x Tris buff ered 
saline (TBS) was purchased from USB (Cleveland, OH).
3.2.4.2. Method
Stock membrane buff er consisted of 50mM Tris and 1mM EDTA.  One tablet of CPI 
was dissolved in 10mL of membrane buff er stock immediately before cell collection (referred 
to as “membrane buff er”).    Cells were propagated and treated in D100 dishes.  Medium was 
aspirated and cells were washed with ice cold PBS.  400μL of membrane buff er was added 
to each dish and cells were scraped off  of the dish and collected.  Samples were stored at 
-80°C for at least 24 hours to lyse the cells.  Next, samples were thawed in ice, vortexed for 
at least 1 minute, and spun at 90,000 x g for 1 hour at 4°C.  Th e supernatant was collected as 
the cytoplasmic fraction and the pellet was suspended in 100μL of Laemmli buff er (with 5% 
β-mercaptoethanol (v/v)) and collected as the membrane fraction.
3.2.5. Western Blot
Western blots were performed as described in Chapter 2.7. AQP8 and AQP9 antibodies 
were provided by Dr. Francis Hughes. β-actin antibodies and goat secondary antibodies were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).  Rabbit secondary antibody was 
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purchased from Jackson ImmunoResearch (West Grove, PA).  Aquaporin antibodies were 
diluted 1:1000 in 5% non-fat dry milk (NFDM) diluted in 1x TBS.  β-actin antibodies were 
diluted 1:500 in 5% NFDM (diluted in 1x TBS).  All secondary antibodies were diluted 1:5000 
in 5% NFDM (diluted in 1x TBS).
3.2.6. Immunohistochemistry & Immunocytochemistry
Immunohistochemistry and immunocytochemistry were performed as described in 
Chapter 2.8.
3.2.7. Statistical Analysis
Group wide stastistical analysis was performed using a one-way, Type I ANOVA model 
(both single variable data and pair-match data).  Pair-wise comparisons were made using 
Student’s t-Test or Tukey-Kramer HSD analysis.  All analyses were performed with SAS JMP 
8.0.2 (Cary, NC).  p < 0.05 was considered signifi cant.
3.3. Results
3.3.1. Analysis of cAMP/PKA  Signaling in Cultured H4IIE Cells.
3.3.1.1. Cyclic-AMP/PKA  signaling does not signifi cantly aff ect AQP8 or 9 mRNA or 
protein  expression in vitro.
Th e mRNA and protein message expression was measured in H4IIE cells.  Analysis by RT-
PCR, using primers specifi c for AQP8, showed no siginifi cant diff erence in response to cAMP/
PKA  pathway modulation (Figure 3.3a: p = 0.168).  Similarly, using primers specifi c for AQP9, 
no signifi cant diff erences were detected (Figure 3.3a).  Western blot analysis, using antibodies 
specifi c for AQP8, demonstrated no signifi cant diff erence in response to cAMP/PKA  pathway 
modulation (Figure 3.3b).  Using antibodies specifi c for AQP9 also demonstrated no signifi cant 
diff erence in response to cAMP/PKA  pathway modulation (Figure 3.3b).
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3.3.1.2. Cyclic-AMP/PKA  signaling does not signifi cantly aff ect AQP8 or 9 localization.
Aquaporin 8 and 9 localization was measured by isolation of total membrane and 
cytoplasmic fractions from cultured H4IIE cells. Western blot analysis was performed using 
membrane or cytoplasmic fractions.  While ANOVA analysis of AQP9 membrane localization 
data did indicate a signifi cant diff erence overall due to cAMP pathway modulation, Tukey-
Kramer HSD analysis of pair-wise combination indicated no siginifi cant diff erence between any 
given pair of cAMP/PKA  pathway modulators (Figure 3.4a).  Analysis of AQP8 localization 
to the plasma membrane was not signifi cant (Figure 3.4a).  Th ere was no signifi cant diff erence 
in AQP8/9 localization to the cytoplasmic compartment in response to cAMP pathway 
modulation (Figure 3.4b).
3.3.2. Analysis of cAMP/PKA  Signaling in Freshly Isolated Tumors.
3.3.2.1. AQP8 and 9 protein expression is unaff ected by 8-Br-cAMP in ex vivo H4IIE cells.
Male, ACI rats (175-225g) were inoculated with H4IIE cells (Chapter 2.3).  Tumors were 
then resected and cultured immediately in the presence of cAMP/PKA  modulating agents for 
48 hours.  Th e medium was replaced with identically treated medium at 24 hours.  Western 
blot analysis indicated no siginifi cant diff erence in AQP8 expression (Figure 3.5a) or in AQP9 
expression (Figure 3.5b).
3.3.3. Analysis of AQP8 and 9 Responses to IL-6 Signaling in Cultured H4IIE Cells.
3.3.3.1. Recombinate Interleukin-6 has no signifi cant aff ect on AQP8 or 9 mRNA or protein 
expression.
Cultured H4IIE cells were exposed to fi ve concentrations of rrIL-6 (0ng/mL – 100ng/
mL) for twenty-four hours and then collected.  RT-PCR analysis for AQP8 demonstrated no 
signifi cant diff erence in response to rrIL-6 (Figure 3.6a).  Probing for AQP9 also indicated no 
signifi cant diff erence in mRNA expression, in response to rrIL-6 (Figure 3.6a).  Also, Western 
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Actin
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Figure 3.3:  Eff ect of cAMP pathway modulation on AQP8/9 mRNA and protein 
expression.  Cultured H4IIE cells were exposed to a cell permeable cAMP analogue (8-Bromo-
cAMP [cAMP]; 10μM), a protein kinase-A (PKA) inhibitor (H89; 10μM) and an adenylate 
cyclase (AC) inhibitor (MDL; 10μM), 10μM H89 pretreatment (1hr) followed by 10μM cAMP 
(H+C) or 10μM MDL pretreatment (1hr) followed by 10μM cAMP (M+C).  a) Representative 
gels from RT-PCR performed on total RNA isolated from H4IIE cells exposed to cAMP +/- 
pathway modulators and probed with primers against AQP8 or AQP9.  b) Representative 
Western blot analyses preformed using whole cell lysates from H4IIE cells exposed to cAMP +/- 
pathway modulators and probed with antibodies against AQP8 or AQP9.  β-actin expression was 
used as an indicator of equal RNA/protein loading and used to normalized AQP8/9 expression 
densitometry.
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Figure 3.4:  Eff ect of cAMP pathway modulation on AQP8/9 expression in membrane 
and cytoplasmic fractions.  Cultured H4IIE cells were exposed to a cell permeable cAMP 
analogue (8-Bromo-cAMP [cAMP]; 10μM), a protein kinase-A (PKA) inhibitor (H89; 
10μM) and an adenylate cyclase (AC) inhibitor (MDL; 10μM), 10μM H89 pretreatment 
(1hr) followed by 10μM cAMP (H+C) or 10μM MDL pretreatment (1hr) followed by 10μM 
cAMP (M+C). a) Representative Western blot analyses preformed using membrane fractions 
from H4IIE cells exposed to cAMP +/- pathway modulators and probed with antibodies 
against AQP8 or AQP9.  Pair-wise densitometric analysis indicates no signifi cant diff erence 
for either AQP8 or 9.  b) Representative Western blot analyses preformed using cytoplasmic 
fractions from H4IIE cells exposed to cAMP +/- pathway modulators and probed with 
antibodies against AQP8 or AQP9.  Pair-wise densitometric analysis indicates no signifi cant 
diff erence for either AQP8 or 9.  β-actin expression was used as an indicator of equal RNA/
protein loading and used to normalized AQP8/9 expression densitometry.
a)
b)
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blot analysis indicated no siginifi cant diff erence in AQP8 expression in response to rrIL-6 
(Figure 3.6b).  Lastly, there was also no signifi cant diff erence in AQP9 protein expression in 
response to rrIL-6 (Figure 3.6b).
3.3.3.2. Recombinate Interleukin-6 signifi cantly aff ects AQP8 localization to the plasma 
membrane.
Membrane preparations of H4IIE cells exposed to fi ve diff erent concentrations of rrIL-6 
(0ng/mL – 100ng/mL), over twenty-four hours, resulted in signifi cant decrease in localization 
of AQP8 to the plasma membrane(Figure 3.7a).  Further, analysis of the data using Dunnett ’s 
method (0ng/mL rrIL-6 was used as control) showed a signifi cant diff erence between 0ng/
mL rrIL-6 and 10ng/mL rrIL-6 (p = 0.038). However, Western blot analysis demonstrated no 
signifi cant diff erence in AQP9 membrane localization (Figure 3.7a).  Also, Western blot analysis 
of cytoplasmic fractions from rrIL-6 treated, H4IIE cells indicated no signifi cant diff erence 
AQP8 localization to the cytoplasm (Figure 3.7b) or in AQP9 localization to the cytoplasm 
(Figure 3.7b).
3.3.3.3. Functional Analysis of cultured H4IIE cells in Response to cAMP/PKA  agents and 
rrIL-6.
3.3.3.4. cAMP pathway modulation aff ects cell swelling in cultured H4IIE cells.
Cultured H4IIE cells were exposed to cAMP pathway modulators for 24 hours and 
were then collected by trypsinization, then a cell swelling assay was performed.  Analysis by 
paired-data ANOVA showed signifi cant diff erences between cells in an isotonic environment 
and cells under osmotic stress (Figure 3.8: p < 0.0001).  Further, analysis of the diff erences 
between isotonic and osmotic challenge conditions, across treatment groups, showed a 
signifi cant diff erence within groups (Figure 3.8: p = 0.02).  Lastly, analysis of H4IIE cells 
exposed to osmotic challenge showed a signifi cant diff erence in cell swelling depending on the 
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Figure 3.5:  Eff ect of cAMP pathway modulation on AQP8 and 9 expression in freshly 
isolated tumor cells. Freshly isolated H4IIE tumors were exposed to a cell permeable cAMP 
analogue (8-Bromo-cAMP [cAMP]; 10μM), a protein kinase-A (PKA) inhibitor (H89; 10μM) 
and an adenylate cyclase (AC) inhibitor (MDL; 10μM), 10μM H89 pretreatment (1hr) followed 
by 10μM cAMP (H+C) or 10μM MDL pretreatment (1hr) followed by 10μM cAMP (M+C).  
Western blot analysis was performed on whole cell lysates using antibodies against, a) AQP8 or 
b) AQP9.  β-actin expression was used as an indicator of equal RNA/protein loading and used to 
normalized AQP8/9 expression densitometry.
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Figure 3.6:  Eff ect of IL-6 on AQP8/9 mRNA and protein expression in H4IIE cells.  
Cultured H4IIE cells were exposed to recombinant rat IL-6 (rrIL-6; 0.1 -100ng/mL) for 24 
hours.  a) Representative gels from RT-PCR performed on total RNA isolated from H4IIE cells 
exposed to rrIL-6 and probed with primers against AQP8 or AQP9.  b) Representative Western 
blot analyses preformed using whole cell lysates from H4IIE cells exposed to rrIL-6 and probed 
with antibodies against AQP8 or AQP9.  β-actin expression was used as an indicator of equal 
RNA/protein loading and used to normalized AQP8/9 expression densitometry.
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Figure 3.7:  Eff ect of IL-6 signaling on AQP8/9 membrane and cytoplasmic localization. 
Cultured H4IIE cells were exposed to recombinant rat IL-6 (rrIL-6; 0.1-100ng/mL) for 24 
hours.  a) Representative Western blot analyses performed using membrane fractions from 
H4IIE cells exposed rrIL-6 and probed with antibodies against AQP8 or AQP9.  Densitometric 
analysis indicated a signifi cant diff erence in AQP8 membrane localization in response to rrIL-6.  
b) Representative Western blot analyses performed using cytoplasmic fractions from H4IIE cells 
exposed to rrIL-6 and probed with antibodies against AQP8 or AQP9.  β-actin expression was 
used to normalize AQP8/9 expression densitometry.
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pharmacological agent used (Figure 3.8: p = 0.004).
3.3.3.5. rrIL-6 does not aff ect cell swelling in cultured H4IIE cells.
H4IIE cells were exposed to rrIL-6 and a cell swelling assay was performed.  Analysis by 
paired-data ANOVA showed signifi cant diff erences between cells in an isotonic environment 
and cells under osmotic stress (Figure 3.9: p < 0.0001).  However,  analysis of the diff erences 
between isotonic and osmotic conditions, across treatment groups, showed no signifi cant 
diff erence (Figure 3.9).
3.4. Discussion
Th ese studies demonstrate that cAMP/PKA  pathway modulation signifi cantly aff ects water 
movement.  However, neither cAMP nor IL-6 signifi cantly aff ected membrane or cytoplasmic 
localization of AQP8 or 9.  Taken together the data from these studies paint a picture in stark 
contrast to the role of cAMP, AQP8 and 9 in normal hepatocytes.
cAMP is a ubiquitous second messenger conserved across a broad array of organisms 
(Cooper 2003).  Previous work by other investigators demonstrate that AQP8 localization 
is regulated by glucagon signaling and that the mechanism for this eff ect is partially cAMP 
dependent in normal rat hepatocytes (Garcia et al. 2001; Gradilone et al. 2003).  Cyclic-AMP 
has also been reported to play a role in proliferation of human HCC cell lines (Schmidt et 
al. 1999).  Th e aim of these studies was to examine the role of cAMP in the expression and 
localization of AQP8 and 9 in a rat tumorogenic cell line, H4IIE.  Previous work by other 
investigators report that AQP8 has increased expression and translocates to the canalicular 
membrane in response to 8-Bromo-cAMP exposure, in normal rat hepatocytes (Huebert et 
al. 2002; Soria et al. 2009).  In contrast, the current studies show no signifi cant role for cAMP 
in the expression of AQP8/9 mRNA or protein in H4IIE cells.  Previous work showed no 
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Figure 3.8:  Eff ect of cAMP pathway modulation on cultured H4IIE cell responsiveness 
to osmotic challenge.  Cultured H4IIE cells were exposed to a cell permeable cAMP analogue 
(8-Bromo-cAMP [cAMP]; 10μM), a protein kinase-A (PKA) inhibitor (H89; 10μM) and an 
adenylate cyclase (AC) inhibitor (MDL; 10μM), 10μM H89 pretreatment (1hr) followed by 
10μM cAMP (H+C) or 10μM MDL pretreatment (1hr) followed by 10μM cAMP (M+C).  
Cells were processed for fl ow cytometry to analyze changes in cell size following osmotic 
challenge.  a) Representative dot plots showing the gating strategy for H4IIE cells (left ) and 
H4IIE cells under osmotic challenge (right).  b) Mean percentage of total cells in quadrant 2 
(Q2) in the presence (dark bars) or absence (light bars) of osmotic challenge.  Bars represent 
3 independent experiments.  * p < 0.05 compared to no osmotic challenge, n = 3 independent 
experiments.
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Figure 3.9:  Eff ect of IL-6 signaling on H4IIE responsiveness to osmotic challenge.  
Cultured H4IIE cells were exposed to recombinant rat IL-6 (rrIL-6; 0.1-100ng/mL) for 
24 hours.  a) Representative dot plots showing the gating strategy for H4IIE cells (left ) and 
H4IIE cells under osmotic challenge (right).  b) Mean percentage of total cells in quadrant 2  
(Q2) in the presence (dark bars) or absence (light bars) of osmotic challenge.  Bars represent 3 
independent experiments.  * p < 0.05, n = 3 independent experiments.
a)
b)
60
signifi cant eff ect on AQP9 protein expression or on localization (Huebert et al. 2002; Soria et 
al. 2009).  Previous work by our lab has reported that AQP8 and 9 expression is signifi cantly 
increased in resected tumor cells 24 hours post resection ( Jablonski et al. 2007).  In the current 
studies, cAMP pathway modulation was unable to alter this eff ect and by 48 hours post tumor 
culture AQP8 and 9 protein expression was at basal levels.
A possible explaination for these discrepancies is the role of nonspecifi c eff ects of 
pharmacological agents.  A main criticism of small molecule protein inhibitors is that they 
tend to have off  target eff ects.  For example, H89 at concentrations higher than 25μM can 
affect myosin light chain, protein kinase C and Rho-associated coiled-coil containing protein 
kinase 2 (Davies et al. 2000).  The role, if any, that these off target effects have cannot be 
discounted out of hand as they do pose a challenge to any case built on the usage of small 
molecule inhibitors but the case against them is not entirely clear.  The rise of molecular gene 
modification techniques was, in part, a direct response to the issues that the off target effects 
of chemical inibitors presented.  However, the advent of embryonic knockout animals, RNAi, 
locked nucleic acids, morpholino based technology and Cre-Lox conditional knockout animals 
presented its own set of issues.  An important one comes in the form of a question: If a given 
a gene is so important why does the animal/cell not die when you knock it out?  Part of the 
answer comes from the observation that a functionally (and usually structurally) related 
protein can compensate for a non-functional protein.  In fact, the data in these studies may be 
presenting a case of just such an occurance.  It may be that the AQP8 pathway (that is all of the 
proteins that go into translocating AQP8 from the cytoplasm to the membrane) is deficient 
at some point(s) and because of the functional, structural and promoter similarities between 
AQP8 and 9, AQP9 is able to compensate.  Though this compensation would not appear to 
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be cAMP dependent.  However, while protein compensation has become scientific dogma, 
no sufficient answer as been put forth in the literature resolving the pharmacological versus 
molecular question. Pharmacological agents will always have off target effects but that does 
not make them redundant.  In fact, H89 is a very specific and potent inhibitor of PKA at low 
concentration.  Genes can be knocked out and the cell/animal will survive but the gene is still of 
critical importance.
IL-6 plays a critical role in many processes, from liver regeneration (Koniaris et al. 2003) 
to promotion of Th 2 T helper cells (Diehl et al. 2002). Interleukin-6 has also been reported to 
arrest HCC cell proliferation in vitro (Moran et al. 2007).  Th e current studies examined the role 
that IL-6 plays in the expression and localization of AQP8 and 9.  Results from these studies 
indicate that IL-6 has no signifi cant aff ect on AQP8 or 9 mRNA or protein expression.  Th ough 
in contrast to the cAMP data, where 8-BrcAMP signifi cantly aff ect AQP9 localization to the 
plasma membrane, IL-6 signifi cantly aff ected AQP8 localization to the plasma membrane.  Th is 
could add another marker to further enhance diagnosis of HCC in humans.  Indeed, previous 
studies by other groups have reported strong IL-6 cytoplasmic and membrane reactivity in 40% 
of HCC patients (Soresi et al. 2006).  
Endoplasmic reticulum (ER) stress provides a potential explaination for the negative 
fi ndings in these studies.  First, a recent article has suggested that AQP8 may be regulated not by 
directly increasing its production, but by decreasing AQP8 degradation (Soria et al. 2009).  But 
a known phenomena of aquaporin production is the high rate of protein misfolding, which, for 
example, is reported as high as 48% for AQP1 (Lu et al. 2000).  Th is leads to a very interesting 
possibility, namely that the design of the experiment maybe backwards.  It has been reported 
that ER stress actually drives IL-6 expression in aortic endothelial cells (Gargalovic et al. 2006).  
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If this observation is true in hepatocytes then it may be the case that instead of IL-6 driving 
AQP8/9 expression, stimulation of AQP8/9 expression may drive IL-6 production due to the 
increased ER stress.
Aquaporins play a critical role in apoptosis in that water effl  ux from the cell is critical for 
apoptotic progression ( Jablonski et al. 2007; Jablonski et al. 2004).  Further, previous work has 
reported that in normal hepatocytes cAMP exposure signifi cantly increased water movement 
(Huebert et al. 2002).  Th e current studies were conducted to see the functional eff ect of 
8-Br-cAMP or IL-6 exposure on cultured H4IIE cells.  H4IIE cells exposed to osmotic stress 
in the context of cAMP pathway modulation swelled signifi cantly diff erent depending on the 
pharmacological agent used.  In contrast, IL-6 had no signifi cant aff ect on cell swelling.  Th e fact 
that 8-Br-cAMP aff ects swelling while IL-6 does not makes logical sense in that feeding animals 
will have increased glucagon and increased glucagon results in the increased expression of 
AQP8 by a cAMP associated mechanism (Soria et al. 2009).
Th e water permeability through an aquaporin is almost 100 times higher compared to 
diff usion (Preston et al. 1993).  Th e question would be with such a high permeability is it 
possible to detect an increase in swelling even if cAMP or IL-6 were increasing the expression 
levels of AQP8/9?  I would speculate that the answer to that question is no.  Th ere are physical 
limits at work here.  First, only a certain number of water molecules can pass through an 
aquaporin at any one time and they must pass through single fi le (Wang et al. 2007).  Also, 
AQP8 and 9 are open channels, there is no gating domain, therefore their activity is determined 
based on their location.  Th erefore, the diff erence in osmolality across the membrane is the 
determining factor for water fl ow rate, not the number of aquaporins.  So even if cAMP or IL-6 
is increasing AQP8/9 expression diff erences in fl ow rate would not be detected because the 
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fl ow rate would naturally increase or decrease based on the diff erence in water concentration.  
However there is undoubtedly much that is unknown about aquaporins.  It has recently been 
reported that plant aquaporins are gated (Wang et al. 2007).  If this is later discovered to be true 
in mammalian aquaporin isoforms, then total aquaporin expression, along with the gating status 
of those aquaporins, could play a large role it total water movement.
Future studies are required to address a number of questions.  In vivo AQP8 expression 
and localization is partially regulated through cAMP signaling (Soria et al. 2009).  And yet 
in this study AQP8 expression and localization was no aff ected by cAMP signaling.  One 
possible explanation is the absence of the 3 dimensional (3D) environment in the in vitro data 
presented.  Indeed, previous work as reported that a 3D environment has signifi cant impact on 
the effi  cacy of anti-cancer drugs (Weigelt et al. 2009).  With this in mind it would interesting 
to repeat these experiments in a 3D cell culture model to examine the eff ects on AQP8 and 9 
expression and localization in the context of a synthetic extracellular matrix.
In summary, cAMP pathway modulation signifi cantly aff ects AQP9 localization to the 
plasma membrane while IL-6 exposure signifi cantly aff ects AQP8 localization to the plasma 
membrane.  Th ough neither cAMP pathway modulation nor IL-6 exposure signifi cantly aff ects 
AQP8 or 9 protein or mRNA expression.  Cyclic-AMP pathway modulation signifi cantly aff ects 
cell swelling while IL-6 exposure does not.  Further research will be required to tease out why 
AQP8 is sensitive to cAMP in normal hepatocytes but not in the H4IIE rat model of HCC.  It 
is tempting to speculate that the genetic instability that is concomitant with cancer (Hanahan et 
al. 2000) is resulting in cellular compensation for the loss of function of AQP8.  Also, typically 
cancer cells evolve mechanisms to evade apoptosis (Hanahan et al. 2000) but in this case the 
ability to move relatively large volumes of water quickly remains intact so these cell posses the 
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machinery to reach the critical concentrations of potassium to activate caspases.  Further, work 
is required to determine exactly how these cells inhibit apoptotic progression in vivo.
CHAPTER 4: AQUAPORIN 8 AND 9 LOCALIZATION IN A MOUSE 
MODEL OF HEPATOCELLULAR CARCINOMA
4.1. Introduction
In normal hepatocytes, AQP8 is expressed and translocated to the canalicular membrane 
in response to glucagon via cyclic-adenosine monophosphate (cAMP) signaling (Garcia et 
al. 2001; Gradilone et al. 2003).  Previous work by the McKillop laboratory, demonstrated 
that aquaporin 8 (AQP8) and 9 (AQP9) expression are reduced to near undetectable level, in 
vivo, in an inoculation rat model of hepatocellular carcinoma (HCC) ( Jablonski et al. 2007).  
However, 24 hours aft er tumors are cultured, AQP8 and 9 expression increased markedly 
compared to freshly isolated tumors ( Jablonski et al. 2007).  One thing these studies did not 
address is the time frame during which aquaporin expression changes.  Th e rat model used 
in those studies is a cell inoculation model which only permits studying mid to late stage 
tumor progression.  Human HCC is a progressive disease having multiple risk factors, the 
most common of which being cirrhosis (Leong et al. 2005).  HCC has a symptom profi le that 
remains subclinical with patients oft en presenting with advanced HCC (Clark et al. 2005).  A 
cell inoculation model would be inappropriate to model these phenomena as early progression 
of the disease is missed entirely, and examination of disease progression through time is 
not possible.  Th erefore, a diff erent model will need to be employed to study the change in 
aquaporin expression from foci formation to mature tumor.
Th e diethylnitrosamine (DEN) mouse model is a model that is suited to studying HCC 
66
from pre-foci formation through mature late stage tumors.  Unlike the cell inoculation rat model 
used previously, which involves the injection of MHC matched cells into a rat, the DEN mouse 
model most commonly involves a single of injection of DEN in young mice, with foci formation 
at approximately six months and mature tumor formation at approximately one year.  One 
aim of the current study will be to compare expression and localization of AQP8 and 9 in the 
inoculation rat model used previously with the DEN mouse model used in this study.
DEN is a known carcinogen in mice and rats (Clapp et al. 1967; Laib et al. 1982; 
Vesselinovitch et al. 1984).  A single intraperitoneal (i.p.) injection of DEN in one day old mice 
is suffi  cient to induce foci formation within 8 weeks (Moore et al. 1981).  In animals injected 
at 15 days old, the fi rst foci are detected at 10 weeks (Vesselinovitch et al. 1983).  Further, at 
exposures of 0.625μg/g, a single i.p. injection of DEN is suffi  cient to induce HCC in treated 
mice in 2 years (Vesselinovitch et al. 1983).  In mice treated with 5μg/g, all had HCC in 
under a year (Vesselinovitch et al. 1983).  Our current understanding is that there are multiple 
mechanisms underlying DEN tumorgenecity.  Previous data has shown polysomies, specifi cally 
chromosomes 11 and 19, in C3H mice (Danielsen et al. 1991).  Additionally, previous work by 
others has shown mutations in the c-Ha-ras gene as early as 11 weeks following DEN injection 
(Bauer-Hofmann et al. 1992).  Lastly, products from DEN metabolism result in DNA alkylation 
(Magee et al. 1964; Swann et al. 1971).  Alkylation results in the formation of preclastogenic 
DNA lesions which are thought to be a primary promoter of HCC development (den Engelse et 
al. 1983; Tates et al. 1986).  Because the DEN mouse model permits the study of HCC during 
the entire course of the disease, this makes it a good model for studying AQP8 and 9 expression 
and localization in a time dependent manner.
An interesting aspect of human HCC, which is also examined in this study, is the role of 
67
gender in HCC.  Human HCC prevalence exhibits gender diff erences.  Th e ratio of men to 
women who develop HCC is as low as 1.3 in South America to as high as 3.6 in Western Europe 
(Bosch et al. 2005).  Th ese are region wide averages and there are localities which have much 
higher sex ratios.  Calvados, France has a HCC incidence sex ratio of 8.8 (McGlynn et al. 2005).  
Th e mechanism underlying higher male predilection for HCC is poorly understood.  Current 
hypotheses for why there is such a strong male predilection in HCC cover a broad range of 
aspects from higher male incidences of viral hepatitis infection and cirrhosis, to higher tobacco 
use in male, to androgens (Leong et al. 2005; McGlynn et al. 2005).  Th e current study will be 
examining what role,if any, sex plays in AQP8 and 9 expression and localization during hepatic 
tumorigenesis.
In summary, previous work by the McKillop laboratory has shown that AQP8 and 9 
expression is inhibited in an cell inoculation rat model of HCC compared to cultured tumors.  
However, this model does not permit examination of pre-foci to mature tumor development.  
Human males have a higher incidence rate for HCC than females.  However, previous chapters 
of this dissertation have not modeled this phenomena of human HCC.  It would logical to use 
a model of HCC that allows for the examination of HCC development through time and to 
include gender as a variable in the model.  Th erefore, a DEN mouse model was selected because 
it is a progressive mouse model of HCC which is eff ective in both male and female mice.
4.2. Materials & Methods
4.2.1. Assurances
All animals were housed in a vivarium approved by the Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC) and all methods were approved by either 
the Carolinas Medical Center Institutional Animal Care and Use Committ ee (IACUC).
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4.2.2. Materials
DEN and olive oil were purchased from Sigma(St. Louis, MO).  C3H/HeJ (C3H) mice 
were purchased from Jacksons Laboratories (Bar Harbor, ME). General animal care (including 
food, water, housing and veterinary care) and anaesthetic were provided by the Department of 
Comparative Medicine, Cannon Research Center, Carolinas Medical Center (Charlott e, NC).  
All surgeries were carried out in the laboratory of Dr. Iain McKillop at Carolinas Medical Center 
(Charlott e, NC).  70 mice were used in this study.  33 were injected with DEN (initiated), 37 
were not injected (control).  In the control group, 20 mice were females, 17 were males.  In the 
initiated group, 18 mice were female, 15 were males.  Immunohistochemical reagents used are 
described in chapters 2.8 – 2.9.
4.2.3. Methods
4.2.3.1. Tumor Initiation
C3H mice, both males and females, were anaesthizied by placing mice in a sealed chamber 
containing gauze soaked in isofl uorane.  Mice were then injected with DEN (1mg/kg i.p.) and 
returned to their cage.  From the control group, 19 animals were euthanized at 24 weeks and 18 
animals were euthanized at 48 weeks.  Frome the initiated group, 17 animals were euthanized at 
24 weeks and 16 animals were euthanized at 48 weeks.
4.2.3.2. Euthanasia, Tissue Collection and Processing
Mice were euthanized by anesthetizing the mouse followed by exsanguination.  Aft er mice 
were euthanized, the liver was resected and a sample of liver was placed in 10% neutral formalin 
(stored at +4°C).  Tissue was then processed as described in chapter 2.8.2.
4.2.3.3. Immunohistochemistry
Immunohistochemical analysis was performed as described chapter 2.8.3.
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4.2.4. Statistical Analysis
Th ree representative fi elds were taken of each slide. Images were then blind scored, those 
values averaged and the average used in further analysis.  Th e model used for the analyzes in this 
chapter was a full factorial type I ANOVA with three factors.  All interactions were included in 
the model.  Pair-wise comparisons were analyzed by Student’s t-Test.  p < 0.05 was considered 
signifi cant.
4.3. Results
4.3.1. Aquaporin 8 localization is signifi cantly aff ected in a DEN model of HCC.
HCC was initiated in C3H mice with a single injection of DEN i.p. (1mg/kg).  Untreated 
mice were maintained as controls.  Mice from each group were euthanized at 24 weeks and 48 
weeks.  Livers from these mice were resected, fi xed and processed for immunohistochemical 
staining.  Slides were stained with an antibody specifi c against AQP8.  Representative AQP8 
stainings from the 24 week control group (Figure 4.2), 24 week DEN initiated group (DEN-
24wk) (Figure 4.3), 48 week control group (Figure 4.4) and 48 week DEN initiated group 
(DEN-48wk) (Figure 4.5) are shown.
Analysis of the scoring data (see  for scoring scale) indicated signifi cant AQP8 plasma 
membrane localiztion diff erences and these diff erences were dependent on exposure to DEN 
and the sex of the mouse or the length of DEN exposure (Figure 4.6a: p < 0.01).  In the 24 week 
group mice,  AQP8 localization to the plasma membrane was signifi cantly higher in hepatocytes 
of female mice exposed to DEN than in hepatocytes in female control mice (Figure 4.6a: p < 
0.01).  However, in the 48 week group mice,  AQP8 localization to the plasma membrane was 
signifi cantly lower in female mice initiated with DEN compared to female control mice (Figure 
4.6a: p < 0.05).  Unlike the 24 week group male mice, where there was no signifi cant diff erence 
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between male mice initiated with DEN and control, there was a signifi cant diff erence in AQP8 
plasma membrane localization, in male mice, between control male mice and male DEN-48wk 
mice (Figure 4.6a: p < 0.01).  Female, DEN-48wk mice had signifi cantly reduced AQP8 plasma 
membrane localization compared to AQP8 plasma membrane localization in female, DEN-
24wk mice (Figure 4.6b: p < 0.01).  Male, DEN-48wk mice also had signifi cantly reduced AQP8 
plasma membrane localization compared to AQP8 membrane localization in male, DEN-24wk 
mice (Figure 4.6c: p < 0.01).
Aquaporin 8 staining also indicated a signifi cant AQP8 cytoplasmic localization diff erences 
and these diff erences were dependent on exposure to DEN and the sex of the mouse or 
the length of DEN exposure (Figure 4.7a: p < 0.01).  AQP9 localization to the cytoplasm 
was signifi cantly higher in normal hepatocytes of female mice relative to plasma membrane 
localization in both the 24 and 48 week group mice (Figure 4.7a: p < 0.01).  In the 48 week 
group mice, AQP8 was signifi cantly higher in the cytoplasm of female and male exposed to 
DEN relative to plasma membrane localization of AQP9 (Figure 4.7a: p < 0.05).  While AQP8 
localization to the cytoplasm was not signifi cantly higher between female DEN-24wk mice 
and male DEN-24wk mice, there was signifi cantly higher AQP8 cytoplasmic localization in 
male DEN-48wk mice compared to female DEN-48wk (Figure 4.7a: p < 0.05).  Female DEN-
48wk mice exhibited signifi cantly increased AQP8 localization to the cytoplasm compared to 
female DEN-24wk mice (Figure 4.7b: p < 0.01).  Male DEN-48wk mice exhibited signifi cantly 
increased AQP8 localization to the cytoplasm compared to male DEN-24wk mice (Figure 4.7c: 
p < 0.01).
4.3.2. Aquaporin 9 localization is signifi cantly aff ected in a DEN model of HCC.
HCC was initiated in C3H mice with a single injection of DEN (1mg/kg i.p.).  Untreated 
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Figure 4.1: Immunohistochemical Scoring Scale.  A reference scoring guide (0-5) for 
membrane and cytoplasmic aquaporin expression was created from human HCC tissue.  Th is 
scale was used as a subsequent reference point for future immunohistochemical analysis.
Membrane
Cytoplasm
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Figure 4.2:  Immunohistochemical staining of liver sections for AQP8 from male and 
female mice in the absence of DEN.  Representative immunohistochemical staining of liver 
sections from male and female C3H mice in the absence of DEN exposure (24 weeks).  Slides 
were stained with antibodies against AQP8 (brown).  Images taken at a) 4x, b) 20x and c) 40x 
magnifi cation.
Male Female
a)
b)
c)
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Figure 4.3:  Immunohistochemical staning of liver sections for AQP8 from male and 
female mice exposed to DEN for 24 weeks.  Representative immunohistochemical staining 
of liver sections from male and female mice injected with DEN (1mg/kg--ip) 24 weeks prior to 
euthanasia.  Slides were stained with antibodies against AQP8 (brown).  Images taken at a) 4x, 
b) 20x and c) 40x magnifi cation.
Male Female
a)
b)
c)
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Figure 4.4:  Immunohistochemical staining of liver sections for AQP8 from male and 
female C3H mice in the absence of DEN.  Representative immunohistochemical staining of 
liver sections from male and female C3H mice in the absence of DEN exposure (48 weeks).  
Slides were stained with an antibody againist AQP8 (brown).  Images taken at a) 4x, b) 20x and 
c) 40x magnifi cation.
Male Female
a)
b)
c)
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Figure 4.5:  Immunohistochemical staining of liver sections for AQP8 from male and 
female mice exposed to DEN for 48 weeks.  Representative immunohistochemical staining 
of liver sections from male and female mice injected with DEN (1mg/kg--ip) 48 weeks prior 
to euthanasia.  Slides stained with an antibody against AQP8 (brown).  Images taken at a) 4x, 
b) 20x and c) 40x magnifi cation.
Male Female
a)
b)
c)
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Figure 4.6:  Aquaporin 8 membrane localization in the presence or absence of DEN.  
Female (F) and male (M) mice were initiated with DEN 24 or 48 weeks (DEN-24, DEN-48 
respectively) prior to being sacrifi ced or were untreated as controls and also sacrifi ced at 24 or 
48 weeks (wks).  Livers from these mice were resected, processed and immunohistochemically 
stained with anti-AQP8 antibodies.  a) Aquaporin 8 membrane localization in male and female 
mice, +/- DEN injection and euthanized at 24 and 48 weeks.  b) Aquaporin 8 membrane 
localization in female  DEN-24 and DEN-48 week mice.  c) Aquaporin 8 membrane localization 
in male DEN-24 and DEN-48 week mice.  * p < 0.01, # p < 0.05.  For 24 week control group, n = 
10(F), 9(M).  For DEN-24, n = 9(F), 5(M).  For 48 week control group, n = 10(F), 8(M).  For 
DEN-48, n = 7(F), 7(M).
77
mice were maintained as controls.  Mice from each group were euthanized at 24 weeks and 48 
weeks.  Livers from these mice were resected, fi xed and processed for immunohistochemical 
staining.  Slides were stained with an antibody specifi c against AQP9.  Representative AQP9 
stainings from the 24 week control group (Figure 4.8), DEN-24wk group (Figure 4.9), 48 week 
control group (Figure 4.10) and DEN-48wk group (Figure 4.11) are shown.
Analysis of the scoring data indicated signifi cant AQP9 localization to the plasma 
membrane, which was dependent on the length of exposure to DEN (Figure 4.12a: p < 0.01).  
In the 24 week group, exposure to DEN resulted in signifi cantly less AQP9 plasma membrane 
localization compared to no DEN exposure (Figure 4.12a: p < 0.05).  In the 48 week group, 
exposure to DEN also resulted in signifi cantly less AQP9 plasma membrane localization 
compared to no DEN exposure.  DEN-48wk mice had signifi cantly less AQP9 localization to 
the plasma membrane compared to DEN-24wk mice (Figure 4.12a: p < 0.01).
Analysis of scoring data indicated signifi cant AQP9 localization to the cytoplasm, which 
was dependent on both exposure to DEN and the length of exposure to DEN (Figure 4.12b: p 
< 0.01).  DEN-48wk mice had signifi cantly higher cytoplasmic localization compared to DEN-
24wk mice as well as 48 week control mice (Figure 4.12b: p < 0.01).
4.4. Discussion
Aquaporins play an important role in the production of bile due to the effi  cient movement 
of water across cellular membranes, which aquaporins facilitate (Masyuk et al. 2006).  
Hepatocytes express three aquaporin isoforms, AQP8, 9 and  0 with AQP8 and 9 playing a 
role in bile production (Masyuk et al. 2006).  Previous reports have also suggested that AQP8 
and 9 play a role in hepatocellular carcinoma ( Jablonski et al. 2007).  However that study 
presented no data on aquaporin localization and expression during HCC progression.  In the 
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Figure 4.7:  Aquaporin 8 membrane/cytoplasmic localization in response to DEN.  
Female and male mice were initiated with DEN 24 (foci) or 48 (HCC) weeks (wks) prior to 
sacrifi ce or were left  untreated as controls.  Livers from these mice were resected, processed and 
immunohistochemically stained with anti-AQP8 antibodies.  a) Membrane and cytoplasmic 
localization of AQP8 in male and female C3H mice, +/- DEN injection, euthanized at 24 
and 48 weeks.  b) Aquaporin 8 cytoplasmic localization in female C3H mice.  c) Aquaporin 8 
cytoplasmic localization in male C3H mice.  * p < 0.01, ¶ p < 0.05 compared to cytoplasmic 
staining  of female mice exposed to DEN for 48 weeks. Cy = Cytoplasm, Mb = Membrane, C = 
Control mice, DEN = DEN initiated mice, F = Female, M = Male.  For 24 week control group, n 
= 10(F), 9(M).  For DEN-24, n = 9(F), 5(M).  For 48 week control group, n = 10(F), 8(M).  For 
DEN-48, n = 7(F), 7(M).
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Figure 4.8:  Immunohistochemical staining of liver sections for AQP9 from male and 
female mice in the absence of DEN.  Representative immunohistochemical staining of liver 
sections from male and female C3H mice in the absence of DEN exposure (24 weeks).  Slides 
were stained with antibodies against AQP9 (brown).  Images taken at a) 4x, b) 20x and c) 40x 
magnifi cation.
Male Female
a)
b)
c)
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Figure 4.9:  Immunohistochemical staning of liver sections for AQP9 from male and 
female mice exposed to DEN for 24 weeks.  Representative immunohistochemical staining 
of liver sections from male and female mice injected with DEN (1mg/kg--ip) 24 weeks prior to 
euthanasia.  Slides were stained with antibodies against AQP9 (brown).  Images taken at a) 4x, 
b) 20x and c) 40x magnifi cation.
Male Female
a)
b)
c)
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Figure 4.10:  Immunohistochemical staining of liver sections for AQP9 from male and 
female C3H mice in the absence of DEN.  Representative immunohistochemical staining of 
liver sections from male and female C3H mice in the absence of DEN exposure (48 weeks).  
Slides were stained with an antibody againist AQP9 (brown).  Images taken at a) 4x, b) 20x and 
c) 40x magnifi cation.
Male Female
a)
b)
c)
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Figure 4.11:  Immunohistochemical staining of liver sections for AQP9 from male and 
female mice exposed to DEN for 48 weeks.  Representative immunohistochemical staining 
of liver sections from male and female mice injected with DEN (1mg/kg--ip) 48 weeks prior 
to euthanasia.  Slides stained with an antibody against AQP9 (brown).  Images taken at a) 4x, 
b) 20x and c) 40x magnifi cation.
Male Female
a)
b)
c)
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Figure 4.12:  Aquaporin localization in response to DEN.  Female and male mice 
were initiated with DEN for 24 (foci) or 48 (HCC) weeks (wks) prior to sacrifi ce or 
were left  untreated as controls.  Livers from these mice were resected, processed and 
immunohistochemical staining with anti-AQP9 antibodies indicated a) Membrane localization 
of AQP9 in C3H mice, +/- DEN injection, euthanized at 24 and 48 weeks.  b) Aquaporin 9 
cytoplasmic localization of AQP9 in C3H mice, +/- DEN injection, euthanized at 24 and 48 
weeks.  + p < 0.01 compared to mice injected with DEN 24 weeks prior to euthanasia, & p < 0.01 
compared to 24 or 48 week control mice, # p < 0.05, * p < 0.01, § p < 0.05 compared to 48 week 
control mice.  For 24 week control group, n = 19.  For DEN-24, n = 14.  For 48 week control 
group, n = 18.  For DEN-48, n = 14.
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current, study a progressive, DEN mouse model was used to examine AQP8 and 9 localization 
and progression during HCC progression.  Mice injected with DEN are then said to have been 
“initiated”.    Th ese data indicate that AQP8 localization to the plasma membrane increases early 
in HCC progression but then falls during disease progression.  Further, as HCC progresses, 
AQP8 localization to the plasma membrane decreases signifi cantly in both male and female 
mice.  However, gender plays no signifi cant role in AQP8 localization to the plasma membrane.  
Th ere was no signifi cant diff erence in AQP8 plasma membrane localization between 24 week or 
48 week male and female initiated mice.  However, there were signifi cant gender diff erences in 
AQP8 localization to the cytoplasm.  Male mice with later stage HCC had higher cytoplasmic 
AQP8 localization than female at a similar stage of HCC.  Regardless of the HCC stage or 
gender, cytoplasmic localization of AQP8 was higher than membrane localization.  In fact, 
AQP8 localization in the plasma membrane fell to barely detectible levels in later stage HCC.  
Aquaporin 9 localization was also signifi cantly aff ected by HCC progression.  In early stage 
HCC, AQP9 is primarily plasma membrane bound, but as the disease progresses transformed 
hepatocytes seem to withdraw AQP9 from the plasma membrane and AQP9 is then strongly 
expressed in the cytoplasm compared to the plasma membrane.
Gender diff erences play a role in a variety of diff erent physiological and pathophysiological 
processes, including cancer genetics (Atwal et al. 2008), metastasis (Naor et al. 2009), T cell 
responses (Roden et al. 2004) and tumor immunology (Page et al. 1995).  In these studies 
gender diff erences played a signifi cant role in AQP8 localization as well.  Previous reports 
indicate that AQP8 expression is modulated in estrogen-induced cholestasis (Carreras et al. 
2007).  Also, a previous report demonstrated that gender diff erences in cytochrome P450 3A4 
expression is growth hormone dependent (Cheung et al. 2006). Th e current study though 
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is the fi rst to show gender diff erences in HCC.  Th ere are reports of AQP9 regulation by 
androgens (Wang et al. 2008) and estrogen (Oliveira et al. 2005) so it is unexpected that gender 
diff erences was no a signifi cant factor in AQP9 localization.  Perhaps, genetic instability, which 
in concomitant with all cancers (Hanahan et al. 2000), has altered AQP9 responsiveness to 
gender mediated AQP9 expression and/or localization.  It also might be that this phenomena is 
an artifact of this model of HCC.
Th ere are a few broad categories of rodent HCC models: chemical, viral, cell inoculation 
(either stem cells or cancer cell lines) and xenograph (Wu et al. 2009).  Chemical models, 
including DEN and carbon tetrachloride (CCl4) induced HCC by a three step process: 
initiation, promotion and progression (Wu et al. 2009).  A single exposure to some of these 
chemicals is suffi  cient to initiate and promote HCC (for example, DEN).  Chemicals such as 
CCl4 require a separate promoter, though promoter chemicals are used with chemicals such 
DEN to decrease time to mature HCC and to increase the aggression of a tumor (Heindryckx 
et al. 2009).  Th e most common promoters are partial hepatectomy and phenobarbital (Wu et 
al. 2009).  Promoters induce clonal expansion of initiated cells (Wu et al. 2009).  Viral models 
of HCC involve the use of transgenic animals to either express viral proteins which initiate and 
promote HCC development through a chronic infl ammation of the liver (Heindryckx et al. 
2009).  Xenograph models of HCC involve using human liver tissue which is then implanted 
into an immunocompromised rodent  (Wu et al. 2009).  Cell inoculation models are similar 
to xenograph models only that in cell inoculation models, a cancer cell line MHC matched 
to the species of rodent to be used are injected back into the animal to yield a tumor (Wu et 
al. 2009).  All of these models are valuable tools to study HCC but they are also specialized 
tools which means that care must be taken when choosing between them.  Cell inoculation 
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models produce tumors more rapidly than any other model and are suitable for studying late 
stage tumor progression (Heindryckx et al. 2009).  However, these models are not particularly  
applicable to human HCC (Heindryckx et al. 2009).  Viral models of HCC are suitable for 
studying HCC in the context of viral hepatitis infection (HBV and HCV encoded proteins are 
commonly used).  However, this model requires the generation of transgenic mice which are 
controversial since there is confl icting data about the extent of liver damage caused in these 
models (Wu et al. 2009).  Chemical models of HCC are the oldest and most studied being in 
use since 1932 (Wu et al. 2009).  Chemical models, such as the DEN model, are preferable for 
studying hepatocarcinogenesis as well as tumor progression (Wu et al. 2009).  However, the 
DEN model also suff ers from caveats that cannot be ignored.  One, DEN can be lethal to young 
rodents and mortality is an issue (Heindryckx et al. 2009).  Second, this model can suff er from 
poor reproducibility (Heindryckx et al. 2009).  It is very diffi  cult to determine exactly when 
an animal will develop foci or mature HCC.  Th is can be an issue if the experimental protocol 
requires exact time points.  Th ird, metastasis rarely, if ever, occurs in this model (Heindryckx et 
al. 2009).  With this being said, the DEN model also has a number of distinct advantages.  One, 
tumor formation rates for this model are routinely reported to be 100% (Wu et al. 2009).  Two, 
the DEN model is versatile and can model many aspects of human HCC.  Instead of a single 
injection in young animals, long-term administration of DEN results in a close model of certain 
human HCC and the time to tumor formation is half that of a single injection DEN models 
(Heindryckx et al. 2009).  Also, human HCC incidence is stratifi ed by gender, with females a 
third as likely to contract HCC as males (Bosch et al. 2005).  Long term administration of DEN, 
not only mirrors this incidence rate, but tumors in this model are aggressive and metastatic 
(Heindryckx et al. 2009).  Lastly, for tumor formation approaching the same rate as cell 
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inoculation models, long-term DEN administration in rats, combined with partial hepatectomy, 
can result in tumor formation in only four weeks (Heindryckx et al. 2009).   
Recent reports have suggested that aquaporins (AQP8 in particular) might be regulated 
by protein degradation (Soria et al. 2009).  Further, a report from the McKillop laboratory 
indicates that AQP8 and 9 expression drops to very low levels in rodent and human HCC 
( Jablonski et al. 2007; Padma et al. 2009).  In the current study, while there were signifi cant 
diff erences in AQP8 and 9 localization, the expression levels in both DEN treated mice and 
control groups rarely scored higher than 3.  However, the scoring process involves judgment on 
the part of the scorer so, any study based on this technique is not truly quantitative.  Th is is not 
to say that it is not of value only that, one must exert caution when interpreting these types of 
data.  While computer imaging analysis has become popular recently, I am unconvinced that it 
provides any more accuracy or reliability than human scoring.
In conclusion, AQP8 plasma membrane localization is signifi cantly lower in later stage 
HCC compared to earlier in the disease process.  AQP8 localization to the cytoplasm is 
signifi cantly higher in later stage HCC compared to earlier in the disease process.  Further, 
AQP8 localization to the cytoplasm is signifi cantly diff erent in female mice compared to 
male.  AQP9 localization to the plasma membrane was also signifi cantly lower in later stage 
HCC compared to earlier in the disease process.  Also, AQP9 localization to the cytoplasm 
was signifi cantly higher in later stage HCC compared to earlier in the disease process.  Th ese 
data bolster results reported by the McKillop laboratory using a rat inoculation model of HCC 
( Jablonski et al. 2007).  Both models seem to be in agreement and the current study suggests 
that the decrease in AQP8/9  plasma membrane localization is a later occurrence in HCC.
CHAPTER 5: ANALYSIS OF AQUAPORIN 8 AND 9 IN HUMAN 
HEPATOCELLULAR CARCINOMA
5.1. Introduction
In previous chapters, data was presented examining a potential mechanism of aquaporin 
(AQP) expression and localization in a rat model of hepatocellular carcinoma (HCC).  In a 
subsequent chapter, data was presented identifying AQP8 and 9 expression and localization 
in a mouse, diethylnitrosamine (DEN) model of HCC.  In the present study, AQP8 and 9 
expression and localization will be examined in a human tissue from HCC patients. 
In 2002, HCC accounted for 5.6% of all human cancers worldwide with more than 
550,000 new cases, and a similar number of deaths (World Health Organization 2002).  North 
American men are more than twice as likely to develop HCC as women with the ratio rising to 
more than three and half times in western European men (Bosch et al. 2005).  Th e prognosis 
for HCC patients was equally bleak, especially in the developing world, with HCC exhibiting a 
fatality ratio of approximately 1 (meaning that most HCC patients die within a year of diagnosis 
(Bosch et al. 2005)).  Further, between 1995 and 2000 the 5-year survival rate of HCC patients 
in the United States was 8.3% (Bosch et al. 2005).
Th e most common treatments for HCC are chemical and thermal ablation, surgical 
resection and liver transplant.  In early stage HCC (uninodular tumor, tumor size < 3 cm), 
ethanol ablation has produced 70% complete ablation rates (Shiina et al. 1993).  Th ough 
the recurrence rate for ethanol ablated tumors was reported to be as high as 60%, 84% of 
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these recurrences were new HCC tumors distant from the original ablation site (Shiina et al. 
1993).  Despite this,  retrospective studies reported 41% — 53% 5-year survival rates, simalar 
to survival rates for patients that underwent surgical resection (Lencioni et al. 2005).  5-year 
survival rates as high 70% were reported for patients undergoing surgical resection on single, 
asymptomatic,  tumors <5cm (Llovet et al. 2000). Radiofrequency ablation was reported to 
be signifi cantly more effi  cacious than ethanol ablation as regards recurrence free survival.  In a 
randomized trial comparing radiofrequency ablation to ethanol ablation across 1- and 2-year 
survival rates, radiofrequency ablation had a 9% and 21% bett er survival rate, respectively 
(Lencioni et al. 2005).  Liver transplant represents the radical end of the HCC treatment 
spectrum.  Unfortunately, cadaveric liver transplantation is contraindicated for large tumors 
(> 5cm) or multifocal/metastatic tumors due to 5-year survival rates of only 15% (Roayaie et 
al. 2005).  Further, severe shortage of donor livers results in up to 30% of patients dying while 
waiting for a liver transplant (Roayaie et al. 2005).
Th e poor prognosis for HCC patients has led to increased interest in HCC screening.  
In part this is due to the insidious nature of HCC; it remains subclinical well into disease 
progression.  Also, the likelihood of survival increases considerably the earlier HCC can be 
detected (Marrero 2005). In breast cancer, the presence of BRCA1 is correlated with young 
onset of cancer, low diff erentiation, high proliferation rates compared to BRCA1 negative 
tumors and increased prevalence of grade III tumors (Klauber-DeMore 2005).  Currently, 
human HCC lacks a marker like BRCA1 , therefore, elucidating the underlying biology of 
HCC is a topic of great importance for generating effi  catious clincial outcomes.  To this end, 
identifying patient populations that have increased risk for worse clinical outcomes is a logical 
place to begin.  An aim of the current study is to examine if AQP8 or 9 expression correlates 
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with other known risk factors for HCC which have known eff ects on clinical outcomes.  Th is 
might allow for pathological determination of tumor aggressiveness and therefore allow 
clinicians to design bett er treatment plans.
Treatment of human HCC is complicated by the subclinical nature of the disease resulting 
in patients presenting with later stage tumors.  Also, human HCC has a known resistance to 
chemotherapeutic agents (Befeler 2005).  Part of this is due to the inhibited responsiveness 
to apoptosis exhibited by all cancers (Hanahan 2000).  Aquaporins play a role in apopotosis 
such that inhibition of aquaporin function inhibits apoptotic progression ( Jablonski 2007).  
Because there is no reported gating domain in mammalian aquaporins, proper aquaporin 
function requires that it be inserted into a membrane.  Further, there is no published report 
of a cytoplasmic function for aquaporins.  Th erefore, if AQP8 or 9 localization correlates with 
other known risk factors this also would assist clinicians in treating patients.  Also, if AQP8 and/
or 9 has reduced localization to the plasma membrane in tumor cells, this represents plausible 
hypothesis as to why human HCC cells are resistant to chemothreapeutic agents.  Namely, that 
the absence of membrane bound aquaporins inhibits apoptotic progession in tumor cells but 
normal hepatocytes are stimulated to undergo apoptosis.  Another aim of the current study will 
be to examine the localization diff erences in human HCC compared to non-tumor liver.
Th e production, secretion and alteration of bile is a primary physiological function of the 
liver.  Bile is greater than 95% water, so a relatively large volume of water must be transported 
from the sinusoidal space to the bile canaliculus (Calamita et al. 2005).  Aquaporins facilitate 
this process by increasing membrane water permeability by up to 100 fold (Borgnia et al. 
1999; Calamita et al. 2005).  Hepatocytes express three aquaporin isoforms, AQP8, AQP9 
and AQP0 (Huebert et al. 2002; Masyuk et al. 2006).  AQP9 is constitutively expressed in 
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sinusoidal membranes while AQP0 is constitutively expressed on intracellular vesicles (Huebert 
et al. 2002).  AQP8 is initially expressed on intracellular vesicles but in response to glucagon, 
via cyclic–adenosine monophosphate (cAMP) stimulation, AQP8 translocates to the bile 
canalicular membranes (Gradilone et al. 2003; Huebert et al. 2002).  Th is mechanism for 
AQP8, 9 and 0 expression and localization was elucidated in mice and rats.  Th ese isoforms of 
aquaporins have been observed in humans but it is only hypothesized that AQP8 localization 
is glucagon mediated.  Mice and rats act as models for human physiology and pathophysiology.  
As with all models, these rodent models must be validated against the human condition.  
Previous chapters in this dissertation have presented data using both rat and mice models, so 
the aim of the present study is to examine the fi delity these rodent models of HCC have with 
human HCC as regards AQP8 and 9 expression and localization. 
5.2. Material & Methods
5.2.1. Materials
Huh7 cells were a generous gift  from Dr. Herbert Bonkovsky (Carolinas Medical Center, 
Charlott e, NC).  Apicidin, trypan blue and HgCl2 were purchased from Sigma-Aldrich(St. 
Louis, MO).  CaspACE colorimetric caspase assay was purchased from Promega (Madison, 
WI).  Countess automated cell counter, Alexa488-conjugated goat anti-rabbit secondary 
antibody, Texas Red goat anti-rabbit secondary antibody, 4′,6-Diamidino-2-phenylindole 
dihydrochloride (DAPI) and anti-fade mounting media were purchased from Invitrogen 
(Carlsbad, CA).
5.2.2. Patient Information
Institutional Review Board approved the use of archived paraffi  n embedded surgical 
specimens from patients who had undergone HCC resection at Carolinas Medical Center.  23 
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patient samples were analyzed in total.  Further, patient histories were removed of identifying 
information and patients were grouped according to known risk factors for HCC including: 
alcohol or drug use, HBV or HCV infection and cirrhosis.  Patients were also grouped according 
to pathological factors including: serum AFP levels, the size of the tumor and cancer stage 
(determined either pathologically or clinically).  Only patients with primary HCC were used in 
this study.
5.2.3. Immunohistochemistry
All immunohistochemical procedures were performed as described in chapter 2.8.4.
5.2.4. Immunofl uorescent Histochemistry
Processing, slide mounting, antigen retreival and blocking were performed as described 
in chapter 2.8.  Aft er blocking, slides were incubated in primary antibody (1:500 dilution, 
30 minutes).  Detection was perfromed using either Alexa488- or Texas red-conjugated goat 
anti-rabbit secondary antibody (1:2000 dilution, 2 hours).  Slides were counterstained with 
DAPI, dehydrated through graded alcohols then cover-slip mounted with anti-fade media.  Th e 
sections were examined by laser scanning confocal microscopy.  Each channel was recorded 
independently and superimposed images generated.
5.2.5. Cell Swelling Analysis
Cell Swelling analysis was preformed as described in chapter 2.4.
5.2.6. Caspase Assay
Th e caspase assay was performed per manufacturer’s instructions.  Briefl y, Huh7 cells were 
exposed to 10μM HgCl2, 2μM apicidin, 10μM HgCl2 + 2μM apicidin or a caspase inhibitor 
(as control,  Z-VAD-FMK was provided by the manufacturer).  Cells alone were used as a 
control.  Cells were collected, washed once with cold PBS, resuspended in cell lysis buff er 
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(provided by the manufacturer), subjected to a single freeze-thaw cycle (-80°C — +4°C) and 
then centrifuged at 15,000 x g for 20 minutes (+4°C).  Th e supernatant fraction was collected an 
assayed.  Quantifi cation of caspase-3 activity was performed using a standard curve with control 
reagents provided by the manufacturer.
5.2.7. Statistical Analysis
Student’s t-Tests were used to analyze, data with only two factors.  One-way, type I ANOVA 
models were used to analyze multifactor data.  All analyzes were performed and charts created 
by SAS JMP 8.0.2 (Cary, NC).  p < 0.05 was considered signifi cant.
5.3. Results
5.3.1. Location of AQP8 and 9 in normal, non-tumor liver.
Staining of normal, non-tumor liver tissue with antibodies specifi c for  AQP8 
demonstrated predominantly cytoplasmic staining (Figure 5.1a).  In contrast,  staining for 
AQP9 indicated localization to the membrane and was zonally distributed (Figure 5.1b). 
5.3.2. Localization of AQP8 and 9 in normal and HCC, in the context of underlying cirrhosis.
Staining for AQP8 in non-tumor liver of HCC patients, in the absence of underlying 
cirrhosis, demonstrated a signifi cantly higher presence of AQP8 in cytoplasm compared to 
the membrane (Figure 5.2a-c: p < 0.001).  In tumors, AQP8 was also signifi cantly higher 
in cytoplasm compared to the membrane (Figure 5.2a-c: p < 0.001).  Staining for AQP8 in 
non-tumor liver of HCC patients, in the presence of underlying cirrhosis demonstrated a 
signifi cantly higher presence of AQP8 in cytoplasm compared to membrane (Figure 5.3a-b: p 
< 0.001).  In tumors, AQP8 was also signifi cantly higher in cytoplasm compared to membrane 
(Figure 5.3a-b: p < 0.001).
Next I analyzed AQP9 staining in non-tumor liver of HCC patients, in the absence of 
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a)
b)
Figure 5.1:  Immunohistochemical staining of normal human liver in the absence of 
hepatic disease.  a) Representative immunohistochemical (IHC) images of normal liver 
sections following IHC staining using an anti-human AQP8 antibody.  b) Representative 
immunohistochemical (IHC) images of normal liver sections following IHC staining using an 
anti-human AQP9 antibody.
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Figure 5.2:  Aquaporin 8 expression/localization in human HCC in the absence of 
cirrhosis.  a) Representative immunohistochemical (IHC) images of HCC and non-tumor 
liver (NTL) following IHC staining using an anti-human AQP8 antibody.  b) Representative 
immunofl uorescent histochemical (IFHC) images of HCC and NTL sections following IFHC 
staining using an anti-human AQP8 antibody and detection with Texas Red secondary (red).  
Sections were counterstained with DAPI (blue) for nuclear localization.  c) Cumulative scoring 
analysis of membrane vs. cytoplasmic staining for AQP8 in NTL vs. HCC.  Values are means +/- 
standard error of the mean of fi ve separate fi elds scored independently.  * p < 0.01, cytoplasmic 
staining compared to membrane. n = 11.
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Figure 5.3:  Aquaporin 8 expression/localization in human HCC in the presence of 
cirrhosis.  a) Representative immunohistochemical (IHC) images of HCC and non-tumor liver 
(NTL) following IHC staining using an anti-human AQP8 antibody.  b) Cumulative scoring 
analysis of membrane vs. cytoplasmic staining for AQP8 in NTL vs. HCC.  Values are means +/- 
standard error of the mean of fi ve separate fi elds scored independently.  * p < 0.01, cytoplasmic 
staining compared to membrane. n = 12
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Figure 5.4:  Aquaporin 9 expression/localization in human HCC in the absence of 
cirrhosis.  a) Representative immunohistochemical (IHC) images of HCC and non-tumor 
liver (NTL) following IHC staining using an anti-human AQP9 antibody.  b) Representative 
immunofl uorescent histochemical (IFHC) images of HCC and NTL sections following IFHC 
staining using an anti-human AQP9 antibody and detection with Fluro488 labelled secondary 
(green).  Sections were counterstained with DAPI (blue) for nuclear localization.  c) Cumulative 
scoring analysis of membrane vs. cytoplasmic staining for AQP9 in NTL vs. HCC.  Values are 
means +/- standard error of the mean of fi ve separate fi elds scored independently.  * p < 0.01. 
n = 11.
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Figure 5.5:  Aquaporin 9 expression/localization in human HCC in the presence of 
cirrhosis.  a) Representative immunohistochemical (IHC) images of HCC and non-tumor 
liver (NTL) following IHC staining using an anti-human AQP9 antibody.  b) Representative 
immunofl uorescent histochemical (IFHC) images of HCC and NTL sections following IFHC 
staining using an anti-human AQP9 antibody and detection with Fluro488 labelled secondary 
(green).  Sections were counterstained with DAPI (blue) for nuclear localization.  c) Cumulative 
scoring analysis of membrane vs. cytoplasmic staining for AQP9 in NTL vs. HCC.  Values are 
means +/- standard error of the mean of fi ve separate fi elds scored independently.  * p < 0.01,  
# p < 0.05. n = 12.
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underlying cirrhosis.  Th is analysis demonstrated a signifi cantly higher presence of AQP9, 
where detected, in the membrane compared to cytoplasm (Figure 5.4a-c: p < 0.01).  In tumors, 
AQP9 was higher in cytoplasm than in the membrane (Figure 5.4a-c: p < 0.001).  Further, 
AQP9 localization in tumor membrane was signifi cantly lower than non-tumor liver (Figure 
5.4c: p < 0.001).
Staining for AQP9 in non-tumor liver of HCC patients, in the context of underlying 
cirrhosis demonstrated a signifi cantly higher presence of AQP9 in cytoplasm compared to 
membrane (Figure 5.5a-c: p < 0.001).  In tumors, AQP9 was also higher in cytoplasm than 
in the membrane (Figure 5.5a-c: p < 0.01).  Membrane localization of AQP9 in tumor cells 
was signifi cantly lower compared to non-tumor liver (Figure 5.5c: p < 0.01).  Cytoplasmic 
localization of AQP9 in tumor cells was signifi cantly lower compared to non-tumor liver 
(Figure 5.5c: p < 0.05).
It should be noted here one other interesting result from these data.  AQP9 is zonally 
distributed in absence of cirrhosis (Figure 5.4a).  However, in the presence of cirrhosis zonal 
distribution of AQP9 is reduced (Figure 5.5a).
Patients, for which there were complete histology scoring data, were grouped according 
to presenece or absence of underlying cirrhosis.  5 of 8 (62.5%) patients with underlying 
cirrhosis had AQP8 and/or 9 membrane localization diff ereces of > 1 between non-tumor liver 
and tumor tissue(Table 5.1).  For patients without underlying cirrhosis 2 of 7 (28.5%) had 
AQP8 and/or 9 membrane localization diff erences of > 1 non-tumor liver and tumor tissue.  
Further, in either the cirrhotic patients or non-cirrhotic patients there does not appear to be a 
common risk factor for the patients with largest diff erences between AQP8 and/or 9 membrane 
localization in non-tumor liver and tumor tissue (Table 5.1).
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Figure 5.6:  Analysis of AQP8 localization in patient subgroups.  Immunohistochemical 
staining of sections from HCC patients which were grouped based on tumor size or whether the 
patient had a single hepatic tumor or multiple hepatic  tumors  a) Analysis indicated a signifi cant 
aff ect of tumor size on AQP8 cytoplasmic localization in non-tumor liver (NTL).  Further, 
Tukey-Kramer HSD analysis indicates a signifi cant diff erence between patients with <5 cm 
tumors and patients with 5-10 cm tumors.  b) Analysis of patients with either a single primary 
hepatic tumor or multiple primary hepatic tumors (determined clinically) indicated a signifi cant 
reduction in AQP8 cytoplasmic localization in patients with multiple primary tumors.  # p < 
0.05,  * p < 0.01. n = 23.
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Figure 5.7:  Analysis of AQP9 localization in patients with a history of chronic alcohol 
and/or drug abuse.  Immunohistochemical staining of sections from patients with a history 
of alcohol or drug abuse indicated a signifi cantly lower AQP9 localization to the cytoplasm 
compared to patients who did not abuse drugs and/or alcohol.  * p < 0.05. n = 23
105
5.3.3. AQP8 localization is signifi cantly aff ected by the tumor size, tumor origin and focality.
Analysis of normal tissue in tumor burdened livers indicated signifi cantly diff erent AQP8 
localization in cytoplasm compared to membrane and this eff ect was dependent on tumor size 
(Figure 5.6a: p < 0.05).  Further, Tukey-Kramer HSD analysis indicated a signifi cant diff erence 
between tumors less than 5cm and tumors 5-10cm (Figure 5.6a: p < 0.01).  In patients with 
multifocal primary HCC, AQP8 was signifi cantly lower in the cytoplasm, compared to 
membrane, in tumor cells (Figure 5.6b:  p < 0.01).
5.3.4. AQP9 localization is signifi cantly diff erent in patients with histories of chronic alcohol 
or drug abuse.
Patients with a history of chronic alcohol or drug abuse had signifi cantly lower AQP9 
localization in cytoplasm of tumor cells compared to patients without a history of alcohol or 
drug abuse (Figure 5.7: p < 0.05).
5.3.5. Role of aquaporins 8 and 9 in apoptotic progression of human HCC cells in vitro.
Apicidin is a known inhibitor of histone deacetylase and is a potent pro-apoptotic 
compound (Kwon et al. 2002).  Apoptosis activates a cascade of caspases which results in the 
cleavage activation of caspase-3, the last known regulation point for apoptosis (Lemasters 
2005).  Huh7 cells, a human HCC cell line, were exposed to four concentrations of apicidin 
(1μM – 10 μM) in the absence or presence of 10μM HgCl2 (added 30 minutes prior to apicidin) 
for 24 hours.  Cells were then collected and analyzed by fl ow cytometry.  Cell swelling in Huh-7 
cells was confi rmed to be an aquaporin mediated process by conducting a cell swelling assay.   
Huh-7 cells were osmotically challenged in the presence or absence of 10μM HgCl 2.  Huh-7 
cells swelled in response to osmotic challenge and the presence of HgCl2(Figure 5.9a-b).
Cells were gated to select live cells then the percentage of live cells under each treatment 
condition was measured (Figure 5.9a top left ).  Analysis of these data indicated a signifi cant 
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Figure 5.8:  Eff ect of osmotic challenge on Huh-7 cells.  a) Representative dot plots, showing 
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to analyze changes in cell size.  b) Representative histograms indicated that Huh-7 cells swells in 
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Figure 5.9:  Eff ect of HgCl2 on apicidin induced Huh-7 cell death.   Huh-7 cells were exposed 
to four concentrations of an apoptotic stimulator (apicidin) in the presence or absence of 
10μM HgCl2 for 24 hours and processed for fl ow cytometry to analyze cell viability.  # p < 0.05, 
ANOVA analysis, * p < 0.01 , compared to no HgCl2. n = 4.
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to apicidin alone.  c) Caspase-3 activity (bars represent fold change compared to Huh-7 cells 
alone) in Huh-7 cells exposed to apicidin +/- HgCl2. Z-VAD-FMK is a pan-caspase inhibitor.  
# p < 0.05. n = 4.
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decrease in the number of live cells in response to apicidin (Figure 5.9: p < 0.05).  Th ere was 
a signifi cant increase in the number of live cells following apicidin exposure in the presence of 
HgCl2 (Figure 5.9: p < 0.01).
To confi rm that the cell death observed was due to apoptosis and was aquaporin mediated, 
a caspase-3 assay was performed.  Huh-7 cells were exposed to 2μM apicidin for 24 hours in the 
presence or absence of 10μM HgCl2.  Th ere was a signifi cant diff erence between cells exposed 
to apicidin and HgCl2 and Huh-7 cells or Huh-7 cells exposed to HgCl2 alone (Figure 5.10c: 
p < 0.05).  Also, there is a signifi cant decrease in the level of caspase-3 activity in cells which 
were exposed to HgCl2 and apicidin compared to apicidin alone (Figure 5.10c: p < 0.05).  
Lastly, there was a signifi cant diff erence between Huh-7 cells exposed to apicidin and HgCl2 
and Huh-7 cells exposed to apicidin and the caspase-3 inhibitor Z-VAD-FMK (Figure 5.10c: p 
< 0.05).
5.4. Discussion
Th ese studies demonstrated that AQP8 and 9 has altered expression and localization 
in human HCC.  AQP8 was primarily located in the cytoplasm in both non-tumor liver and 
HCC. In contrast, AQP9 was localized to the membrane in non-tumor liver but in HCC AQP9 
was predominantly localized to the cytoplasm.  However, these diff erences in AQP8 and 9 
localization did not appear to of clustered with any given known risk factor for HCC.  Th e 
human HCC cell line, Huh-7 was used to assess the functional role of aquaporins in apoptotic 
progression in human HCC.  Cell death was signifi cantly inihibited as was caspase-3 activity 
in Huh-7 cells exposed to apicidin and HgCl2 compared to apicidin alone.  Indicating that 
apoptosis in Huh-7 cells mediated by aquaporins.  Th is fi nding supports previous data reported 
from the McKillop laboratory indicating that apoptosis in rat HCC is also aquaporin mediated 
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( Jablonski et al. 2007).
Localization plays a critical role in aquaporin function.  Only by membrane insertion 
can the rapid effl  ux of water occur (Masyuk 2006).  Data from the current study indicated 
that AQP8 localization was low in the membrane in both non-tumor liver and HCC.  More 
interestingly, AQP9 localization was also lower in the membrane.  Th erefore, these data suggest 
that HCC has lower total aquaporin membrane expression compared to non-tumor tissue.  In 
fact AQP8 and 9 were barely detectable in HCC (Figure 5.2 and Figure 5.4). Th is presents 
an hypothesis.  Perhaps it is this lack of membrane localized aquaporin that is responsible 
for chemotherapeutic resistence by HCC.  Further, AQP9 is localized to the membrane in 
non-tumor tissue.  Th is fact makes chemotherapy a contraindicated treatment option as the 
chemotherapeutic agent would be an ineffi  cient apoptotic agent in tumor cells but a very 
effi  cient apoptotic agent in normal hepatocytes.  So the question arises, is there a way to 
stimulate cells to express AQP8 or 9 on the plasma membrane?  Th is question is partially 
addressed in this dissertation.  Cyclic-AMP is known to stimulate AQP8 expression and 
translocation to the bile canaliculi in normal rat hepatocytes (Gradilone et al. 2003).  So it 
was reasonable to examine if cAMP produces the same response to HCC cells.  Data from this 
dissertation indicates cAMP does not stimulate AQP8 expression or translocation.  However, 
cAMP is not the only potential candidate.  Th ere is a great deal of cross-talk in the cAMP 
pathway so perhaps one of the signaling molecules will stimulate AQP8 or 9 translocation to 
the membrane.  Interleukin-6 (IL-6) is a cytokine involved in a number physiological processes, 
from liver regeneration (Koniaris et al. 2003) to T-cell diff erentiation (Diehl et al. 2002).  
IL-6 activates signal transducers and activators of transcription 3 (STAT3), a transcription 
factor that stimulates the expression of genes with cAMP response elements.  Aquaporin 8 
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and 9 expression and localization in response to IL-6 stimulation was also examined in this 
dissertation.  However, data indicated that IL-6 does not stimulate AQP8 or 9 expression or 
localization.  However, data from the current in vitro studies suggested that perhaps apoptosis in 
human HCC is a partially regulated by aquaporins.
Th ough cAMP and IL-6 do not appear to be promising candidates for therapies for human 
HCC, there other possibilities for future studies.  Protein kinase C (PKC) is involved in a 
number of physiological processes, among them the establishment of cell polarity (Rosse et al. 
2010).  Perhaps one process by which HCC arises is due to a loss of hepatocyte polarity.  In 
normal liver, hepatocytes are polarized with distinct canilicular and sinusoidal membranes and 
since AQP8 and 9 are localized to these membranes (respectively) then perhaps AQP8 and 9 
play some role in hepatocyte polarization.  Th erefore, it is tempting to speculate that since PKC 
plays a role in coordinating cell polarity that it might also regulate AQP8 or 9.
In conclusion, AQP8 and 9 membrane localization is signifi cantly reduced in HCC. 
Further, these diff erences in AQP8 and 9 localization did not correlate with any given risk factor 
for HCC.  Apoptosis of Huh-7 cells is partially regulated by aquaporin function suggesting 
that aquaporin function modulation might be an eff ective treatment for human HCC.  
Previous work in this dissertation reported that neither Cyclic-AMP nor IL-6 were eff ective at 
modulating AQP8 or 9 localization.  Th ere are, however, other candidiate genes which may be 
eff ective at modulating AQP8 and/or 9 localization.  More work will be required to determine if 
a gene such as PKC modulates AQP8 and/or expression and localization.
CHAPTER 6:TETRA CYCLINE CONTROLLED EXPRESSION OF 
AQUAPORIN 8 & 9 IN A RA T MODEL OF HEPATOCELLULAR 
CARCINOMA IN VIVO.
6.1. Introduction
Aquaporin 8 (AQP8) and 9 (AQP9) have been reported to play a role in apoptosis 
and expression of AQP8 and 9 are inhibited in a rat model of hepatocellular carcinoma 
(HCC) ( Jablonski et al. 2007).  However, no published study has reported examining tumor 
progression by modulating AQP8 or 9 expression in vivo.  Th ere are several methods available 
for in vivo genetic manipulation, popular techniques including: RNA interference (RNAi), cre-
loxP knockout animals and promoter switch systems (tetracycline promoter switches being the 
most common) (Ryding et al. 2001).  Th e strength of RNAi lies in the simplicity of constructing 
RNAi sequences.  However, there are stability issues when using them in vivo (Pushparaj et al. 
2008).  Cre-loxP systems involves the generation of transgenic mice to express Cre recombinase 
bacteriophage topoisomerase which catalyzes site specifi c removal or inversion at loxP sites 
(Maddison et al. 2005).  By fl anking the gene cassett e of interest with loxP sites, one can 
knockout that gene in vivo (Maddison et al. 2005).  While, RNAi and cre-loxP systems are a 
vital tool in molecular studies both, in vitro and in vivo they are only suitable for knocking down 
or knocking out a gene.  Aquaporin 8 and 9 expression is already inhibited in HCC in vivo, 
therefore the focus of these studies will be to overexpress AQP8 or 9 in vivo.
One of the oldest methods of overexpressing a gene in vivo is the promoter switch system 
(Ryding et al. 2001).  Promoter switch systems permit controlled expression of any gene, is 
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relatively inexpensive, has been used extensively (Ryding et al. 2001) and is a validated tool, 
readily accepted by the scientifi c community.  Originally developed by Gossen and Bujard, 
tetracycline controlled gene expression has been used in a wide variety of eukaryotic cells 
(Gossen et al. 1993a; Gossen et al. 1993b).  Th e basic mechanism of the system involves the 
tetracycline repressor (tetR) protein which binds specifi cally to the tetracycline operator (tetO) 
DNA sequence (Gossen et al. 1993b).  Th e binding of tetR to tetO renders genes with tetO 
in their promoters silent.  An added feature of this system is that it is derived from E. coli. and 
eukaryotic genomes do not possess the tetO sequence, nor do they incode for tetR protein 
production.  Th is serves to reduce leakage expression of the gene of interest.  Th e original 
system was further enhanced by fusing the acidic domain of VP16 to tetR (this fusion being 
named rTA) resulting a more eff ective transactivator (Gossen et al. 1993a).
Along with being a validated and relatively inexpensive (compared to cre-loxP systems 
for example), tetracycline system has other advantages.  First, in can provide graduated 
control of gene expression.  Production of the tetR transactivator is dose dependent, thereby 
allowing for subtle manipulation of the gene of interest.  Second, the system works equally well 
with analogues of tetracycline.  Tetracycline is toxic to HeLa cells at 10μg/mL (Gossen et al. 
1993b).  Doxycycline, an analogue of tetracycline, has less toxicity than tetracycline and is more 
eff ective at inducing tetR production (Ryding et al. 2001).  Also, doxycycline is more stable 
than tetracycline thereby allowing for doxycycline incorporation into rodent chow for in vivo 
activation of rTA.
Th e ability to use a tetracycline system in vivo is critically import to the study in this chapter 
and to the studies in this dissertation as whole.  Aquaporin 8 and 9 have a document expression 
phenotype whereby AQP8 and 9 expression in vivo is barely detectable by immunofl uorescent 
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analysis of tissue and freshly isolated tumors, in vitro, are relatively resistant to TGF-β induced 
apoptosis ( Jablonski et al. 2007).  However, culturing tumors results in signifi cantly increased 
expression of AQP8 and 9 accompanied by the restoration of apoptotic sensitivity ( Jablonski 
et al. 2007).  One of the fundamental aims of this dissertation was to see if a small molecule, 
known to aff ect AQP8 localization in normal hepatocytes (Garcia et al. 2001), could prevent 
or delay the in vivo to in vitro expression profi le change seen normally with AQP8 and 9 
( Jablonski et al. 2007) in rat HCC. Chapter 3 looked at using cyclic-andensine monophosphate 
(cAMP) and interleukin-6 (IL-6) to perform this function.  Unfortunately, neither cAMP or 
IL-6 signifi cantly aff ected AQP8 or 9 expression or localization.  However, this does not mean 
that no small molecule will work, only that it will be left  to others to examine other potential 
candidate genes.  Further, the lack of response by AQP8 and 9 to cAMP or IL-6 in vitro does 
mean that these aquaporins do not have a role in HCC initiation or progression.  In fact, data 
from Chapter 4, examining a DEN mouse model of HCC, suggests that AQP8 and 9 play a role 
in HCC progression as evidenced by their being inhibited in late stage hepatic tumorigenesis.  
Further, data from human HCC samples suggests a role for at least AQP9 in tumor progression, 
since AQP9 was signifi cantly lower in the majority of tumor plasma membrane as compared 
to non-tumor cells (Chapter 5).  Neither of these studies, though, directly examines the role of 
AQP 8 and 9 in tumor progression as the model used was not an in vivo model of HCC and the 
other used humans which are typically only suitable for descriptive studies.  Th e model of HCC 
used in the current study is a cell inoculation model using a clonal cell line, transfected with 
a tetracycline switch system (Tet-on) plasmid system.  As the parent cell, H4IIE, was derived 
from the same rat strain into which it will be injected, the cells and the animal MHC matched.  
In the current study, a tetracycline switch system was used to control AQP8 or 9 expression in 
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vivo.  Th is system placed expression of AQP8 or 9 under the control of a tetracycline promoter 
in H4IIE cells in vitro.  Use of a tumorogenic cell line and customized rodent chow, thus made 
it possible to control aquaporin expression in vivo.  In vivo manipulation of AQP8 or 9 allowed 
direct examination of the role these aquaporins play in tumor progression in vivo.
6.2. Methods
6.2.1. Assurances
All animals were housed in a vivarium approved by the Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC) and all methods were approved by the 
Carolinas Medical Center Institutional Animal Care and Use Committ ee (IACUC)
6.2.2. Materials
Tet-On Advanced Inducible Gene Expression System (Tet-On system), HA antibody, 
TetR antibody, pTRE2-pur-HA plasmid, Doxycycline, G418 and puromycin were purchased 
from Clontech (Mountain View, CA).  Rodent chow with 200ppm doxycycline was purchased 
from Research Diets (New Brunswick, NJ).  Agar, LB broth, SOB, SOC and terrifi c broth 
powder were purchased from USB (Cleveland, OH).  BD Falcon 5mL snap-capped tubes were 
purchased from Fisher Scientifi c (Waltham, MA).  Lipofectin®  reagent was purchased from 
Invitrogen (Carlsbad, CA).  Carbenicillin was purchased from Sigma-Aldrich (St. Louis, MO).  
Suicide vector system (pJet1.2) was purchased from Fermentas (Glen Burnie, MD).  DNA 
gel isolation kit and midi-plasmid isolation kit were purchased from Qiagen (Valencia, CA).  
Mini-plasmid isolation kit was purchased from Omega Bio-tek (Norcross, GA).  E.coli. bacterial 
strain  and all restriction endonucleases were purchased from New England Biolabs (Ipswich, 
MA).  Primers were purchased from IDT (Coralville, IA).
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6.2.3. Cell Culture Material and Methods
Material for cell culture were described in chapter 2.2.1.  Cell culture methods were 
described in chapter 2.2.2-2.2.6.
6.2.4. Immunohistochemical Analysis
Materials for immunohistochemical as described in chapter 2.8.1.  Immunohistochemical 
methods described in chapters 2.8.2 and 2.8.3.
6.2.5. Construction of pTRE2-AQP-HA.
Th e Tet-On system works by a two plasmid system both of which must be stably expressed 
(Figure 6.1).  Th e fi rst plasmid contains a sequence encoding a modifi ed version of the bacterial 
tetracycline repressor (TetR) protein.  Th e modifi ed TetR protein is constitutively expressed 
due to its promoter being fused to a CMV promoter (Figure 6.1a).  Th e second plasmid 
contains a modifi ed tetracycline response element (TRE) which permits the high affi  nity 
binding of the TetR protein only in the presence of doxycycline (a tetracycline analogue) 
(Figure 6.1b).  
Th e entire CDS for AQP8 and 9 were amplifi ed by PCR and blunt-end ligated into the 
pJet1.2 suicide plasmid.  E. coli. were then transduced and plated on agar plates, containing 
100μg/mL of carbenicillin.  Plates were stored in a dry 37°C incubator over night.  Th e next 
day, fi ve colonies were picked and placed in 5mL tubes containing 2mL of LB broth with 50μg/
mL of carbenicillin.  Tubes were placed in a heated, orbital shaker (300 RPM) for ~16 hours at 
37°C.  Bacterial suspension was then transferred to a 2mL centrifuge tube and plasmid DNA 
isolated using mini-prep plasmid kit, as per the manufacturer’s instructions.  Primers were 
created to amplify the complete CDS of AQP8 or 9 along with restriction sites which were 
included with the primers (Table 6.1).  Th e restriction sites were chosen because they do not 
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Figure 6.1:  Maps of vectors used to generate pTet-AQP cells.  a) Th e pTet-On Advanced 
vector expresses a transcription factor whose expression is initiated in response to tetracycline 
exposure.  Th e transcription factor expressed (rtTA-Advanced) binds to the TRE2 (tetracycline 
response element 2).  b) Th e pTRE2-pur-HA vector contains the gene of interest in frame with 
the TRE2 response element.  In response to rtTA-Advanced binding, the gene of interest is 
expressed.
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Gene Sense (5'-3') Antisense (5'-3')
AQP8-CDS AGATATGTCTGGGGAGCAGA TCACCTCGACTT TAGAATCA
AQP9-CDS ATGCCTT CTGAGAAGGACGG CTACATGATGACACTGAGCTCG
AQP8-Vec ATATATCGATCCGCCATGTCT-GGGGAGCAGACGCC
ATATT CTAGATCACCTCGACTT -
TAGAATCAGGCGGGTT TT 
AQP9-Vec ATATATCGATCCACCATGCCTT CT-GAGAAGGACGG
ATATT CTAGACTACATGAT-
GACACTGAGCTCGTGTT TCTC
Table 6.1:  Primer sequences used for gene amplifi cation (CDS) and restriction site 
addition (Vec).  Th e same restriction enzymes were used for AQP8 and 9 (ClaI and XbaI).
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cleave inside either aquaporin gene and are only located on the multiple cloning site (MCS) of 
the pTRE2-pur-HA vector.  Th e amplifi ed AQP8 or 9 were gel purifi ed and cut with restriction 
enzymes.  pTRE2-pur-HA vector was also cut with the same restriction enzymes.  AQP8 or 9 
was then ligated into the ClaI, XbaI cut sites and E. coli were transduced with the created vector, 
plated on agar plates containing 100μg/mL of carbenicillin and stored in a dry incubator at 
37°C overnight.  Th e next day, fi ve colonies were picked and placed in 5mL tubes containing 
2mL of LB broth with 50μg/mL of carbenicillin.  Tubes were placed in a heated, orbital shaker 
(300 RPM) for ~16 hours at 37°C.  Following, the bacterial suspension was transferred to a 
2mL centrifuge tube and plasmid DNA isolated using mini-prep plasmid isolation kit.  Plasmids 
were then confi rmed by restriction endonuclease analysis to determine the presence of AQP8 
or 9.  Once a clone was confi rmed it was transduced into E. coli, plated on agar plates containing 
100μg/mL carbenicillin and stored overnight in a dry incubator at 37°C.  Th en, a clone was 
picked placed into a 5mL tube containing 2mL of LB broth with 50μg/mL carbenicillin 
and placed in a heated, orbital shaker (300 RPM) for ~8 hours.  Aft er 8 hours, 200μL of the 
bacterial suspension was placed into an Erlenmeyer fl ask containing 50mL of LB broth with 
50μg/mL of carbenicillin.  Th e fl ask was incubated on an orbital shaker (100 RPM), at room 
temperature, overnight.  Th e next day, plasmid DNA was isolated using a mini-prep plasmid 
isolation kit, following  manufacturer’s instructions.  Th e plasmid yielded was used for H4IIE 
cell transfections.
6.2.6. Generation of double stable H4IIE cells.
 Transfection of H4IIE cells was performed using Lipofectin® per manufacturer’s 
instructions.  All steps were carried out under sterile conditions.  Th e same procedure was 
performed for both transfections.  Briefl y, 15,000 cells were plated in 6-well plates in 10% 
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FBS (v/v) medium without antibiotics.  Th is seeding density resulted in approximately 40% 
confl uence the following day.  On that day, 20μL of Lipofectin was diluted into a total volume 
of 100μL of EMEM medium (medium only) and let stand at room temperature for 45 minutes.  
During this time, 2μg of plasmid DNA was diluted into a total volume of 100μL of EMEM 
medium (medium only).  Aft er the 45 minute incubation, complex formation was initiated by 
combining the Lipofectin solution with the DNA solution and incubated for 15 minutes at 
room temperature.  Ten minutes aft er the beginning of this incubation, medium was aspirated 
from the 6-well plate and cells were washed once with EMEM (medium only).  Next, 1.8mL 
of EMEM (medium only) was added to the Lipofectin-DNA complex solution, mixed gently 
and instilled into the 6-well plate.  Plates were then incubated for 24 hours at 37°C / 5% CO2 
(v/v).  Aft er 24 hours, 1mL of 20% FBS medium (v/v) was added and the plate incubated for 
48 hours at 37°C / 5% CO2 (v/v).  Aft er 48 hours, each well of the 6-well plate was split into 2 
D100 dishes contain selective medium.  Selective medium was then changed every other day 
for two weeks and then every 2 days until clone colonies were visible (approximately 6 weeks in 
total).  Clones were then picked and instilled into 12-well plates in selective medium.  Clones 
were then expanded, tested and frozen down.  For the pTet-On plasmid, clones were tested 
by Western blot for expression of TetR.  Th e top three clones with the highest expression of 
TetR were used for transfections of pTRE2-AQP-HA.  Th ese transfections were also done with 
Lipofection and were tested by RT-PCR using forward primers internal to AQP8 or 9 and 
reverse a primer internal to HA (Table 6.2) (Figure 6.2).
6.2.7. Establishing tumorigenicity of transformed H4IIE cells
H4IIE cells exhibit diminished tumorigenicity in vivo with repeated passaging in vitro 
(Evans et al. 1977; Kovacs et al. 1977).  Th e transfection and selection processes results in cell 
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of approximately P10.  To ensure in vivo tumorgenecity, cells were inoculated subcutaneously 
into the fl anks of male, ACI rats (175-225g).  Twenty-one days later, the resultant tumors were 
present in approximately 15% of animals.  Th ese tumors were then harvested and cultured in 
selective medium, expanded.  At P1 107 cells were inoculated into the left  hepatic lobe of male, 
ACI rats (175-225g).  Fourteen to sixteen days later tumors were resected (success rates were 
comparable to P0-P2 untransfected H4IIE) and cultured in selection medium.  Cells were 
allowed to reach 80% confl uency and used in the studies presented.
Prior to the experimental period, male, ACI rats (175-225g) were maintained on standard 
rodent chow and conditions.  Seven days prior to inoculation, standard chow was removed and 
switched to standard rodent chow containing 200ppm doxycycline.  pTet-On/pTRE2-AQP-HA 
H4IIE (pTet-AQP H4IIE) cells were used to initiate tumors in male, ACI rats (175-225g) as 
described in 2.3.
6.2.8. Necropsy
Fourteen days aft er pTet-AQP H4IIE inoculation, rats were euthanized, livers resected, 
and gross examination performed to detect tumor presence.  Liver samples were then fi xed 
and stored (+4°C) in 10% neutral buff ered formalin until immunohistochemical analysis was 
performed.
6.2.9. Statistical Analysis
Tumors were considered to be cuboid in shape therefore tumor volume was calcuted by 
the equation: Volume = (x*y*z), where x is the width, y is hight and z the depth of the tumor.  
Student’s t-Test was used to analyze data in this study and was performed using SAS JMP 8.0.2 
(Cary, NC).  p < 0.05 was considered signifi cant.
124
Gene Sense (5'-3') Antisense (5'-3')
AQP8 TCTCATT GACGGCACCCATACACA ——
AQP9 TAAATGCCAAAGACCGTT GCAGCC ——
HA —— ACCCATACGATGTT CCAGATT AC-GCTCTT 
Table 6.2:  Primer sequences for testing of pTet-AQP-HA constructs.
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1 2 3
Figure 6.2:  Test for the presence of AQP8-HA in H4IIE cells in three clones.  pTet-AQP8-
HA tumorogenicity was regained and clones were tested for the expression of HA tagged AQP8 
by RT-PCR using a forward primer against AQP8 and a reverse primer against HA tag. Clone 2 
was used for all experiments using pTet-AQP8.
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6.3. Results
6.3.1. Constitutive AQP8 expression signifi cantly aff ected tumor formation and tumor 
volume.
Male, ACI rats (175-225g) were placed on a doxycycline diet for seven days prior to 
surgery.  Aft er seven days, the left  hepatic lobes of these rats were inoculated with 107 pTet-
AQP8 H4IIE cells.  In parallel, 107 untransfected H4IIE cells were inoculated into the left  
hepatic lobe of diff erent male, ACI rats (175-225g).  Fourteen days later, rats were euthanized, 
livers harvested and a gross examination of the livers was performed.  For rats with tumors, 
sample tissue was fi xed and stored (+4°C) for further immunohistochemical analysis.  Control 
animals (2 of 2) had tumors, and tumor volume measurements were taken (Figure 6.3),  50% 
(2 of 4) of doxycycline fed animals had tumors and volume measurements of the tumor were 
taken.  Analysis of these data indicated that animals with constitutively expressed AQP8 formed 
signifi cantly smaller tumors compared to regular H4IIE (Figure 6.4: p < 0.01).
6.3.2. pTet-AQP9 H4IIE cells fail to reestablish tumorigenicity.
Establishing tumorigenicity of pTet-AQP H4IIE cells requires that these cells be inoculated 
into ACI rats twice, once in the fl ank and then a second time in the liver.  pTet-AQP9 H4IIE cells 
formed tumors in the fl anks of ACI rats with an approximate success rate of 15%.  However, 
subsequent inoculation in livers failed to produce usable tumors.  Of the liver group, one rat 
had an apparent cystic lesion which was later confi rmed to be a tumor by histological analysis 
(Figure 6.5 a-b).
6.4. Discussion
Aquaporins play an important role in apoptosis  by mediating the apoptotic volume 
decrease (AVD) ( Jessica Chen et al. 2008).  Th e AVD is a required event in apoptosis and 
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aquaporin activity aff ects the rate of apoptosis before AVD progression ( Jablonski et al. 2004).  
Previous reports have shown that AQP9 is inhibited in human HCC (Padma et al. 2009).  
Chapter 5 of this dissertation reported decreased AQP8 and 9 expression in human HCC.  
Previous work from the McKillop laboratory reported decreased AQP8 and 9 expression in rat 
HCC ( Jablonski et al. 2007).  However, all of these studies, though important, were descriptive.  
Th e current study is the fi rst to provide direct evidence that inhibiting AQP8 expression is 
suffi  cient to signifi cantly inhibit tumor progression.  In the current study, H4IIE cells were 
transfected with a vector placing  AQP8 placed under the control of a tetracycline promoter.  
Th is permitt ed eff ective control of AQP8 expression.  Constitutive expression of AQP8, in a rat 
model of HCC which was known to have inhibited AQP8 expression, signifi cantly inhibited 
tumor progression.  Unfortunately, technical issues prevented a similar examination of AQP9.
  While these results are promising there are potential issues.  First, with any stable 
transfection there is the possibility that the introduced DNA will be removed by the host cell. 
Th is potential was reduced by strigent antibiotic selection the transfected cells were placed 
under during in vitro propagation.  Second, there is the potential that transfection reagents 
and/or high concentrations of antibiotics modifi ed these cells to decrease their tumorgenecity.  
I submit that this potentiality is reduced by the multiple times these cells were passaged 
through a rat to restore the tumorgenecity of these cells.  Th e greatest technical issue in this 
study was the failure to reestablish tumorigenicity in pTet-AQP9 H4IIE cells.  Th ere are many 
possible explanations but the one that I submit is most likely is a well known phenomena to 
molecular biologists but I have yet to see published in a peer reviewed journal.  Th e recurrent 
issue that molecular biologists face has to do with cells, somehow, ejecting the gene of 
interest but retaining the resistance gene.  Th at is, a cell loses the gene of interest but cannot 
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Figure 6.3:  pTet-AQP8 H4IIE cells form tumors in the absence of doxycycline.  pTet-AQP8 
cells were injected into the left  hepatic lobe of male, ACI rats.  Approximately 14 days later livers 
were resected and a-c) tumors were evident upon gross examination.  d) Tumor presence was 
confi rmed histologically.  
a) b)
c) d)
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Figure 6.4:  Eff ect of doxycycline on pTet-AQP8 cells.  pTet-AQP8 cells were injected into the 
left  hepatic lobe of male ACI rats in the presence (200ppm, 7 days prior to operation) or absence 
of doxycycline (Dox).  a) Approximately 14 days later livers were resected at tumor volume 
measurements calculated. Of the rats fed dox, b) half of the animals did not have tumors, c) while 
the other half did have tumors.  * p < 0.01.  n = 4.
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Figure 6.5:  pTet-AQP9 H4IIE cells did not regain tumorigenicity.  pTet-AQP9 H4IIE cells 
were injected into the left  hepatic lobe of male, ACI rats in the absence of doxycycline (dox).  
Approximately 14 days later the livers were resected and examined for the presence of tumors.  
a-c) All animals had no clearly evident tumors upon gross examination, though an injection 
cyst was evident on one rat (white arrow).  One animal had an apparent injection cyst but upon 
histological analysis it was confi rmed to be a tumor by examination at d) 4x, e) 20x and f) 40x 
magnifi cations.  
a)
b)
c)
d)
e)
e)
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be killed by the selection antibiotic because it still retains the enzyme which neutralizes the 
antibiotic.  Unpublished work by the McKillop laboratory suggest that the incidence rate of 
this phenomena can be as high as 90%.  Th is puts a premium on conducting tests to confi rm 
the presence of your construct.  However, an issue that arose in the course of acquiring 
data for this dissertation is the diffi  culty transfecting H4IIE cells.  Preliminary experiments 
involving siRNAs against AQP8 and 9 had to be abandoned because of the inability to get 
eff ective knockdown.  Later, a collaboration between Dr. McKillop and Dr. Qi Lu (Carolinas 
Medical Center), using morpholino antisense oligonucleotides  also yielded unsatisfactory 
results.  However, using fl uorescently labeled morpholinos yielded close to 30% transfection 
effi  ciency but still poor knockdown.  Examination of the cells showed what appeared to be the 
morpholinos becoming localized within vesicles which were then being “ejected” from the cell.  
A potential side project is to examine this phenomena in greater detail.  A fi rst step might be to 
inhibit vesicular traffi  cking to examine if these morpholinos are indeed trapped in a vesicle.
 Another solution to the technical issues encountered in this study would be to switch 
models entirely.  Th e rat model used has several advantages.  It is a well characterized model, 
is reproducible, uses a readily available strain of rats and a commercially available cell line.  
However, the diffi  culty transfecting H4IIE cells is enough to warrant consideration of other 
models.  A similar model to the cell inoculation model used in this study is a mouse inoculation 
model.  Hepa1-6 cells are a mouse hepatoma cell line derived from C57L mice.  However, 
Hepa1-6 are MHC matched to C57BL/6 mice.  In fact, a recent article demonstrated that 
Hepa1-6 cells form tumors in C57BL/6 mice following inoculation into the portal vein, 
resulting in widespread tumor nodules two weeks post inoculation (Chen et al. 2007).   Th ere 
are two advantages in switching to a mouse model.  One, from a practical standpoint, standard 
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strains of mice are less expensive to purchase than rats and mice are less expensive to house.  
Two, from a scientifi c standpoint, there is a wide array of tools that are available when using a 
mouse background that just are not available on a rat background.
Findings such as the ones in this study always present the possibility that they might be 
translated into clinical therapies .  However, the structure of AQP8 and 9 seem to preclude 
this.  Despite best eff orts, every proposed small molecule aquaporin inhibitor has failed 
(Verkman 2009).  Th ere is a known genetic loss-of-function mutation of AQP2 which result 
in diabetes (Fujiwara et al. 2005).  However, this mutation is rare with less than one in 20 
million births resulting in this mutation (Verkman 2009).  Th e rarity of this event strong limits 
its therapeutic potential.  Th ere are no published hereditary conditions resulting from AQP8 
or 9 loss-of-function mutation.  In Chapter 3 of this dissertation, cAMP and IL-6 both failed 
to modulating AQP8 or 9 expression or localization.  Th is is in contrast to published studies, 
in normal hepatocytes, that cAMP increases AQP8 expression and causes its translocation to 
the canalicular membranes (Garcia et al. 2001; Gradilone et al. 2003).  However, these studies 
suggest that AQP8 plays a decisive role in HCC progression.  Th erefore, the answer may not 
lie in small molecule design, instead it might lie in eff ect non-viral construct delivery in vivo.  
Despite the lack of success, there is a new technology for introducing non-viral vectors in vivo 
and  in situ.  Electroporation has typically been used to introduce foreign DNA to cells in vitro.  
Recent advances have produced a technique involving the electroporation of tissue in vivo to 
introduce a non-viral construct to cells around the electroporation probe (Wells 2010).  Th is 
technique suggests a future experiment whereby a rodent liver is inoculated with a tumorogenic 
cell line and then the introduced cells are transfected in situ with a construct containing AQP8 
or 9.
CHAPTER 7:DISCUSSION
Hepatocellular carcinoma (HCC) accounts for 5.6% of all human cancers worldwide 
(Bosch et al. 2005).  Th ere are several risk factors for HCC.  Afl atoxin, Hepatitis B and C virus 
infection, steatohepatitis and ethanol are known risk factors for HCC development (McGlynn 
et al. 2005; McKillop et al. 2006a; McKillop et al. 2005).  However, the largest risk factor for 
HCC is cirrhosis, with 80-90% of HCC patients having underlying cirrhosis (Leong et al. 
2005).    Of the top fi ft een most lethal cancers in the United States between 1997 and 2006, 
only HCC has an annual average percent increase of at least 2% in men and greater than 1% in 
women (Edwards et al. 2010).  In fact, no other cancer has an average year-over-year percent 
change greater that 0.5% over the same period (Edwards et al. 2010). With a yearly fatality ratio 
of approximately one (meaning most patients die within a year of diagnosis) and a worldwide 
5-year survival rate of just 6.5%, HCC is a highly lethal cancer compared to other types of 
cancer (Bosch et al. 2005).  Th e clinical outcomes for HCC are in part due to the fact that no 
cancer is genetically stable (Hanahan et al. 2000).  Th erefore, no two HCC tumors are the 
same.  Th ough some cancers do have known genetic aberrations which strongly contribute to 
their tumorigenicity (BRCA1 in breast cancer being a heavily studied example) which present 
as therapeutic and/or diagnostic targets (Klauber-DeMore 2005).   Unfortunately, there is no 
genetic marker for HCC (Leong et al. 2005).
Diagnosis of HCC typically starts with a blood test and an ultrasound examination of the 
liver.   Measuring the levels of  α-fetoprotein (AFP) in blood is a common test administered to 
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aid in the diagnosis of HCC (Ferenci et al. 2010).  However, AFP is a poor diagnostic tool.  In 
patients with HCC, 40% of these patients produce no AFP (Ferenci et al. 2010).  Further, black 
African patients have normal AFP levels above the diagnostic level of 500ng/mL (Ferenci et 
al. 2010).  Currently, ultrasound, computer-aided topography (CT) and magnetic resonance 
imaging (MRI) scans are the most common non-invasive means of diagnosis for HCC 
(Sherman 2007).  Ultrasound is the fi rst diagnostic tool used and with contrast-enhanced 
ultrasound an overall accuracy in diff erentiating malignant tumors from benign of 85% is 
achieved (Liu et al. 2010).  However,  ultrasounds are not practical for screening purposes and 
most people only present in clinic at the onset of symptoms by which point patients are usually 
presenting with advanced HCC (Clark et al. 2005).
Th e low 5-year survival time, the increasing death rate, the subclinical nature and the 
absence of accurate screening places a premium on eff ective treatment for HCC.  Unfortunately, 
treatment options for HCC are limited for intermediate to advanced HCC and typically 
HCC is not detected early.  However, with early detection the best clinical outcomes are 
possible since the most eff ective treatments are usually available (Llovet et al. 2000).  For early 
stage HCC in the absence portal hypertension, surgical resection provides the best clinical 
outcome, with 5-year survival rates of greater than 75% (Llovet et al. 2000).  Unfortunately, 
few patients present this early (Clark et al. 2005).  For intermediate to advanced HCC, typical 
treatment options included surgical resection (in special cases), liver transplantation, ablation 
and embolization.  For small tumors surgical resection is an option in certain cases, namely, 
a single tumor less than 5cm (or no more than 3 tumors less than 3cm) and absence of both 
portal hypertension and vascular invasion (Truty et al. 2010).  Ablation therapies fall into 
two broad groups, chemical and thermal.  Chemical ablation therapies involve ethanol, acetic 
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acid and hot saline (Lencioni et al. 2005).  Th ermal ablation therapies involve using radio 
waves,  microwaves and lasers to destroy the tumor (Lencioni et al. 2005).  In early stage HCC, 
ethanol ablation has comparable 3- and 5-year survival rates to surgical resection (Yamamoto 
et al. 2001a).  Radiofrequency (RF) ablation also has survival rates comparable to surgical 
resection but RF has bett er 3- and 5-year survival rates than ethanol ablation (Lencioni et al. 
2005).  Embolization involves injecting microspheres which block blood fl ow to the tumor and 
typically, chemotherapeutic agents are included (Befeler 2005).  Chemoembolization however 
does not signifi cantly extent 1-year survival times and are not curative therapies (Befeler 2005).   
It should be noted that systemic chemotherapy is not eff ective in HCC because typically 
patients present with compromised liver function so higher dosages of chemotherapeutic 
agents are required (Tanaka et al. 2010; Zhu 2010).  Th ese higher dosages result in unacceptable 
toxicity eff ects for patients, including death (Tanaka et al. 2010).    All of these therapy options 
suff er from the same weakness, 60% of patients die within fi ve years and 80% of patients die 
within ten years (Yamamoto et al. 2001a).  
Orthotopic liver transplantation (OLT) is the most eff ective treatment for HCC, providing 
a worldwide 5-year survival rate of 71% (Dutkowski et al. 2010).  However widespread OLT 
for HCC treatment is compromised by the severe shortage of donor organs (Mazzaferro et al. 
2008).  Th e shortage of livers has resulted in the adoption of living donor liver transplantation 
(LDLT) (Dutkowski et al. 2010).  However, OLT and LDLT has generated a number of ethical 
issues.  Is transplanting a high risk patient (e.g. a recovering alcoholic or HCV positive patient) 
a justifi ed usage of a scarce resource such as a cadaveric liver?  Th e viability of cadaveric livers 
decreases with time where transplant within 24 hours is necessary to maintain optimum liver 
function (Guarrera et al. 2008).  Th erefore, if there are two potential patients for a liver but 
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one more than 24 hours away, is it ethical to transplant a recovering alcoholic because he is 
closer?  Lastly, is it always permissible for a parent to donate a liver graft  to their child?  It would 
fi rst appear that the answer would be yes but the eleven deaths that were reported in 2006 has 
slowed the rush to fi ll the shortage of cadaveric livers with live donors (Fan 2006).  Regardless 
of the answers to these questions, given the rising mortality from HCC one thing is clear; 
standard treatments have not been suffi  cient in reducing deaths from HCC.
A central function of hepatocytes is to produce bile.   Bile is comprised of more than 
95% and is a major function of normal hepatocytes.  In order to make bile, hepatocytes must 
transport water from sinusoidal space into the bile canaliculi.  Previous work has demonstrated a 
role for aquaporins in bile formation by facilitating this water movement (Huebert et al. 2002).  
All cancers share six functional abilities: 1) self-suffi  ciency in growth signals, 2) insensitive to 
anti-growth signals, 3) they invade adjacent tissue and metastasis to distance sites, 4) they have 
limitless replicative potential, 5) sustained angiogenesis and 6) they evade apoptosis (Hanahan 
et al. 2000).  For HCC, one other can be added, moderately to well diff erentiated HCCs do 
not typically produce bile (Dominguez-Malagon et al. 2001).  Th is lack of bile production 
however carries other potential consequences; it may also assist an HCC cell in evading 
apoptosis.  Previous work has demonstrated that aquaporins play an important role in apoptotic 
progression ( Jablonski et al. 2007; Jablonski et al. 2004; Seitz et al. 2007).   Previous work has 
also demonstrated that AQP8 expression and membrane localization is increased in response to 
cAMP (Garcia et al. 2001; Gradilone et al. 2003).  Work in this dissertation has demonstrated 
that AQP8 and 9 localization to the membrane is lower compared to non-tumor tissue (Chapter 
5).  Proper function of aquaporins is dependent on membrane insertion as aquaporins are 
passive membrane channels (Frigeri et al. 2007).  Aquaporins play a role in apoptosis and AQP8 
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and 9 membrane localization is reduced in HCC. Th us if HCC cells could be forced to express 
AQP8 and/or 9, then this would sensitize these cells to apoptosis.  Th is hypothesis was an initial 
motivation for the work presented in this dissertation.
A previous report from the McKillop laboratory demonstrated that AQP8 and 9 expression 
is decreased in a rat, H4IIE inoculation model of HCC, in vivo ( Jablonski et al. 2007).  So I used 
this model to examine the possibility of maintaining the in vivo state in vitro.  Previous work 
had demonstrated that in rat hepatocytes, AQP8 expression and localization to the canalicular 
membrane was stimulated by glucagon and that glucagon was signaling via a cAMP dependent 
pathway (Garcia et al. 2001; Gradilone et al. 2003).  Th erefore, cAMP may also regulate AQP8 
(and potentially AQP9) expression and localization in HCC.  Th e Jablonski paper also indicated 
that AQP8 and 9 was strongly expressed (compared to tumors) 24-36 hours aft er tumors 
were isolated from the liver and placed in cultured ( Jablonski et al. 2007).  So I examined 
whether I could preserve the in vivo state by culturing tumors in the presence of cAMP pathway 
modulators.  Th ese studies demonstrated, modulation of the cAMP pathway does not aff ect 
AQP8 or 9 expression in freshly isolated tumors immediately exposed to cAMP pathway 
modulators.  So a logical next step would be to examine AQP8 and 9 in long term cultured 
H4IIE cells.  Unfortunately, cAMP does not alter AQP8/9 mRNA or protein expression, nor 
does cAMP aff ect AQP8/9 localization (membrane or cytoplasm).  In normal rat hepatocytes, 
AQP9 expression and localization are not aff ected by cAMP signaling (Soria et al. 2009).
IL-6 is a pleiotropic cytokine involved in liver regeneration (Koniaris et al. 2003), is 
mitogenic in some cells (Culig et al. 2005) and growth inhibitory in others (Moran et al. 2005).  
Further, as described in Chapter 3, the promoter regions of AQP8 and 9 contain response 
elements some of whose transcription factors are activated by IL-6 signaling. Also, because of 
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the results from the cAMP pathway modulation experiments, it would be interesting to examine 
if another signaling pathway would aff ect AQP8 and 9 localization the same way as cAMP 
pathway modulation did.  As with the cAMP pathway modulation experiments, recombinant 
rat IL-6 (rrIL-6) did not aff ect AQP8 or 9 mRNA or protein expression.  However, AQP8 
membrane localization was aff ected by rrIL-6 exposure.
To examine the function aff ect of cAMP pathway modulation and rrIL-6 exposure, I 
performed a cell swelling assay following exposure to cAMP pathway modulators and rrIL-6.  
Interestingly, while cAMP pathway modulation signifi cantly aff ected H4IIE cell swelling in 
response to osmotic challenge, rrIL-6 did not. 
An unresolved question in HCC is, by what mechanism is AQP8 and 9 expression 
inhibited in vivo?  Perhaps a bett er way to state the question is not, “by what mechanism” but 
“by what mechanisms”.  Th ere is substantial cross-talk between IL-6 and cAMP (Irvin et al. 
2001) and it is reasonable to examine whether they stimulate the same response from AQP8 
and 9.  In this case however, they stimulated AQP8 or 9 expression in a counter intuitive 
way.  Th e AQP8 promoter region contains a cAMP response element and yet cAMP pathway 
modulation did not aff ect AQP8 expression or localization.  Th e AQP9 promoter region 
does not contain a cAMP response element and yet cAMP pathway modulation signifi cantly 
aff ected AQP9 localization to the membrane.  Conversely, the AQP9 promoter region contains  
AP-1, NF-κB and C/EBP response elements (all known downstream target of IL-6 pathway 
activation (Fausto 2000)) and yet activation of IL-6 signaling did not signifi cantly aff ect AQP9 
expression or localization.  A possible explanation of these data is that AQP8 and 9 signaling 
occurs through entirely diff erent signaling pathways and because the amount of cross-talk 
between cAMP, IL-6 and the rest of the signaling pathways for which cAMP and/or IL-6 
141
are constituents.  Table 7.1 shows a complete list of promoter binding sites for AQP8 and 9.  
Perhaps AQP8 and 9 expression and localization are stimulated through a pathway that is not 
a priori apparent.  For example, perhaps instead of 8-Br-cAMP, expose H4IIE cells to glucagon.  
Perhaps due to genetic instability, signaling through glucagon receptors activates a G-protein 
other than GS,  or maybe glucagon activates a signaling pathway not associated with glucagon 
in normal hepatocytes.   Future study will be required to further elucidate how cAMP and IL-6 
signaling regulates AQP8 or 9 expression and localization.
One fundamental question about the inoculation rat model of HCC is: to what extent does 
this model accurately represent human HCC? A rationale way to approach such a question is 
by switching the model and observing if the observations from the inoculation rat model hold.  
A potential criticism of the H4IIE inoculation model is that it is essentially using rats as “an in 
vivo cell culture” model.  ACI rats are immunocompetent but the H4IIE cell line was derived 
from ACI rats and is MHC matched.  Th erefore, the probability of host rejection of H4IIE cells 
is very low.  Also, the usual immune response to tumors would also be absent.  Th e immune 
system of ACI rats would, most likely, not be stimulated in a way that a foreign tumor would.  In 
brief, what is missing from the H4IIE inoculation model is tumor initiation.
In 1971, Alfred Knudson demonstrated that retinoblastoma arises through biallelic 
disruption (Knudson 1971).  Biallelic disruption is the core of the two-hit hypothesis.  It 
states that cancer requires that both alleles of a tumor suppressor gene be mutated.  Further, 
the mutation of both alleles is suffi  cient for cancer to arise.  Th e two-hit hypothesis was 
controversial in Knudson’s day since data presented at the time indicated that multiple 
gene mutations were also observed in patients, suggesting that biallelic disruption alone 
was insuffi  cient for cancer to arise (Ashley 1969).  Indeed, the two-hit hypothesis is still a 
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Table 7.1:  Complete promoter map for AQP8 and 9.   Downstream targets for cAMP (yellow) 
and IL-6 (blue) are highlighted.
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controversial topic (Paige 2003).  Th ough, in the thirty-nine years since Knudson published 
his hypothesis many tumor suppressor genes have been identifi ed that support his “two-hit 
hypothesis” (Cook et al. 2000; MacPherson et al. 2007).  However, there have also been several 
genes identifi ed that are tumor suppressors but a single mutated allele is suffi  cient to abrogate 
the function of these genes, thereby resulting in cancer (Paige 2003).  One area of agreement 
is that whether a given cancer requires two mutations or many, cancer does arise through a 
two stage process (Ashley 1969; Knudson 1971).  Th e two stage hypothesis of cancer states 
that for a tumor to arise an “initiation” stage must occur whereby cells experience a mutational 
event which confers neoplastic potential and a “promotion” stage whereby any number of 
agents confers limitless  replicative potential to the cell (Berenblum et al. 1949; Hanahan et al. 
2000).  Later, a “progression” stage was added to described the complex events that lead to, and 
promote, metastasis.  Th erefore, the answer to the question regarding to what extent does the 
H4IIE inoculation model accurately represent human HCC suggests that this model is one best 
suited to study HCC progression but is silent in studies where initiation and promotion are of 
interest.  Th us, this would make the inoculation model useful for studying the progression stage 
of human HCC.  Human cancers however do follow the two stage model (Ashley 1969).  An 
additional point to be highlighted is that the incidence of human HCC is not gender neutral 
(Bosch et al. 2005).  Males are more than three times more likely to develop HCC than women 
(Bosch et al. 2005).  Th erefore, to gain a more complete picture of the role of  AQP8 and 9 in 
cancer requires the usage of an animal model that includes an initiation step and both genders.
To examine AQP8 and 9 expression and localization in a model of cancer involving 
initiation, a diethylnitrosamine (DEN) mouse model, with males and females, was used.  Fift een 
day old C3H mice were injected with DEN (1mg/kg).  Mice separated into groups where one 
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group of mice exposed to DEN was euthanized at 24 weeks (DEN-24wk) and another group of 
mice were euthanized at 48 weeks (DEN48wk).  Untreated mice were euthanized in parallel as 
control.  For both AQP8 and 9, DEN48wk mice had signifi cantly lower membrane localization 
compared to DEN-24wk mice.  Further, DEN-48wk mice had signifi cantly lower AQP8 and 
9 membrane localization compared to either normal 24 week mice or normal 48 week mice.  
DEN-48wk mice had signifi cantly higher AQP8 and 9 cytoplasmic localization compared 
DEN-24wk mice.  Lastly, male, DEN-48wk mice had signifi cantly higher AQP8 cytoplasmic 
localization compared to female, DEN-48wk mice.
In the H4IIE inoculation model, expression of  AQP8 and 9 was inhibited not localization.  
However, in the DEN mouse model, AQP8 and 9 expression does not appear to change, rather 
AQP8 and 9 localized diff erently depending on exposure to DEN.  Interestingly AQP8 was 
localized diff erently depending on the sex of the mouse, while AQP9 was not.  Human HCC has 
gender diff erences as well and perhaps human AQP8 plays a role in the higher incidence rates 
in males compared to females.  However, these diff erences must be viewed cautiously.  First, at 
no point did I detect AQP8 or 9 membrane staining greater than 2.2 or cytoplasmic staining 
greater than 3.1 in the mouse model samples.  I would not classify this scoring as indicating 
heavy expression.  Th is leads to the second point, immunohistochemical scoring has a 
subjective component.  It is semi-quantitative and for this reason the detected diff erences, while 
important, must be approached carefully.  In the end, the fact that H4IIE inoculation model and 
the DEN mouse do not match exactly is not surprising.  Th ese models start from diff erent stages 
of cancer and the diff erences detected may just be a refl ection of this fact.  Diethylnitrosamine is 
carcinogenic in rats as well and in similar dosages, so perhaps to truly compare these models we 
either need to use a DEN rat model or a cell inoculation mouse model;  one does exist.  Hepa1-
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6 cells are a mouse hepatoma cell line derived from C57L mice.  C57L mice MHC matched to 
C57BL/6 mice and there is a published study demonstrating the tumorigenicity of Hepa1-6 
cells in C57BL/6 mice (Chen et al. 2007).
What these diff erences between the mouse and rat models actually indicate is that AQP8 
and 9 expression and localization need to be examined in human HCC samples.  At bott om, 
these models are designed to mimic the human disease and it is by examining human disease 
that an honest evaluation of these models can take place.  Th erefore, human HCC samples 
were acquired and immunohistochemical analysis was performed.  Analysis of these samples 
demonstrated that AQP8 is predominantly localized to the cytoplasm in both non-tumor 
liver and HCC.  Further, AQP8 membrane localization is unchanged between non-tumor 
liver and HCC.  Th is was true whether patients had underlying cirrhosis or not.  Aquaporin 
9 however, did exhibit a dramatic reduction in membrane localization in HCC compared to 
non-tumor liver.  Th ough there was no diff erence in AQP9 membrane localization in HCC, in 
cirrhotic versus non-cirrhotic patients.  An original hope for this study was that  AQP8 and/
or 9 expression and/or localization would correlate with a risk factor for HCC.  Th ere are not 
any eff ective screens for human HCC (Marrero 2005).  Further, there have been no confi rmed 
inheritable genetic factors that contribute to HCC (Leong et al. 2005).  So fi nding a protein 
marker that correlates with a subset of patients whom could then be studied to determine if 
that patient population has worse clinical outcomes is of clear clinical value.  Unfortunately,  
the greatest AQP8 or 9 localization changes in membranes between nontumor liver and HCC 
did not reveal any common risk factor.  Th ough one must use care when interpreting studies in 
humans.  First, the sample size in this study was small (23 patients).  Carolinas Medical Center 
specializes in providing thermal ablation therapies.  Th e number of surgical resections done 
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is smaller compared to other hepatopancreobilliary surgical centers.  Th erefore, the issue may 
be that there is a risk factor for HCC that correlates with AQP8 and/or 9 expression and/or 
localization but the sample size we have available is too small to detect it.
As part of the human study, I also examined the functional eff ect of aquaporins on cell 
swelling and apoptosis in a human cancer cell line (Huh-7).  Exposing Huh-7 to osmotic stress 
resulted in cell swelling and cell swelling was inhibited by blocking aquaporin function.  Further, 
exposing Huh-7 cells to an apoptotic agent in the presence or absence of HgCl2 (a non-specifi c 
aquaporin inhibitor) demonstrated that inhibiting aquaporin function inhibited caspase-3 
activity.  Th ese data support similar experiments performed in H4IIE cells ( Jablonski et al. 
2007).
So far I have provided data that suggests that AQP8 and 9 can be stimulated to localize to 
the membrane by activating either the IL-6 pathway or the cAMP pathway (Chapter 3).  I have 
also shown that inhibiting aquaporin function, inhibits caspase-3 activity (Chapter 5).  What 
ties these two sets of experiments together is an eff ort to alter the balance between pro- and 
anti-apoptotic factors in favor pro-apoptotic factors.  We know that cancer cells, in general, 
evade apoptosis (Hanahan et al. 2000).  So inhibiting that ability to evade apoptosis would most 
certainly be a valuable clinical tool in treating HCC.  However, systemic IL-6 injections would 
probably have extremely unsatisfactory side eff ects and I do not believe that systemic injection 
of a cell permeable analogue to cAMP would fare any bett er.  So if stimulating an HCC cell to 
express AQP8 and/or 9 on the plasma membrane is not feasible, then perhaps inserting AQP8 
and/or 9 into the plasma membrane might be a more effi  cacious course of action.  Th ough 
even if one can get AQP8 or 9 into a cell, would introduction of a either of these be suffi  cient 
to inhibit tumor growth?  To fi nd out I transfected H4IIE cells with a Tet-on construct which 
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allows for the controlled expression of AQP8 or 9 by the introduction of tetracycline (or 
analogues of tetracycline such as doxycycline).  Th e Tet-on system is a double plasmid system 
that requires that a cell stably express both plasmids.  But once this is achieved, the gene of 
interest can be expressed by exposing the cell to doxycycline.  H4IIE cells bearing this Tet-
on system, engineered to express AQP8 in response to doxycycline, were injected into ACI 
rats pretreated with standard rodent chow containing doxycycline.  Th e rats injected with the 
transfected H4IIE cells, which also received doxycycline formed signifi cantly smaller tumors 
than untransfected H4IIE cells. Th is fi nding is signifi cant because it is direct evidence which 
suggests that modulating aquaporin expression in vivo can inhibit tumor progression.  Th ere was 
however an interesting issue which arose.  Th e tumorigenicity of H4IIE is inversely proportional 
to the passage number (Evans et al. 1977).  Th e transfection protocol results in H4IIE cells that 
are approximately  passage 10 by the time they stably express both plasmids.  Unfortunately, 
these cells are not tumorigenic in the liver of ACI rats.  But tumorigenicity can be restored by 
inoculating the cells into fl anks of male, ACI rats, culturing and expanding the resultant tumors, 
then inoculating these cells into the liver, culturing and expanding the resultant tumors and at 
the end of this H4IIE cells are tumorigenic in the liver.  For H4IIE cells transfected with the 
AQP8 construct this is exactly what we observed, for AQP9, liver tumors never developed.  
Th e least likely possibility as to why the H4IIE cells with the AQP9 construct did not work 
as expected is that the construct was not there to begin with or degraded by the cell at some 
point.  Th ese cells were almost always under very hard selection and always the week before 
any inoculation into rats.  To give an indication of the selection pressure these cells were 
under consider the following: the plasmids provided resistance to G418 and puromycin.  Th e 
recommended dosage (from Sigma) of G418 is 400μg/mL and the recommended dosage of 
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puromycin is 1-10μg/mL.  I used 1mg/mL of G418 and 40μg/mL of puromycin.  One potential 
possibility why pTet-AQP9 H4IIE did not regain tumorigenicity is that AQP9 is a potent 
inhibitor of tumor progression and the leaking expression of AQP9 was suffi  cient to halt tumor 
formation.  It is rare that tetracycline switch systems are completely binary, there is always 
some leaking expression of the gene of interest.  In this case though this is not a confounding 
variable for the actual experiment.  Th ere is litt le to no AQP8 or 9 expression with in vivo 
tumors ( Jablonski et al. 2007) so what leaking expression there was would not aff ect the results 
as I continuously treated the rats with doxycycline.  But if AQP9 is in fact a potent inhibitor, 
much more so than AQP8, then the leaking expression would result in no tumor formation 
in the preliminary stages as the tumorigenicity of these cells is already reduced.  Th e tumors 
resulting from inoculation with the AQP9 constructs did exhibit some interesting phenotypes.  
First, fewer fl ank tumors resulted from inoculation with the AQP9 constructs compared to the 
AQP8 constructions.  Second, while this was not quantifi ed, the fl ank tumors from the AQP9 
constructs appeared to have a size limit.  For untransfected H4IIE, inoculation into the fl ank can 
result in extremely large tumors if the tumor is not resected within approximately 14-20 days.   
But in the case of the AQP9 construct, the tumors tended to appear in the small range (4-6mm) 
in the few instances (≈ 15%) that tumors formed at all.  Now that data suggests that expressing 
AQP8, in a context where it would not normally be expressed, inhibits tumor progression, the 
question of what inhibits AQP8 and 9 expression in HCC becomes very important.
Future studies on this project should focus on the question of by what mechanism is 
AQP8 and 9 down regulated in HCC.  Other small molecules can certainly be examined.  
Protein kinase C (PKC) has been shown to regulate aquaporins in the brain (Yamamoto et al. 
2001b).  Further, it also plays a role in cell polarity (Rosse et al. 2010).  In normal hepatocytes, 
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AQP8 and 9 are inserted into lipid raft s, into diff erent membranes of the cell (Mazzone et al. 
2006), perhaps they too play a role in cell polarity.  Another possibility is ionic calcium (Ca2+).  
Aquaporin 2 traffi  cking is regulated by intracellular Ca2+ mobilization (Balasubramanian et al. 
2008; Szaszak et al. 2008).  Further, the HBV antigen, HBx, has been reported to activate Ca2+ 
signaling (Bouchard et al. 2001).  Th is is not an exhaustive list of candidates and while they 
should be studied, I submit that effi  cacious treatments for HCC lie elsewhere;  specifi cally, they 
lie with gene therapy.
Work has already begun on brining gene therapy to the bedside and there are several 
clinical trials ongoing (Hernandez-Alcoceba et al. 2006; Hwang 2006).  All but one of the trials 
in progress uses viral vectors as the delivery system (Hwang 2006).  I submit that a bett er way 
to proceed would be non-viral plasmids introduced in situ.  My objection to the usage of viruses 
in this instance is that the benefi ts do not out weight the costs.  When introducing a virus into 
a patient you run the risk of initiating autoimmune disease (Chistiakov 2010).  Also, the viral 
vector can only be used once as the host will develop an immune memory response to the virus.  
Further, there is no need to use viral vectors, there are other technologies which not only permit 
the introduction of foreign DNA into the cell but that can also be performed in situ.
Electroporation has been used for the introduction of foreign DNA for almost 30 years 
(Neumann et al. 1982).  However, for most of that 30 years it was of limited use for in vivo 
studies due to having to put the sample in a special sample chamber (Neumann et al. 1982).  
Recently, however electroporation has been successfully used in various tissues, including 
the liver (Wells 2010).  Further, the recent introduction of commercial ultrasound and 
microbubble-aided transfection, has also been successfully used in liver and adds another tool 
for in vivo gene transfer (Wells 2010).
150
Th e place to start examining how AQP8 and 9 are inhibited in HCC is by having detailed 
data on when this inhibition occurs.  Data presented in this dissertation suggests that inhibition 
occurs between 24 and 48 weeks.  In order to perform a detailed analysis, a tighter time frame 
will be needed.  Bioluminescence imaging would be an ideal technology for doing detailed time 
courses of AQP8 and 9 inhibition.  A relatively simple method to examine this would be to use 
Hepa1-6 cells which would be transfected with AQP-fi refl y luciferase fusion protein.  Th ese cells 
would then be inoculated into the liver and bioluminescence measures would be taken daily.  
With these data, a detailed examination of the genes involved as AQP8 and/or 9 expression is 
inhibited could be performed using micro arrays to select potential targets.
Another experiment would be to breed condition cre-loxP-AQP mice which will allow for 
a liver specifi c AQP8 or 9 knockout.  Th ese mice can then be used in a DEN model to examine 
what role AQP8 and/or 9 play in tumor initiation and early progression.  Lastly, a Tet-on 
conditional cre-loxP mouse could be generated.  By fl oxing the DNA sequence encoding the 
Tet-on transactivator protein, it would be possible to specifi cally, potently inhibit AQP8 or 
9 expression at an investigator chosen time point.  Further, AQP 8 and 9 knockout mice are 
available, both of which are on a C57BL/6 background (Rojek et al. 2007; Yang et al. 2005).  
Th is is important because cre-loxP animals have to be breed from crossing cre mice with mice 
which have the gene of fl oxed (i.e. fl anked by loxP sequences).  Using a common mouse strain 
such as C57BL/6 means a cre animal  can be purchased instead of breeding.  Th erefore, using 
AQP8 or 9 knockout mice for the loxP mice in the system, generates mice which have a liver 
specifi c, controllable expression of AQP8 or 9.
In conclusion, AQP8 and 9 membrane localization, in an in vitro model of HCC, are 
aff ected by IL-6 and cAMP, respectively.  Further,  in a DEN mouse model of HCC, AQP 8 
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and 9 membrane localization is lower the longer HCC progresses.  Th ough during early HCC, 
in the DEN model, AQP8 membrane localization is lower in female mice compared to males.  
In human HCC, AQP9 membrane localization is lower in HCC compared to non-tumor but 
there is no diff erence in AQP8 membrane localization between non-tumor liver and HCC.  Th is 
suggests that while neither the rat nor mouse models of HCC are a perfect fi t, each is suitable 
for modeling specifi c stages of cancer.  Also, there appears to be no common human HCC 
risk factor which correlates with the largest diff erences in  membrane localization between 
non-tumor liver and HCC.   Lastly, constitutive AQP8 expression results in inhibited tumor 
progression in a rat model of HCC.  Th e role of AQP9 expression in this model remains unclear.
REFERENCES
Akira, S. 1999. Functional Roles of Stat Family Proteins: Lessons from Knockout Mice. Stem 
Cells 17 (3):138-46.
Alonzi, T., D. Maritano, B. Gorgoni, G. Rizzuto, C. Libert, and V. Poli. 2001. Essential Role of 
Stat3 in the Control of the Acute-Phase Response as Revealed by Inducible Gene Inactivation 
[Correction of Activation] in the Liver. Mol Cell Biol 21 (5):1621-32.
Anwer, M. S. 2004. Cellular Regulation of Hepatic Bile Acid Transport in Health and 
Cholestasis. Hepatology 39 (3):581-90.
Ashley, D. J. 1969. Th e Two “Hit” and Multiple “Hit” Th eories of Carcinogenesis. Br J Cancer 23 
(2):313-28.
Atwal, G. S., R. Rabadan, G. Lozano, L. C. Strong, M. W. Ruijs, M. K. Schmidt, L. J. van’t Veer, 
H. Nevanlinna, J. Tommiska, K. Aitt omaki, G. Bougeard, T. Frebourg, A. J. Levine, and G. 
L. Bond. 2008. An Information-Th eoretic Analysis of Genetics, Gender and Age in Cancer 
Patients. PLoS One 3 (4):e1951.
Badaut, J, and L Regli. 2004. Distribution and Possible Roles of Aquaporin 9 in the Brain. 
Neuroscience 129 (4):971-81.
Balasubramanian, L., J. S. Sham, and K. P. Yip. 2008. Calcium Signaling in Vasopressin-Induced 
Aquaporin-2 Traffi  cking. Pfl ugers Arch 456 (4):747-54.
Bartsch, H., and J. Nair. 2004. Oxidative Stress and Lipid Peroxidation-Derived DNA-Lesions in 
Infl ammation Driven Carcinogenesis. Cancer Detect Prev 28 (6):385-91.
———. 2005. Accumulation of Lipid Peroxidation-Derived DNA Lesions: Potential Lead 
Markers for Chemoprevention of Infl ammation-Driven Malignancies. Mutat Res 591 (1-2):34-
44.
Bauer-Hofmann, R., F. Klimek, A. Buchmann, O. Muller, P. Bannasch, and M. Schwarz. 1992. 
Role of Mutations at Codon 61 of the C-Ha-Ras Gene During Diethylnitrosamine-Induced 
Hepatocarcinogenesis in C3h/He Mice. Mol Carcinog 6 (1):60-7.
Beauvais, F., L. Michel, and L. Dubertret. 1995. Human Eosinophils in Culture Undergo 
a Striking and Rapid Shrinkage During Apoptosis. Role of K+ Channels. J Leukoc Biol 57 
(6):851-5.
153
Befeler, A. S. 2005. Chemoembolization and Bland Embolization: A Critical Appraisal. Clin 
Liver Dis 9 (2):287-300, vii.
Benga, G. 2003. Birth of Water Channel Proteins-the Aquaporins. Cell Biol Int 27 (9):701-9.
Benga, G., O. Popescu, V. I. Pop, and R. P. Holmes. 1986. P-(Chloromercuri)Benzenesulfonate 
Binding by Membrane Proteins and the Inhibition of Water Transport in Human Erythrocytes. 
Biochemistry 25 (7):1535-8.
Berenblum, I., and P. Shubik. 1949. An Experimental Study of the Initiating State of 
Carcinogenesis, and a Re-Examination of the Somatic Cell Mutation Th eory of Cancer. Br J 
Cancer 3 (1):109-18.
Bleackley, R. Chris. 2005. A Molecular View of Cytotoxic T Lymphocyte Induced Killing. 
Biochemistry & Cell Biology 83 (6):747-751.
Borgnia, M., S. Nielsen, A. Engel, and P. Agre. 1999. Cellular and Molecular Biology of the 
Aquaporin Water Channels. Annu Rev Biochem 68:425-58.
Bortner, CD, and JA Cidlowski. 2002. Apoptotic Volume Decrease and the Incredible Shrinking 
Cell. Cell Death Diff er 9 (12):1307-10.
Bortner, CD, FM Hughes, and JA Cidlowski. 1997. A Primary Role for K+ and Na+ Effl  ux in 
the Activation of Apoptosis. J Biol Chem 272 (51):32436-42.
Bosch, FX, J Ribes, R Cléries, and M Díaz. 2005. Epidemiology of Hepatocellular Carcinoma. 
Clinics in liver disease 9 (2):191-211, v.
Bouchard, M. J., L. H. Wang, and R. J. Schneider. 2001. Calcium Signaling by Hbx Protein in 
Hepatitis B Virus DNA Replication. Science 294 (5550):2376-8.
Boulanger, M. J., D. C. Chow, E. E. Brevnova, and K. C. Garcia. 2003. Hexameric Structure and 
Assembly of the Interleukin-6/Il-6 Alpha-Receptor/Gp130 Complex. Science 300 (5628):2101-
4.
Brooks, P. J., and J. A. Th eruvathu. 2005. DNA Adducts from Acetaldehyde: Implications for 
Alcohol-Related Carcinogenesis. Alcohol 35 (3):187-93.
Bünemann, M., M. Frank, and M. J. Lohse. 2003. Gi Protein Activation in Intact Cells Involves 
Subunit Rearrangement Rather Th an Dissociation. Proceedings of the National Academy of 
Sciences of the United States of America 100 (26):16077-82.
Calamita, G., D. Ferri, P. Gena, G. E. Liquori, R. A. Marinelli, G. Meyer, P. Portincasa, and M. 
Svelto. 2005. Water Transport into Bile and Role in Bile Formation. Curr Drug Targets Immune 
Endocr Metabol Disord 5 (2):137-42.
Cantwell, C. A., E. Sterneck, and P. F. Johnson. 1998. Interleukin-6-Specifi c Activation of the 
154
C/Ebpdelta Gene in Hepatocytes Is Mediated by Stat3 and Sp1. Mol Cell Biol 18 (4):2108-17.
Carbia-Nagashima, A., and E. Arzt. 2004. Intracellular Proteins and Mechanisms Involved in the 
Control of Gp130/Jak/Stat Cytokine Signaling. IUBMB Life 56 (2):83-8.
Carbrey, JM, DA Gorelick-Feldman, D Kozono, J Praetorius, S Nielsen, and P Agre. 2003. 
Aquaglyceroporin Aqp9: Solute Permeation and Metabolic Control of Expression in Liver. Proc 
Natl Acad Sci USA 100 (5):2945-50.
Carreras, F. I., G. L. Lehmann, D. Ferri, M. F. Tioni, G. Calamita, and R. A. Marinelli. 2007. 
Defective Hepatocyte Aquaporin-8 Expression and Reduced Canalicular Membrane Water 
Permeability in Estrogen-Induced Cholestasis. Am J Physiol Gastrointest Liver Physiol 292 
(3):G905-12.
Chen, Y. X., K. Man, G. S. Ling, Y. Chen, B. S. Sun, Q. Cheng, O. H. Wong, C. K. Lo, I. O. Ng, 
L. C. Chan, G. K. Lau, C. L. Lin, F. Huang, and F. P. Huang. 2007. A Crucial Role for Dendritic 
Cell (Dc) Il-10 in Inhibiting Successful Dc-Based Immunotherapy: Superior Antitumor 
Immunity against Hepatocellular Carcinoma Evoked by Dc Devoid of Il-10. J Immunol 179 
(9):6009-15.
Cheng, EH, MC Wei, S Weiler, RA  Flavell, TW Mak, T Lindsten, and SJ Korsmeyer. 2001. 
Bcl-2, Bcl-X(L) Sequester Bh3 Domain-Only Molecules Preventing Bax- and Bak-Mediated 
Mitochondrial Apoptosis. Mol Cell 8 (3):705-11.
Cherfi ls, J., and M. Chabre. 2003. Activation of G-Protein Galpha Subunits by Receptors 
through Galpha-Gbeta and Galpha-Ggamma Interactions. Trends in biochemical sciences 28 
(1):13-7.
Cheung, C., A. M. Yu, C. S. Chen, K. W. Krausz, L. G. Byrd, L. Feigenbaum, R. J. Edwards, 
D. J. Waxman, and F. J. Gonzalez. 2006. Growth Hormone Determines Sexual Dimorphism 
of Hepatic Cytochrome P450 3a4 Expression in Transgenic Mice. J Pharmacol Exp Th er 316 
(3):1328-34.
Chiang, J. Y. 1998. Regulation of Bile Acid Synthesis. Front Biosci 3:d176-93.
Chistiakov, D. A. 2010. Interferon Induced with Helicase C Domain 1 (Ifi h1) and Virus-
Induced Autoimmunity: A Review. Viral Immunol 23 (1):3-15.
Cho-Chung, Y. S., M. Nesterova, K. G. Becker, R. Srivastava, Y. G. Park, Y. N. Lee, Y. S. Cho, M. 
K. Kim, C. Neary, and C. Cheadle. 2002. Dissecting the Circuitry of Protein Kinase a and Camp 
Signaling in Cancer Genesis: Antisense, Microarray, Gene Overexpression, and Transcription 
Factor Decoy. Annals of the New York Academy of Sciences 968:22-36.
Clapp, N. K., and A. W. Craig. 1967. Carcinogenic Eff ects of Diethylnitrosamine in Rf Mice. J 
Natl Cancer Inst 39 (5):903-16.
Clark, H. P., W. F. Carson, P. V. Kavanagh, C. P. Ho, P. Shen, and R. J. Zagoria. 2005. Staging and 
155
Current Treatment of Hepatocellular Carcinoma. Radiographics 25 Suppl 1:S3-23.
Cook, W. D., and B. J. McCaw. 2000. Accommodating Haploinsuffi  cient Tumor Suppressor 
Genes in Knudson’s Model. Oncogene 19 (30):3434-8.
Cooper, D. M. 2003. Regulation and Organization of Adenylyl Cyclases and Camp. Th e 
Biochemical journal 375 (Pt 3):517-29.
Crews, FT, R Bechara, LA Brown, DM Guidot, P Mandrekar, S Oak, L Qin, G Szabo, M 
Wheeler, and J Zou. 2006. Cytokines and Alcohol. Alcoholism: Clinical and Experimental 
Research 30 (4):720-730.
Culig, Z., H. Steiner, G. Bartsch, and A. Hobisch. 2005. Interleukin-6 Regulation of Prostate 
Cancer Cell Growth. J Cell Biochem 95 (3):497-505.
Danielsen, H. E., A. Brogger, and A. Reith. 1991. Specifi c Gain of Chromosome 19 in 
Preneoplastic Mouse Liver Cells aft er Diethylnitrosamine Treatment. Carcinogenesis 12 
(10):1777-80.
Dash, S, S Haque, V Joshi, R Prabhu, S Hazari, C Fermin, and R Garry. 2005. Hcv-
Hepatocellular Carcinoma: New Findings and Hope for Eff ective Treatment. Microsc Res Tech 
68 (3-4):130-48.
Davies, S. P., H. Reddy, M. Caivano, and P. Cohen. 2000. Specifi city and Mechanism of Action 
of Some Commonly Used Protein Kinase Inhibitors. Biochem J 351 (Pt 1):95-105.
den Engelse, L., B. G. Floot, R. J. de Brij, and A. D. Tates. 1983. Th e Induction of Chromosomal 
Damage in Rat Hepatocytes and Lymphocytes. Ii. Alkylation Damage and Repair of Rat-Liver 
DNA aft er Diethylnitrosamine, Dimethylnitrosamine and Ethyl Methanesulphonate in Relation 
to Clastogenic Eff ects. Mutat Res 107 (1):153-66.
Dessauer, C. W., J. J. Tesmer, S. R. Sprang, and A. G. Gilman. 1998. Identifi cation of a Gialpha 
Binding Site on Type V Adenylyl Cyclase. Th e Journal of biological chemistry 273 (40):25831-9.
Diehl, A. M., S. Q. Yang, D. Wolfgang, and G. Wand. 1992. Diff erential Expression of Guanine 
Nucleotide-Binding Proteins Enhances Camp Synthesis in Regenerating Rat Liver. Th e Journal 
of clinical investigation 89 (6):1706-12.
Diehl, S., and M. Rincon. 2002. Th e Two Faces of Il-6 on Th 1/Th 2 Diff erentiation. Mol Immunol 
39 (9):531-6.
Dominguez-Malagon, H., and S. Gaytan-Graham. 2001. Hepatocellular Carcinoma: An Update. 
Ultrastruct Pathol 25 (6):497-516.
Donovan, M, and TG Cott er. 2004. Control of Mitochondrial Integrity by Bcl-2 Family 
Members and Caspase-Independent Cell Death. Biochimica et Biophysica Acta (BBA) - Molecular 
Cell Research 1644 (2-3):133-147.
156
Dutkowski, P., O. De Rougemont, B. Mullhaupt, and P. A. Clavien. 2010. Current and Future 
Trends in Liver Transplantation in Europe. Gastroenterology 138 (3):802-9 e1-4.
Edwards, B. K., E. Ward, B. A. Kohler, C. Eheman, A. G. Zauber, R. N. Anderson, A. Jemal, M. 
J. Schymura, I. Lansdorp-Vogelaar, L. C. Seeff , M. van Ballegooijen, S. L. Goede, and L. A. Ries. 
2010. Annual Report to the Nation on the Status of Cancer, 1975-2006, Featuring Colorectal 
Cancer Trends and Impact of Interventions (Risk Factors, Screening, and Treatment) to Reduce 
Future Rates. Cancer 116 (3):544-73.
El-Serag, HB, and AC Mason. 2000. Risk Factors for the Rising Rates of Primary Liver Cancer 
in the United States. Arch Intern Med 160 (21):3227-30.
Elkjaer, M, Z Vajda, LN Nejsum, T Kwon, UB Jensen, M Amiry-Moghaddam, J Frokiaer, and 
S Nielsen. 2000. Immunolocalization of Aqp9 in Liver, Epididymis, Testis, Spleen, and Brain. 
Biochem Biophys Res Commun 276 (3):1118-28.
Engel, A, Y Fujiyoshi, and P Agre. 2000. Th e Importance of Aquaporin Water Channel Protein 
Structures. Embo J 19 (5):800-6.
Epstein, DJ, E Marti, MP Scott , and AP McMahon. 1996. Antagonizing Camp-Dependent 
Protein Kinase a in the Dorsal Cns Activates a Conserved Sonic Hedgehog Signaling Pathway. 
Development 122 (9):2885-94.
Evans, M. J., and C. J. Kovacs. 1977. Properties of the H-4-Ii-E Tumor Cell System. I. Growth 
and Cell Proliferation Kinetics of an Experimental Hepatoma. Cell Tissue Kinet 10 (3):233-43.
Fan, S. T. 2006. Live Donor Liver Transplantation in Adults. Transplantation 82 (6):723-32.
Fausto, N. 2000. Liver Regeneration. J Hepatol 32 (1 Suppl):19-31.
Ferenci, P., M. Fried, D. Labrecque, J. Bruix, M. Sherman, M. Omata, J. Heathcote, T. 
Piratsivuth, M. Kew, J. A. Otegbayo, S. S. Zheng, S. Sarin, S. S. Hamid, S. B. Modawi, W. Fleig, S. 
Fedail, A. Th omson, A. Khan, P. Malfertheiner, G. Lau, F. J. Carillo, J. Krabshuis, and A. Le Mair. 
2010. Hepatocellular Carcinoma (Hcc): A Global Perspective. J Clin Gastroenterol 44 (4):239-
45.
Fimia, G. M., and P. Sassone-Corsi. 2001. Cyclic Amp Signalling. Journal of Cell Science 114 (Pt 
11):1971-2.
Forse, R. A. 2000. Biology of Heterotrimeric G-Protein Signaling. Critical care medicine 28 (4 
Suppl):N53-9.
Frigeri, A, GP Nicchia, and M Svelto. 2007. Aquaporins as Targets for Drug Discovery. Curr 
Pharm Des 13 (23):2421-7.
Fujiwara, T. M., and D. G. Bichet. 2005. Molecular Biology of Hereditary Diabetes Insipidus. J 
Am Soc Nephrol 16 (10):2836-46.
157
Garcia, F., A. Kierbel, M. C. Larocca, S. A. Gradilone, P. Splinter, N. F. LaRusso, and R. A. 
Marinelli. 2001. Th e Water Channel Aquaporin-8 Is Mainly Intracellular in Rat Hepatocytes, 
and Its Plasma Membrane Insertion Is Stimulated by Cyclic Amp. Th e Journal of biological 
chemistry 276 (15):12147-52.
Gargalovic, P. S., N. M. Gharavi, M. J. Clark, J. Pagnon, W. P. Yang, A. He, A. Truong, T. Baruch-
Oren, J. A. Berliner, T. G. Kirchgessner, and A. J. Lusis. 2006. Th e Unfolded Protein Response 
Is an Important Regulator of Infl ammatory Genes in Endothelial Cells. Arterioscler Th romb Vasc 
Biol 26 (11):2490-6.
Gonen, T, and T Walz. 2006. Th e Structure of Aquaporins. Q Rev Biophys 39 (4):361-96.
Gossen, M., A. L. Bonin, and H. Bujard. 1993a. Control of Gene Activity in Higher Eukaryotic 
Cells by Prokaryotic Regulatory Elements. Trends Biochem Sci 18 (12):471-5.
Gossen, M., and H. Bujard. 1993b. Anhydrotetracycline, a Novel Eff ector for Tetracycline 
Controlled Gene Expression Systems in Eukaryotic Cells. Nucleic Acids Res 21 (18):4411-2.
Gradilone, SA, F García, RC Huebert, PS Tietz, MC Larocca, A Kierbel, FI Carreras, NF 
Larusso, and RA  Marinelli. 2003. Glucagon Induces the Plasma Membrane Insertion of 
Functional Aquaporin-8 Water Channels in Isolated Rat Hepatocytes. Hepatology 37 (6):1435-
41.
Guarrera, J. V., and N. A. Karim. 2008. Liver Preservation: Is Th ere Anything New Yet? Curr 
Opin Organ Transplant 13 (2):148-54.
Guicciardi, ME, and GJ Gores. 2005. Apoptosis: A Mechanism of Acute and Chronic Liver 
Injury. Gut 54 (7):1024-33.
Gunnarson, E., M. Zelenina, and A. Aperia. 2004. Regulation of Brain Aquaporins. Neuroscience 
129 (4):947-55.
Hanahan, D, and RA  Weinberg. 2000. Th e Hallmarks of Cancer. Cell 100 (1):57-70.
Hara-Chikuma, M., E. Sohara, T. Rai, M. Ikawa, M. Okabe, S. Sasaki, S. Uchida, and A. S. 
Verkman. 2005. Progressive Adipocyte Hypertrophy in Aquaporin-7-Defi cient Mice: Adipocyte 
Glycerol Permeability as a Novel Regulator of Fat Accumulation. J Biol Chem 280 (16):15493-6.
Harwood, S. M., M. M. Yaqoob, and D. A. Allen. 2005. Caspase and Calpain Function in Cell 
Death: Bridging the Gap between Apoptosis and Necrosis. Ann Clin Biochem 42 (Pt 6):415-31.
Hassan, S., and F. Ziba. 2007. Antibody Titer in Iranian Children 6 Years aft er Hepatitis B 
Vaccine Administration. Vaccine 25 (17):3511-4.
Heindryckx, F., I. Colle, and H. Van Vlierberghe. 2009. Experimental Mouse Models for 
Hepatocellular Carcinoma Research. Int J Exp Pathol 90 (4):367-86.
158
Henke, K., and J. Eigsti. 2005. Self-Annihilation: A Cell’s Story of Suicide. Dimens Crit Care 
Nurs 24 (3):117-9.
Hernandez-Alcoceba, R., B. Sangro, and J. Prieto. 2006. Gene Th erapy of Liver Cancer. World J 
Gastroenterol 12 (38):6085-97.
Hoque, A., Y. Z. Patt , B. Yoff e, J. D. Groopman, M. S. Greenblatt , Y. J. Zhang, and R. M. Santella. 
1999. Does Afl atoxin B1 Play a Role in the Etiology of Hepatocellular Carcinoma in the United 
States? Nutrition and cancer 35 (1):27-33.
Houssiau, F., and J. Van Snick. 1992. Il6 and the T-Cell Response. Res Immunol 143 (7):740-3.
Huebert, RC, PL Splinter, F Garcia, RA  Marinelli, and NF LaRusso. 2002. Expression and 
Localization of Aquaporin Water Channels in Rat Hepatocytes. Evidence for a Role in 
Canalicular Bile Secretion. J Biol Chem 277 (25):22710-7.
Hughes, FM, CD Bortner, GD Purdy, and JA Cidlowski. 1997. Intracellular K+ Suppresses the 
Activation of Apoptosis in Lymphocytes. J Biol Chem 272 (48):30567-76.
Hwang, L. H. 2006. Gene Th erapy Strategies for Hepatocellular Carcinoma. J Biomed Sci 13 
(4):453-68.
Irvin, B. J., C. L. Hanson, L. H. Smith, and C. K. Daniels. 2001. Cyclic Amp- and Il6-Signaling 
Cross Talk: Comodulation of Proliferation and Apoptosis in the 7td1 B Cell Hybridoma. Exp 
Cell Res 265 (1):73-9.
Ishibashi, K, M Kuwahara, Y Gu, Y Tanaka, F Marumo, and S Sasaki. 1998. Cloning and 
Functional Expression of a New Aquaporin (Aqp9) Abundantly Expressed in the Peripheral 
Leukocytes Permeable to Water and Urea, but Not to Glycerol. Biochem Biophys Res Commun 
244 (1):268-74.
Jablonski, EM, MA Matt ocks, E Sokolov, LG Koniaris, FM Hughes, N Fausto, RH Pierce, 
and IH McKillop. 2007. Decreased Aquaporin Expression Leads to Increased Resistance to 
Apoptosis in Hepatocellular Carcinoma. Cancer Lett  250 (1):36-46.
Jablonski, EM, AN Webb, NA McConnell, MC Riley, and FM Hughes. 2004. Plasma Membrane 
Aquaporin Activity Can Aff ect the Rate of Apoptosis but Is Inhibited aft er Apoptotic Volume 
Decrease. Am J Physiol, Cell Physiol 286 (4):C975-85.
Jessica Chen, M., S. Sepramaniam, A. Armugam, M. Shyan Choy, J. Manikandan, A. J. 
Melendez, K. Jeyaseelan, and N. Sang Cheung. 2008. Water and Ion Channels: Crucial in the 
Initiation and Progression of Apoptosis in Central Nervous System? Curr Neuropharmacol 6 
(2):102-16.
Kensler, T. W., P. A. Egner, J. B. Wang, Y. R. Zhu, B. C. Zhang, P. X. Lu, J. G. Chen, G. S. Qian, 
S. Y. Kuang, P. E. Jackson, S. J. Gange, L. P. Jacobson, A. Mu√±oz, and J. D. Groopman. 2004. 
Chemoprevention of Hepatocellular Carcinoma in Afl atoxin Endemic Areas. Gastroenterology 
159
127 (5 Suppl 1):S310-8.
King, L. S., M. Choi, P. C. Fernandez, J. P. Cartron, and P. Agre. 2001. Defective Urinary-
Concentrating Ability Due to a Complete Defi ciency of Aquaporin-1. N Engl J Med 345 
(3):175-9.
Klauber-DeMore, N. 2005. Tumor Biology of Breast Cancer in Young Women. Breast Dis 23:9-
15.
Knudson, A. G., Jr. 1971. Mutation and Cancer: Statistical Study of Retinoblastoma. Proc Natl 
Acad Sci U S A 68 (4):820-3.
Knüpfer, Heike, and Rainer Preiß. 2007. Signifi cance of Interleukin-6 (Il-6) in Breast Cancer 
(Review). Breast Cancer Research and Treatment 102 (2):129-135.
Koniaris, L. G., I. H. McKillop, S. I. Schwartz, and T. A. Zimmers. 2003. Liver Regeneration. J 
Am Coll Surg 197 (4):634-59.
Kovach, SJ, JA Price, CM Shaw, NG Th eodorakis, and IH McKillop. 2006. Role of Cyclic-
Amp Responsive Element Binding (Creb) Proteins in Cell Proliferation in a Rat Model of 
Hepatocellular Carcinoma. J Cell Physiol 206 (2):411-9.
Kovacs, C. J., M. J. Evans, and H. A. Hopkins. 1977. Properties of the H-4-Ii-E Tumor Cell 
System. Ii. In Vitro Characteristics of an Experimental Tumor Cell Line. Cell Tissue Kinet 10 
(3):245-54.
Koyama, Y, T Yamamoto, D Kondo, H Funaki, E Yaoita, K Kawasaki, N Sato, K Hatakeyama, 
and I Kihara. 1997. Molecular Cloning of a New Aquaporin from Rat Pancreas and Liver. J Biol 
Chem 272 (48):30329-33.
Kwon, S. H., S. H. Ahn, Y. K. Kim, G. U. Bae, J. W. Yoon, S. Hong, H. Y. Lee, Y. W. Lee, H. W. 
Lee, and J. W. Han. 2002. Apicidin, a Histone Deacetylase Inhibitor, Induces Apoptosis and 
Fas/Fas Ligand Expression in Human Acute Promyelocytic Leukemia Cells. J Biol Chem 277 
(3):2073-80.
Labbozzett a, M., M. Notarbartolo, P. Poma, L. Giannitrapani, M. Cervello, G. Montalto, and N. 
D’Alessandro. 2006. Signifi cance of Autologous Interleukin-6 Production in the Ha22t/Vgh Cell 
Model of Hepatocellular Carcinoma. Ann N Y Acad Sci 1089:268-75.
Laib, R. J., B. Brockes, A. Schwaier, and H. M. Bolt. 1982. Strain and Species Diff erences in the 
Induction of Atpase-Defi cient Hepatic Foci by Diethylnitrosamine. Cancer Lett  15 (2):145-8.
Lasky, T., and L. Magder. 1997. Hepatocellular Carcinoma P53 G > T Transversions at Codon 
249: Th e Fingerprint of Afl atoxin Exposure? Environmental health perspectives 105 (4):392-7.
Lavanchy, D. 2005. Worldwide Epidemiology of Hbv Infection, Disease Burden, and Vaccine 
Prevention. J Clin Virol 34 Suppl 1:S1-3.
160
Leitch, Virginia, Peter Agre, and Landon S. King. 2001. Altered Ubiquitination and Stability of 
Aquaporin-1 in Hypertonic Stress. Proceedings of the National Academy of Sciences 98 (5):2894-
2898.
Lemasters, J. J. 2005. Dying a Th ousand Deaths: Redundant Pathways from Diff erent 
Organelles to Apoptosis and Necrosis. Gastroenterology 129 (1):351-60.
Lencioni, R., and L. Crocett i. 2005. A Critical Appraisal of the Literature on Local Ablative 
Th erapies for Hepatocellular Carcinoma. Clin Liver Dis 9 (2):301-14, viii.
Leong, T. Y., and A. S. Leong. 2005. Epidemiology and Carcinogenesis of Hepatocellular 
Carcinoma. HPB (Oxford) 7 (1):5-15.
LeSage, G., S. Glaser, and G. Alpini. 2001. Regulation of Cholangiocyte Proliferation. Liver 21 
(2):73-80.
Lewis, S. A. 1983. Control of Na+ and Water Absorption across Vertebrate “Tight Epithelia by 
Adh and Aldosterone. J Exp Biol 106 (1):9-24.
Liu, G. J., W. Wang, X. Y. Xie, H. X. Xu, Z. F. Xu, Y. L. Zheng, J. Y. Liang, F. Moriyasu, and M. 
D. Lu. 2010. Real-Time Contrast-Enhanced Ultrasound Imaging of Focal Liver Lesions in Fatt y 
Liver. Clin Imaging 34 (3):211-21.
Liu, L., Y. Xie, and L. Lou. 2005. Cyclic Amp Inhibition of Proliferation of Hepatocellular 
Carcinoma Cells Is Mediated by Akt. Cancer biology & therapy 4 (11):1240-7.
Llovet, J. M., and J. Bruix. 2000. Early Diagnosis and Treatment of Hepatocellular Carcinoma. 
Baillieres Best Pract Res Clin Gastroenterol 14 (6):991-1008.
Lu, Y., I. R. Turnbull, A. Bragin, K. Carveth, A. S. Verkman, and W. R. Skach. 2000. 
Reorientation of Aquaporin-1 Topology During Maturation in the Endoplasmic Reticulum. 
Mol Biol Cell 11 (9):2973-85.
Ma, Tonghui, and A. S. Verkman. 1999. Aquaporin Water Channels in Gastrointestinal 
Physiology. J Physiol 517 (2):317-326.
Mackay, Judith, Ahmedin Jemal, Nancy C Lee, and D Maxwell Parkin. 2006. Th e Cancer Atlas. 
Atlanta: American Cancer Society & C.D.C.
MacPherson, D., and M. A. Dyer. 2007. Retinoblastoma: From the Two-Hit Hypothesis to 
Targeted Chemotherapy. Cancer Res 67 (16):7547-50.
Maddison, K., and A. R. Clarke. 2005. New Approaches for Modelling Cancer Mechanisms in 
the Mouse. J Pathol 205 (2):181-93.
Magee, P. N., and K. Y. Lee. 1964. Cellular Injury and Carcinogenesis. Alkylation of Ribonucleic 
Acid of Rat Liver by Diethylnitrosamine and N-Butylmethylnitrosamine in Vivo. Biochem J 91 
161
(1):35-42.
Majno, G., and I. Joris. 1995. Apoptosis, Oncosis, and Necrosis. An Overview of Cell Death. Am 
J Pathol 146 (1):3-15.
Malhi, H., G. J. Gores, and J. J. Lemasters. 2006. Apoptosis and Necrosis in the Liver: A Tale of 
Two Deaths? Hepatology 43 (2 Suppl 1):S31-44.
Manley, G. T., M. Fujimura, T. Ma, N. Noshita, F. Filiz, A. W. Bollen, P. Chan, and A. S. 
Verkman. 2000. Aquaporin-4 Deletion in Mice Reduces Brain Edema aft er Acute Water 
Intoxication and Ischemic Stroke. Nat Med 6 (2):159-63.
Marinelli, R. A., and N. F. LaRusso. 1997. Aquaporin Water Channels in Liver: Th eir 
Signifi cance in Bile Formation. Hepatology 26 (5):1081-4.
Marrero, J. A. 2005. Screening Tests for Hepatocellular Carcinoma. Clin Liver Dis 9 (2):235-51, 
vi.
Masyuk, AI, and NF LaRusso. 2006. Aquaporins in the Hepatobiliary System. Hepatology 43 (2 
Suppl 1):S75-81.
Matsuzaki, T, Y Tajika, A Ablimit, T Aoki, H Hagiwara, and K Takata. 2004. Aquaporins in the 
Digestive System. Med Electron Microsc 37 (2):71-80.
Matsuzaki, T., Y. Tajika, N. Tserentsoodol, T. Suzuki, T. Aoki, H. Hagiwara, and K. Takata. 2002. 
Aquaporins: A Water Channel Family. Anat Sci Int 77 (2):85-93.
Mayer, D., F. Klimek, and P. Bannasch. 1998. Cytochemical and Biochemical Studies on 
Adenylate Cyclase Activity in Preneoplastic and Neoplastic Liver Tissue and Cultured Liver 
Cells. Microscopy research and technique 40 (6):463-72.
Mayr, B., and M. Montminy. 2001. Transcriptional Regulation by the Phosphorylation-
Dependent Factor Creb. Nat Rev Mol Cell Biol 2 (8):599-609.
Mazzaferro, V., Y. S. Chun, R. T. Poon, M. E. Schwartz, F. Y. Yao, J. W. Marsh, S. Bhoori, and 
S. G. Lee. 2008. Liver Transplantation for Hepatocellular Carcinoma. Ann Surg Oncol 15 
(4):1001-7.
Mazzone, A., P. Tietz, J. Jeff erson, R. Pagano, and N. F. LaRusso. 2006. Isolation and 
Characterization of Lipid Microdomains from Apical and Basolateral Plasma Membranes of Rat 
Hepatocytes. Hepatology 43 (2):287-96.
McConnell, NA, RS Yunus, SA Gross, KL Bost, MG Clemens, and FM Hughes. 2002. Water 
Permeability of an Ovarian Antral Follicle Is Predominantly Transcellular and Mediated by 
Aquaporins. Endocrinology 143 (8):2905-12.
McGlynn, K. A., and W. T. London. 2005. Epidemiology and Natural History of Hepatocellular 
162
Carcinoma. Best Pract Res Clin Gastroenterol 19 (1):3-23.
McKillop, I. H., D. M. Moran, X. Jin, and L. G. Koniaris. 2006a. Molecular Pathogenesis of 
Hepatocellular Carcinoma. J Surg Res 136 (1):125-35.
McKillop, I. H., and L. W. Schrum. 2005. Alcohol and Liver Cancer. Alcohol 35 (3):195-203.
McKillop, IH, DM Moran, X Jin, and LG Koniaris. 2006b. Molecular Pathogenesis of 
Hepatocellular Carcinoma. J Surg Res 136 (1):125-35.
McKillop, IH, Y Wu, PA Cahill, and JV Sitzmann. 1998. Altered Expression of Inhibitory 
Guanine Nucleotide Regulatory Proteins (Gi-Proteins) in Experimental Hepatocellular 
Carcinoma. J Cell Physiol 175 (3):295-304.
McKnight, J. J., S. B. Gray, H. F. O’Kane, S. R. Johnston, and K. E. Williamson. 2005. Apoptosis 
and Chemotherapy for Bladder Cancer. J Urol 173 (3):683-90.
Miller, R. T., S. B. Masters, K. A. Sullivan, B. Beiderman, and H. R. Bourne. 1988. A Mutation 
Th at Prevents Gtp-Dependent Activation of the Alpha Chain of Gs. Nature 334 (6184):712-5.
Montminy, Marc. 1997. Transcriptional Regulation by Cyclic Amp. Annual review of 
biochemistry 66 (1):807-822.
Moore, M. R., N. R. Drinkwater, E. C. Miller, J. A. Miller, and H. C. Pitot. 1981. Quantitative 
Analysis of the Time-Dependent Development of Glucose-6-Phosphatase-Defi cient Foci in the 
Livers of Mice Treated Neonatally with Diethylnitrosamine. Cancer Res 41 (5):1585-93.
Moran, D. M., L. G. Koniaris, E. M. Jablonski, P. A. Cahill, C. R. Halberstadt, and I. H. 
McKillop. 2006. Microencapsulation of Engineered Cells to Deliver Sustained High Circulating 
Levels of Interleukin-6 to Study Hepatocellular Carcinoma Progression. Cell Transplant 15 (8-
9):785-98.
Moran, D. M., N. Mayes, L. G. Koniaris, P. A. Cahill, and I. H. McKillop. 2005. Interleukin-6 
Inhibits Cell Proliferation in a Rat Model of Hepatocellular Carcinoma. Liver Int 25 (2):445-57.
Moran, DM, MA Matt ocks, PA Cahill, LG Koniaris, and IH McKillop. 2007. Interleukin-6 
Mediates G(0)/G(1) Growth Arrest in Hepatocellular Carcinoma through a Stat 3-Dependent 
Pathway. J Surg Res.
Morishita, R., H. Nakayama, T. Isobe, T. Matsuda, Y. Hashimoto, T. Okano, Y. Fukada, K. 
Mizuno, S. Ohno, and O. Kozawa. 1995. Primary Structure of a Gamma Subunit of G Protein, 
Gamma 12, and Its Phosphorylation by Protein Kinase C. Th e Journal of biological chemistry 270 
(49):29469-75.
Naor, R., V. Domankevich, S. Shemer, L. Sominsky, E. Rosenne, B. Levi, and S. Ben-
Eliyahu. 2009. Metastatic-Promoting Eff ects of Lps: Sexual Dimorphism and Mediation by 
Catecholamines and Prostaglandins. Brain Behav Immun 23 (5):611-21.
163
Neuman, M. G. 2003. Cytokines--Central Factors in Alcoholic Liver Disease. Alcohol research & 
health : the journal of the National Institute on Alcohol Abuse and Alcoholism 27 (4):307-16.
Neumann, E., M. Schaefer-Ridder, Y. Wang, and P. H. Hofschneider. 1982. Gene Transfer into 
Mouse Lyoma Cells by Electroporation in High Electric Fields. Embo J 1 (7):841-5.
Nobel, C. S., J. K. Aronson, D. J. van den Dobbelsteen, and A. F. Slater. 2000. Inhibition of Na+/
K(+)-Atpase May Be One Mechanism Contributing to Potassium Effl  ux and Cell Shrinkage in 
Cd95-Induced Apoptosis. Apoptosis 5 (2):153-63.
Noda, Y., and S. Sasaki. 2005. Traffi  cking Mechanism of Water Channel Aquaporin-2. Biol Cell 
97 (12):885-92.
Oliveira, C. A., K. Carnes, L. R. Franca, L. Hermo, and R. A. Hess. 2005. Aquaporin-1 and 
-9 Are Diff erentially Regulated by Oestrogen in the Eff erent Ductule Epithelium and Initial 
Segment of the Epididymis. Biol Cell 97 (6):385-95.
Padma, S., A. M. Smeltz, P. M. Banks, D. A. Iannitt i, and I. H. McKillop. 2009. Altered 
Aquaporin 9 Expression and Localization in Human Hepatocellular Carcinoma. HPB (Oxford) 
11 (1):66-74.
Page, G. G., S. Ben-Eliyahu, and A. N. Taylor. 1995. Th e Development of Sexual Dimorphism 
in Natural Killer Cell Activity and Resistance to Tumor Metastasis in the Fischer 344 Rat. J 
Neuroimmunol 63 (1):69-77.
Paige, A. J. 2003. Redefi ning Tumour Suppressor Genes: Exceptions to the Two-Hit 
Hypothesis. Cell Mol Life Sci 60 (10):2147-63.
Parola, M., and G. Robino. 2001. Oxidative Stress-Related Molecules and Liver Fibrosis. Journal 
of hepatology 35 (2):297-306.
Pavio, N, S Batt aglia, D Boucreux, B Arnulf, R Sobesky, O Hermine, and C Brechot. 2005. 
Hepatitis C Virus Core Variants Isolated from Liver Tumor but Not from Adjacent Non-Tumor 
Tissue Interact with Smad3 and Inhibit the Tgf-Beta Pathway. Oncogene 24 (40):6119-32.
Poli, G. 2000. Pathogenesis of Liver Fibrosis: Role of Oxidative Stress. Molecular aspects of 
medicine 21 (3):49-98.
Portincasa, P, A Moschett a, A Mazzone, G Palasciano, M Svelto, and G Calamita. 2003. Water 
Handling and Aquaporins in Bile Formation: Recent Advances and Research Trends. J Hepatol 
39 (5):864-74.
Poschl, G., and H. K. Seitz. 2004. Alcohol and Cancer. Alcohol and alcoholism (Oxford, 
Oxfordshire) 39 (3):155-65.
Preston, GM, TP Carroll, WB Guggino, and P Agre. 1992. Appearance of Water Channels in 
Xenopus Oocytes Expressing Red Cell Chip28 Protein. Science 256 (5055):385-7.
164
Preston, GM, JS Jung, WB Guggino, and P Agre. 1993. Th e Mercury-Sensitive Residue at 
Cysteine 189 in the Chip28 Water Channel. Journal of Biological Chemistry 268 (1):17-20.
Puig, M., K. Mihalik, J. C. Tilton, O. Williams, M. Merchlinsky, M. Connors, S. M. Feinstone, 
and M. E. Major. 2006. Cd4+ Immune Escape and Subsequent T-Cell Failure Following 
Chimpanzee Immunization against Hepatitis C Virus. Hepatology 44 (3):736-45.
Pushparaj, P. N., J. J. Aarthi, J. Manikandan, and S. D. Kumar. 2008. Sirna, Mirna, and Shrna: In 
Vivo Applications. J Dent Res 87 (11):992-1003.
Rall, TW, and EW Sutherland. 1958. Formation of a Cyclic Adenine Ribonucleotide by Tissue 
Particles. Journal of Biological Chemistry 232 (2):1065-1076.
Imagej 1.43. National Institutes of Health.  Bethesda, Maryland, Bethesda.
Rehermann, B., and M. Nascimbeni. 2005. Immunology of Hepatitis B Virus and Hepatitis C 
Virus Infection. Nat Rev Immunol 5 (3):215-29.
Roayaie, S., and J. M. Llovet. 2005. Liver Transplantation for Hepatocellular Carcinoma: Is 
Expansion of Criteria Justifi ed? Clin Liver Dis 9 (2):315-28.
Robishaw, J. D., and C. H. Berlot. 2004. Translating G Protein Subunit Diversity into Functional 
Specifi city. Current opinion in cell biology 16 (2):206-9.
Roden, A. C., M. T. Moser, S. D. Tri, M. Mercader, S. M. Kuntz, H. Dong, A. A. Hurwitz, D. J. 
McKean, E. Celis, B. C. Leibovich, J. P. Allison, and E. D. Kwon. 2004. Augmentation of T Cell 
Levels and Responses Induced by Androgen Deprivation. J Immunol 173 (10):6098-108.
Rojek, A. M., M. T. Skowronski, E. M. Fuchtbauer, A. C. Fuchtbauer, R. A. Fenton, P. Agre, 
J. Frokiaer, and S. Nielsen. 2007. Defective Glycerol Metabolism in Aquaporin 9 (Aqp9) 
Knockout Mice. Proc Natl Acad Sci U S A 104 (9):3609-14.
Rosse, C., M. Linch, S. Kermorgant, A. J. Cameron, K. Boeckeler, and P. J. Parker. 2010. Pkc and 
the Control of Localized Signal Dynamics. Nat Rev Mol Cell Biol 11 (2):103-12.
Ryding, A. D., M. G. Sharp, and J. J. Mullins. 2001. Conditional Transgenic Technologies. J 
Endocrinol 171 (1):1-14.
Saadoun, S., M. C. Papadopoulos, M. Hara-Chikuma, and A. S. Verkman. 2005. Impairment 
of Angiogenesis and Cell Migration by Targeted Aquaporin-1 Gene Disruption. Nature 434 
(7034):786-92.
Sambrook, Joseph, and David W. Russell. 2001. Molecular Cloning: A Laboratory Manual. 3rd 
ed. 3 vols. Vol. 3. Cold Spring Harbor: Cold Spring Harbor Laboratory Press.
Saparov, SM, K Liu, P Agre, and P Pohl. 2006. Fast and Selective Ammonia Transport by 
Aquaporin-8. J Biol Chem.
165
Sarfaraz, Darya, and Cosmo L. Fraser. 1999. Eff ects of Arginine Vasopressin on Cell Volume 
Regulation in Brain Astrocyte in Culture. Am J Physiol Endocrinol Metab 276 (3):E596-601.
Schiller, M, F Verrecchia, and A Mauviel. 2003. Cyclic Adenosine 3’,5’-Monophosphate-
Elevating Agents Inhibit Transforming Growth Factor-Beta-Induced Smad3/4-Dependent 
Transcription Via a Protein Kinase a-Dependent Mechanism. Oncogene 22 (55):8881-8890.
Schmidt, C. M., I. H. McKillop, P. A. Cahill, and J. V. Sitzmann. 1999. Th e Role of Camp-
Mapk Signalling in the Regulation of Human Hepatocellular Carcinoma Growth in Vitro. Eur J 
Gastroenterol Hepatol 11 (12):1393-9.
Schmidt, CM, IH McKillop, PA Cahill, and JV Sitzmann. 1997. Alterations in Guanine 
Nucleotide Regulatory Protein Expression and Activity in Human Hepatocellular Carcinoma. 
Hepatology 26 (5):1189-94.
Schuppan, D., and N. H. Afdhal. 2008. Liver Cirrhosis. Lancet 371 (9615):838-51.
Seitz, H. K., S. Matsuzaki, A. Yokoyama, N. Homann, S. V√§kev√§inen, and X. D. Wang. 2001. 
Alcohol and Cancer. Alcoholism, clinical and experimental research 25 (5 Suppl ISBRA ):137S-
143S.
Seitz, H. K., and F. Stickel. 2007. Molecular Mechanisms of Alcohol-Mediated Carcinogenesis. 
Nat Rev Cancer 7 (8):599-612.
Servillo, G, MA Della Fazia, and P Sassone-Corsi. 2002. Coupling Camp Signaling to 
Transcription in the Liver: Pivotal Role of Creb and Crem. Exp Cell Res 275 (2):143-54.
Shepard, CW, L Finelli, and MJ Alter. 2005. Global Epidemiology of Hepatitis C Virus 
Infection. Th e Lancet infectious diseases 5 (9):558-67.
Sherman, M. 2007. Surveillance for Hepatocellular Carcinoma and Early Diagnosis. Clin Liver 
Dis 11 (4):817-37, viii.
Sherman, Morris. 2004. Pathogenesis and Screening for Hepatocellular Carcinoma. Clinics in 
liver disease 8 (2):419-443.
Shiina, S., K. Tagawa, Y. Niwa, T. Unuma, Y. Komatsu, K. Yoshiura, E. Hamada, M. Takahashi, Y. 
Shiratori, A. Terano, and et al. 1993. Percutaneous Ethanol Injection Th erapy for Hepatocellular 
Carcinoma: Results in 146 Patients. AJR Am J Roentgenol 160 (5):1023-8.
Siegmund, S. V., and D. A. Brenner. 2005. Molecular Pathogenesis of Alcohol-Induced Hepatic 
Fibrosis. Alcoholism, clinical and experimental research 29 (11 Suppl):102S-109S.
Simonds, W. F. 1999. G Protein Regulation of Adenylate Cyclase. Trends in pharmacological 
sciences 20 (2):66-73.
Soresi, M., L. Giannitrapani, F. D’Antona, A. M. Florena, E. La Spada, A. Terranova, M. 
166
Cervello, N. D’Alessandro, and G. Montalto. 2006. Interleukin-6 and Its Soluble Receptor 
in Patients with Liver Cirrhosis and Hepatocellular Carcinoma. World J Gastroenterol 12 
(16):2563-8.
Soria, L. R., S. A. Gradilone, M. C. Larocca, and R. A. Marinelli. 2009. Glucagon Induces the 
Gene Expression of Aquaporin-8 but Not Th at of Aquaporin-9 Water Channels in the Rat 
Hepatocyte. Am J Physiol Regul Integr Comp Physiol 296 (4):R1274-81.
Sprang, S. R. 1997. G Proteins, Eff ectors and Gaps: Structure and Mechanism. Current opinion 
in structural biology 7 (6):849-56.
Stickel, F., D. Schuppan, E. G. Hahn, and H. K. Seitz. 2002. Cocarcinogenic Eff ects of Alcohol in 
Hepatocarcinogenesis. Gut 51 (1):132-9.
Sunahara, R. K., J. J. Tesmer, A. G. Gilman, and S. R. Sprang. 1997. Crystal Structure of the 
Adenylyl Cyclase Activator Gsalpha. Science (New York, NY) 278 (5345):1943-7.
Swann, P. F., and P. N. Magee. 1971. Nitrosamine-Induced Carcinogenesis. Th e Alkylation of 
N-7 of Guanine of Nucleic Acids of the Rat by Diethylnitrosamine, N-Ethyl-N-Nitrosourea and 
Ethyl Methanesulphonate. Biochem J 125 (3):841-7.
Szaszak, M., F. Christian, W. Rosenthal, and E. Klussmann. 2008. Compartmentalized Camp 
Signalling in Regulated Exocytic Processes in Non-Neuronal Cells. Cell Signal 20 (4):590-601.
Tajkhorshid, E., P. Nollert, M. O. Jensen, L. J. Miercke, J. O’Connell, R. M. Stroud, and K. 
Schulten. 2002. Control of the Selectivity of the Aquaporin Water Channel Family by Global 
Orientational Tuning. Science 296 (5567):525-30.
Tanaka, S., and S. Arii. 2010. Current Status of Molecularly Targeted Th erapy for Hepatocellular 
Carcinoma: Basic Science. Int J Clin Oncol.
Tani, T, Y Koyama, K Nihei, S Hatakeyama, K Ohshiro, Y Yoshida, E Yaoita, Y Sakai, K 
Hatakeyama, and T Yamamoto. 2001. Immunolocalization of Aquaporin-8 in Rat Digestive 
Organs and Testis. Arch Histol Cytol 64 (2):159-68.
Taskén, K., and E. M. Aandahl. 2004. Localized Eff ects of Camp Mediated by Distinct Routes of 
Protein Kinase A. Physiological reviews 84 (1):137-67.
Tates, A. D., I. Neuteboom, A. H. Rott eveel, N. de Vogel, G. J. Menkveld, and L. den 
Engelse. 1986. Persistence of Preclastogenic Damage in Hepatocytes of Rats Exposed to 
Ethylnitrosourea, Diethylnitrosamine, Dimethylnitrosamine and Methyl Methanesulphonate. 
Correlation with DNA O-Alkylation. Carcinogenesis 7 (7):1053-8.
Taylor, S. S., E. Radzio-Andzelm, Madhusudan, X. Cheng, L. Ten Eyck, and N. Narayana. 1999. 
Catalytic Subunit of Cyclic Amp-Dependent Protein Kinase: Structure and Dynamics of the 
Active Site Cleft . Pharmacology & therapeutics 82 (2-3):133-41.
167
Th omas, DL, and LB Seeff . 2005. Natural History of Hepatitis C. Clinics in liver disease 9 
(3):383-98, vi.
Tietz, P, J Jeff erson, R Pagano, and NF Larusso. 2005. Membrane Microdomains in 
Hepatocytes: Potential Target Areas for Proteins Involved in Canalicular Bile Secretion. J Lipid 
Res 46 (7):1426-32.
Tran, T. T., and P. Martin. 2004. Hepatitis B: Epidemiology and Natural History. Clin Liver Dis 8 
(2):255-66.
Tritt o, S., G. Gastaldi, S. Zelenin, M. Grazioli, M. N. Orsenigo, U. Ventura, U. Laforenza, and 
M. Zelenina. 2007. Osmotic Water Permeability of Rat Intestinal Brush Border Membrane 
Vesicles: Involvement of Aquaporin-7 and Aquaporin-8 and Eff ect of Metal Ions. Biochem Cell 
Biol 85 (6):675-84.
Truty, M. J., and J. N. Vauthey. 2010. Surgical Resection of High-Risk Hepatocellular 
Carcinoma: Patient Selection, Preoperative Considerations, and Operative Technique. Ann Surg 
Oncol 17 (5):1219-25.
U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2003 Incidence 
and Mortality Web-Based Report. U.S. Department of Health and Human Services, Centers 
for Disease Control and Prevention and National Cancer Institute 2007 [cited 10/5/2007. 
Available from htt p://www.cdc.gov/uscs.
van IJzendoorn, SC, and D Hoekstra. 1999. Polarized Sphingolipid Transport from the 
Subapical Compartment: Evidence for Distinct Sphingolipid Domains. Mol Biol Cell 10 
(10):3449-61.
van Ijzendoorn, SC, MM Zegers, JW Kok, and D Hoekstra. 1997. Segregation of 
Glucosylceramide and Sphingomyelin Occurs in the Apical to Basolateral Transcytotic Route in 
Hepg2 Cells. J Cell Biol 137 (2):347-57.
van Lieburg, A. F., M. A. Verdijk, V. V. Knoers, A. J. van Essen, W. Proesmans, R. Mallmann, 
L. A. Monnens, B. A. van Oost, C. H. van Os, and P. M. Deen. 1994. Patients with Autosomal 
Nephrogenic Diabetes Insipidus Homozygous for Mutations in the Aquaporin 2 Water-Channel 
Gene. Am J Hum Genet 55 (4):648-52.
Verkman, A. S. 2005. More Th an Just Water Channels: Unexpected Cellular Roles of 
Aquaporins. J Cell Sci 118 (Pt 15):3225-32.
———. 2009. Aquaporins: Translating Bench Research to Human Disease. J Exp Biol 212 (Pt 
11):1707-15.
Verkman, AS, and AK Mitra. 2000. Structure and Function of Aquaporin Water Channels. Am J 
Physiol Renal Physiol 278 (1):F13-28.
Vesselinovitch, S. D., M. Koka, N. Mihailovich, and K. V. Rao. 1984. Carcinogenicity of 
168
Diethylnitrosamine in Newborn, Infant, and Adult Mice. J Cancer Res Clin Oncol 108 (1):60-5.
Vesselinovitch, S. D., and N. Mihailovich. 1983. Kinetics of Diethylnitrosamine 
Hepatocarcinogenesis in the Infant Mouse. Cancer Res 43 (9):4253-9.
Villeneuve, J. P. 2005. Th e Natural History of Chronic Hepatitis B Virus Infection. J Clin Virol 
34 Suppl 1:S139-42.
Voigt, MD. 2005. Alcohol in Hepatocellular Cancer. Clinics in liver disease 9 (1):151-69.
Wang, J. S., T. Huang, J. Su, F. Liang, Z. Wei, Y. Liang, H. Luo, S. Y. Kuang, G. S. Qian, G. Sun, 
X. He, T. W. Kensler, and J. D. Groopman. 2001. Hepatocellular Carcinoma and Afl atoxin 
Exposure in Zhuqing Village, Fusui County, People’s Republic of China. Cancer epidemiology, 
biomarkers & prevention : a publication of the American Association for Cancer Research, 
cosponsored by the American Society of Preventive Oncology 10 (2):143-6.
Wang, J., N. Tanji, T. Sasaki, T. Kikugawa, X. Song, and M. Yokoyama. 2008. Androgens 
Upregulate Aquaporin 9 Expression in the Prostate. Int J Urol 15 (10):936-41.
Wang, L. Y., M. Hatch, C. J. Chen, B. Levin, S. L. You, S. N. Lu, M. H. Wu, W. P. Wu, L. W. Wang, 
Q. Wang, G. T. Huang, P. M. Yang, H. S. Lee, and R. M. Santella. 1996. Afl atoxin Exposure and 
Risk of Hepatocellular Carcinoma in Taiwan. International journal of cancer Journal international 
du cancer 67 (5):620-5.
Wang, Y, and E Tajkhorshid. 2007. Molecular Mechanisms of Conduction and Selectivity in 
Aquaporin Water Channels. J Nutr 137 (6 Suppl 1):1509S-1515S; discussion 1516S-1517S.
Watson, A. J., A. Katz, and M. I. Simon. 1994. A Fift h Member of the Mammalian G-Protein 
Beta-Subunit Family. Expression in Brain and Activation of the Beta 2 Isotype of Phospholipase 
C. Th e Journal of biological chemistry 269 (35):22150-6.
Weigelt, B., A. T. Lo, C. C. Park, J. W. Gray, and M. J. Bissell. 2009. Her2 Signaling Pathway 
Activation and Response of Breast Cancer Cells to Her2-Targeting Agents Is Dependent 
Strongly on the 3d Microenvironment. Breast Cancer Res Treat.
Wells, D. J. 2010. Electroporation and Ultrasound Enhanced Non-Viral Gene Delivery in Vitro 
and in Vivo. Cell Biol Toxicol 26 (1):21-8.
Whisnant, R. E., A. G. Gilman, and C. W. Dessauer. 1996. Interaction of the Two Cytosolic 
Domains of Mammalian Adenylyl Cyclase. Proceedings of the National Academy of Sciences of the 
United States of America 93 (13):6621-5.
Wilson, H. L., and W. J. Roesler. 2002. Ccaat/Enhancer Binding Proteins: Do Th ey Possess 
Intrinsic Camp-Inducible Activity? Mol Cell Endocrinol 188 (1-2):15-20.
World Health Organization. 2007. Revised Global Burden of Disease 2002. World Health 
Organization 2002 [cited 10/02/2007 2007]. Available from htt p://www.who.int/healthinfo/
169
bodgbd2002revised/en/index.html.
Wu, L., Z. Y. Tang, and Y. Li. 2009. Experimental Models of Hepatocellular Carcinoma: 
Developments and Evolution. J Cancer Res Clin Oncol 135 (8):969-81.
Yamamoto, J., S. Okada, K. Shimada, T. Okusaka, S. Yamasaki, H. Ueno, and T. Kosuge. 2001a. 
Treatment Strategy for Small Hepatocellular Carcinoma: Comparison of Long-Term Results 
aft er Percutaneous Ethanol Injection Th erapy and Surgical Resection. Hepatology 34 (4 Pt 
1):707-13.
Yamamoto, N, K Sobue, T Miyachi, M Inagaki, Y Miura, H Katsuya, and K Asai. 2001b. 
Diff erential Regulation of Aquaporin Expression in Astrocytes by Protein Kinase C. Brain Res 
Mol Brain Res 95 (1-2):110-6.
Yan, S. Z., Z. H. Huang, V. D. Rao, J. H. Hurley, and W. J. Tang. 1997. Th ree Discrete Regions 
of Mammalian Adenylyl Cyclase Form a Site for Gsalpha Activation. Th e Journal of biological 
chemistry 272 (30):18849-54.
Yang, B, Y Song, D Zhao, and AS Verkman. 2005. Phenotype Analysis of Aquaporin-8 Null 
Mice. Am J Physiol Cell Physiol 288 (5):C1161-70.
Yu, A. S., R. C. Cheung, and E. B. Keeff e. 2004. Hepatitis B Vaccines. Clin Liver Dis 8 (2):283-
300.
Zhang, X, DT Odom, SH Koo, MD Conkright, G Canett ieri, J Best, H Chen, R Jenner, E 
Herbolsheimer, E Jacobsen, S Kadam, JR Ecker, B Emerson, JB Hogenesch, T Unterman, RA  
Young, and M Montminy. 2005. Genome-Wide Analysis of Camp-Response Element Binding 
Protein Occupancy, Phosphorylation, and Target Gene Activation in Human Tissues. Proc Natl 
Acad Sci USA 102 (12):4459-64.
Zhang, Y. J., Y. Chen, H. Ahsan, R. M. Lunn, P. H. Lee, C. J. Chen, and R. M. Santella. 2003. 
Inactivation of the DNA Repair Gene O6-Methylguanine-DNA Methyltransferase by Promoter 
Hypermethylation and Its Relationship to Afl atoxin B1-DNA Adducts and P53 Mutation in 
Hepatocellular Carcinoma. International journal of cancer Journal international du cancer 103 
(4):440-4.
Zhang, Y. J., P. Rossner, Jr., Y. Chen, M. Agrawal, Q. Wang, L. Wang, H. Ahsan, M. W. Yu, P. H. 
Lee, and R. M. Santella. 2006. Afl atoxin B1 and Polycyclic Aromatic Hydrocarbon Adducts, 
P53 Mutations and P16 Methylation in Liver Tissue and Plasma of Hepatocellular Carcinoma 
Patients. Int J Cancer 119 (5):985-91.
Zhu, A. X. 2010. Systemic Treatment of Hepatocellular Carcinoma: Dawn of a New Era? Ann 
Surg Oncol 17 (5):1247-56.
Zimmers, T. A., I. H. McKillop, R. H. Pierce, J. Y. Yoo, and L. G. Koniaris. 2003. Massive Liver 
Growth in Mice Induced by Systemic Interleukin 6 Administration. Hepatology 38 (2):326-34.
